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Summary
The current study compared the clinical, microbiological and immunological parameters 
of chronic periodontitis patients that received two different treatment strategies: one-day 
full-mouth scaling and root planing (FM-SRP) versus quadrant scaling and root planing 
at two-weekly intervals (Q-SRP). In addition, the effects of smoking on the periodontal 
status, subgingival micro flora and humoral immune response were examined.
Clinical measurements, subgingival plaque samples, gingival crevicular fluid (GCF) and 
sera were collected from 42 patients with moderate to advanced chronic periodontitis 
before and after treatment over a period of six months. Patients were randomly 
allocated into two treatment groups and received FM-SRP or Q-SRP. Polymerase chain 
reaction (PCR) was used to determine the presence of P. gingivalis, A. 
actinomycetemcomitans, P. intermedia, T. denticola and B. forsythus in plaque. 
Enzyme-linked immunosorbent assay (ELISA) was used to examine systemic and local 
antibody titres to these bacteria and thiocyanate disassociation was used to determine 
antibody avidity.
Q-SRP and FM-SRP were found to be equally efficacious periodontal treatments. 
Therefore, the clinician should decide which treatment strategy to choose on a practical 
basis. No evidence emerged from this study to document a strong immunological 
reaction elicited by FM-SRP, as was speculated by Quirynen et al. (1995). In fact, 
during therapy the host responses of patients in both treatment groups followed a similar 
pattern. In general, both treatments resulted in significant clinical improvement and 
reduced titres of antibodies, but which were of similar avidity for the majority of the 
tested organisms. These changes paralleled marked reductions in the site and subject 
prevalence of putative periodontopathogens. In addition the present data do not support 
the hypothesis that, during the active phase of quadrant root planing therapy, the treated 
sites are re-infected with organisms that are possibly transmitted from the remaining 
untreated pockets and from other intra-oral niches (Quirynen et al. 1995). In contrast, 
the commencement of quadrant root planing and meticulous oral hygiene measures had 
a significant positive effect on the periodontal conditions of the remaining untreated 
quadrants. Nevertheless, this clinical improvement was smaller compared to changes 
seen after the completion of mechanical debridement. Despite the fact that FM-SRP
xxii
resulted in significantly higher pain scores and more patients taking analgesics 
compared to Q-SRP, it still seemed to be well tolerated by patients.
Smoking had a significant adverse effect on the inflammatory response to the bacterial 
challenge and on the treatment outcome. The outcome of each treatment strategy (Q- 
SRP and FM-SRP) was affected significantly by smoking over the course of treatment, 
having a significant impact on pocket depth (PD) and relative attachment level (RAL) 
of selected sites. A smaller PD reduction and less gain in RAL were noted after both 
treatment strategies at selected sites of smokers compared with those of non-smokers. 
Smoking appeared to modify both local and systemic host responses by producing lower 
levels of GCF and serum antibodies, respectively, but appeared to have no significant 
effect on the subgingival microflora.
This study associated systemic antibody levels with the presence of homologous 
organisms in subgingival plaque. Furthermore, the present study showed that subjects 
with less severe disease and a better clinical outcome retained higher levels of serum 
antibodies compared to patients who had more advanced disease and a moderate clinical 
outcome. These findings confirm the suggestions from other studies that antibodies are 
protective against the progression of periodontal disease. GCF antibody titres were low 
compared to serum antibody levels, which agrees with previous findings and a large 
site-to-site variability was evident, making interpretation of the results difficult. 
Nevertheless, it was apparent that deep pockets and sites that harboured a bacterial 
species gave rise to higher levels of GCF antibodies for that species.
CHAPTER 1 
GENERAL INTRODUCTION
1. General Introduction
1.1 The periodontium in health and disease
Periodontium is a word of Greek origin, referring to the tissues that surround and 
support the tooth. It is comprised of 1) gingiva, 2) periodontal ligament, 3) root 
cementum and 4) alveolar bone.
In health, the gingiva is pink in colour, often stippled in appearance, firm in texture with 
no bleeding on probing. The healthy gingival margin has a scalloped outline. The oral 
epithelium which covers the gingiva and faces the oral cavity is keratinised and is 
continuous with the sulcular epithelium and the junctional epithelium, which line the 
inner surface of the gingival sulcus. The junctional epithelium provides the contact with 
the tooth surface via hemidesmosomes and, unlike the oral and sulcular epithelium, is 
not keratinized and lacks epithelial ridges projecting into the connective tissue, called 
rete pegs. The connective tissue, which is a major component of the gingiva and of the 
periodontal ligament, comprises collagen fibres, cells, vessels, nerves and extracellular 
matrix. Fibroblasts, mast cells and infiltrating leukocytes such as, macrophages, 
polymorphonuclear leukocytes, lymphocytes and plasma cells reside in the connective 
tissues even in health, but more so during periods of inflammation.
The periodontal ligament consists of cellular connective tissue and is highly vascular. It 
is defined topographically by the space between the root surface of the tooth and the 
lamina dura. Bundles of collagen fibres run through the ligament and attach the alveolar 
bone to the tooth. The dimensions (width and height) and characteristics of the ligament 
(including level of inflammation) determine the tooth mobility. The cells of the 
periodontal ligament are fibroblasts, osteoblasts, cementoblasts, osteoclasts, epithelial 
cells and nerves.
The root cementum shares many common features with the alveolar bone. It is a 
mineralized tissue that covers the root surface and, rarely, small parts of the tooth 
crown. The cementum has no vessels and nerves, is produced by the cementoblasts and, 
unlike the alveolar bone, it is characterised by continuous deposition and no remodeling. 
The fibres of the ligament that are embedded in the cementum and alveolar bone are 
called Sharpey’s fibres.
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The alveolar process supports the sockets of the teeth and consists of the compact bone, 
which lines the sockets, and the cancellous bone, which occupies the space between the 
sockets. The compact bone is perforated providing the periodontal ligament with blood 
and lymph vessels and nerves. The part of bone where Sharpey’s fibres are embedded is 
called “bundle bone”. The bone formation sites on the outer surface of the bone are 
lined with the osteoid and on top of this with the periosteum while, inside the bone, the 
bone marrows are lined with endosteum. Bone resorption and deposition is a continual 
process and is achieved by the osteoclasts and osteoblasts.
Gingival and periodontal inflammation has been classified into four categories based on 
clinical and histopathological findings: the initial and early gingival lesion, the 
established gingival lesion and the advanced lesion (Page and Schroeder, 1976). The 
initial and early lesions represent histopathologically the early stages of gingivitis, while 
the established lesion represents chronic gingivitis with a predominance of plasma cells. 
The advanced lesion reflects, histopathologically, the shift from gingivitis to 
periodontitis.
However, this classification does not seem to be suitable for the human model of disease 
progression. The human established lesion requires more than six months to develop 
severe plasma cell infiltration and plasma cells are still not the predominant cells at this 
stage of the disease (Brecx et al. 1988). Therefore, the above classification should be 
used for describing non-human periodontal disease patterns as suggested by other 
investigators (Kinane and Lindhe, 1997). Table 1 shows the new classification of 
periodontal disease based on histopathological evidence. Even in the early stages of 
gingival inflammation, that is not clinically detectable, the connective tissue and 
junctional epithelium are infiltrated by inflammation cells with an increase in the 
vascular components. “Clinically healthy gingiva”, differs from “pristine gingiva” in 
that the latter shows little or no evidence of histologic inflammation. “Pristine gingiva” 
is almost impossible to see in everyday clinical practice and is considered to be an 
experimental condition.
1.2 Classification of periodontal diseases
In 1989, a classification system for periodontal diseases was developed by the American 
Academy of Periodontology at the World Workshop in Clinical Periodontics (Caton,
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Table 1. Histopathologial evidence for the new classification of periodontal disease.
Clinical condition Histopathological condition
Pristine gingiva Histologic perfection
Normal gingiva Initial lesion (Page and Schroeder 1976)
Early gingivitis Early lesion (Page and Schroeder 1976). Few plasma cells.
Established gingivitis Established lesion with no bone loss nor apical epithelial 
migration (plasma cell density between 10 and 30% of leukocyte 
infiltrate)
Periodontitis Established lesion with bone loss and apical epithelial migration 
from the amelocemental junction (plasma cell density > 50%)
1989). Subsequently, a simpler classification was agreed at the 1st European Workshop 
in Periodontology in 1993 (Attstrom and van der Velden, 1994). More recently, the 
American Academy of Periodontology, in an International Workshop, revised the 
classification system for periodontal disease (Armitage, 1999) and this is illustrated in 
Figure 1 (Kinane, 2001). This classification system is used to describe different forms 
of periodontal diseases throughout this thesis.
1.2.1 Chronic periodontitis
The workshop participants in 1999 agreed that the term “adult periodontitis” should be 
replaced by “chronic periodontitis” in an attempt to discard the age-dependent nature of 
the adult periodontitis classification. This form of periodontitis is commonly found in 
adults, but also in adolescents (Papapanou, 1996). It has been characterised as a slowly 
progressive disease (Papapanou et al. 1989; Brown and Loe, 1993), although short 
periods of rapid progression were also noted in some patients (Socransky et al. 1984; 
Jeffcoat and Reddy, 1991).
1.2.2 Aggressive periodontitis
As has been stated, the new classification system (Armitage, 1999) revised previous 
terminologies that were age-dependent or were based on the rates of disease 
progression. Therefore, the previous designations of “prepubertal”, “juvenile”, and 
“rapidly progressive periodontitis” (Caton, 1989) or “early-onset periodontitis” 
(Attstrom and van der Velden, 1994) were replaced by the term “aggressive 
periodontitis”. With the new classification “generalised aggressive periodontitis” 
replaces the older terms of “generalised juvenile periodontitis” and “generalised early- 
onset periodontitis” and “localised aggressive periodontitis” replaces the terms 
“localised juvenile periodontitis” and “localised early-onset periodontitis”. The 
“prepubertal” forms of disease are described now as “generalised aggressive” or 
“localised aggressive periodontitis” that occur prepubertally.
1.2.3 Periodontitis as a manifestation of systemic disease
At the International Workshop (Armitage, 1999), the older term “periodontitis 
associated with systemic disease” (Caton, 1989) was retained. Among the systemic 
diseases that are closely associated with periodontitis, diabetes mellitus is not included, 
since there is not enough evidence to document a diabetes mellitus-associated form of
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Figure taken from Kinane (2001). The latest classification for periodontal diseases, agreed at the 1999 
International Workshop by the American Academy o f Periodontology.
periodontitis. In addition, the new classification does not include a separate disease 
category for the impact of smoking on periodontitis.
1.2.4 Necrotising periodontal diseases
At present, there is not enough evidence to support the notion that necrotising ulcerative 
gingivitis and necrotising ulcerative periodontitis are different forms of disease. In 
addition, there is lack of data to clarify whether these clinical conditions are related to 
systemic diseases (e.g. HIV) or to other factors such as stress and smoking. Therefore, 
the new classification (Armitage, 1999), combined necrotising ulcerative gingivitis and 
necrotising ulcerative periodontitis in one disease category, designated as “necrotising 
periodontal diseases”.
1.3 The pathogenic process
Periodontal pathogens cause disease after colonising subgingival sites and producing 
factors that induce direct or indirect destruction of the host tissues. In order to achieve 
this, the pathogen should be able to attach to the host tissues, multiply, compete with 
other subgingival species and finally escape from the host defence mechanisms. There 
are a number of difficulties a microorganism may encounter in colonising a periodontal 
pocket. The constant outflow of the gingival crevicular fluid (GCF) and the presence of 
saliva washing out the tissues tends to prevent the attachment of pathogens. In addition, 
the constituents of saliva and GCF have many innate and adaptive antimicrobial 
properties. The anatomy of the local tissues, desquamation of the epithelial cells and 
mechanical masticatory forces are innate processes that limit aggregation of dental 
plaque on the gingivae and provide defensive mechanisms against the pathogens.
As microorganisms attempt to escape the surveillance of the host immune responses, 
they are able to multiply and infect subgingival sites. The factors they produce irritate 
the local tissues and trigger an inflammatory process. Even during the early stages of 
periodontal disease, vasodilatation is evident and many lymphocytes and neutrophils 
(but few plasma cells) migrate through the capillaries and infiltrate the tissues (Seymour 
et al. 1983; Brecx et al. 1987). The cell infiltrates at this stage may occupy up to 15% 
of the connective tissue volume. As the inflammation advances, tissue breakdown 
(collagen fibres and matrix) and swelling become more severe and plasma cell 
populations increase. The dentogingival epithelium continues to proliferate and the rete
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pegs extend deeper into the connective tissue. The junctional epithelium becomes 
detached from the crown surface, forming a periodontal pocket, and heavy leukocyte 
infiltration is present in the connective tissue and eventually in the gingival crevice. The 
junctional epithelium migrates apically and alveolar bone loss occurs, resulting in a 
denser and more anaerobic subgingival microbial flora. There is also a predominance of 
plasma cells, which account for over 50% of the connective tissue volume. Plasma cells 
are shown to out-number the other infiltrating cell types in periodontitits lesions (Garant 
and Mulvihill, 1972). While the destruction of the host tissues continues, increasing 
tooth mobility and drifting occurs and finally tooth loss may occur when the supporting 
structures are eventually destroyed.
1.4 Infectious aetiology of periodontal diseases
Periodontitis is a multifactorial inflammatory disease process, leading to destruction in the 
periodontium of the tissues supporting the teeth. It has been proven that oral bacteria and 
their products play an important role in the initiation and progression of periodontal 
diseases. This is documented by numerous investigations, which associate: 1) the 
successful use of antibiotics and antiseptic mouthrinses with the control of various forms 
of periodontitis, such as necrotising periodontal diseases (Mitchell and Baker, 1968; 
Winkler and Robertson, 1992), 2) optimal plaque control with the successful treatment of 
periodontal diseases (Lindhe and Nyman, 1975; Nyman et al. 1975), 3) microorganisms 
isolated from human periodontal pockets with periodontal destructive properties in animal 
experimental models (Jordan et al. 1972; Holt et al. 1988; Wray and Grahame, 1992), 4) 
immune responses elicited by the host with specific subgingival microorganisms (Ebersole 
et al. 1987; Ebersole and Taubman, 1994).
Despite the fact that the microbial aetiology of periodontal diseases has been accepted 
generally, there has been controversy. Questions arose as to why some teeth or even 
specific sites of certain teeth within the same individual underwent more severe 
periodontal destruction than others. Researchers sought to understand the 
characteristics of the microbial populations in dental plaques. The specific plaque 
hypothesis (Loesche, 1979) was introduced and, unlike the non-specific plaque 
hypothesis (Theilade, 1986), it suggested that specific periodontal pathogens are related 
to certain forms of periodontal diseases and when found in periodontal lesions they 
indicate increased risk of future periodontal breakdown. After refining sampling
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strategies and laboratory techniques for the analyses of plaque samples the specific role 
of certain plaque organisms along with variations between subjects and sites within a 
subject have been documented. Each subgingival site designates a specific 
microenvironment, which may be at a different stage of disease severity from other 
affected sites within the same individual.
Many investigators have attempted to relate certain subgingival species to the aetiology 
of periodontal diseases. It appears that some periodontal lesions are caused by mixed 
infections and that the subgingival microbiota is in a state of continual flux with 
dynamic changes through the different stages of disease. This makes the definition of 
the role of a single species in the aetiology and pathogenesis of periodontitis difficult. 
Haffajee and Socransky, (1994) suggested the following subgingival species: 
Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella 
intermedia, Bacteroides forsythus, and Treponema denticola as putative periodontal 
pathogens. The authors summarised the literature relating to these putative periodontal 
pathogens with periodontal disease and attempted to rank specific organisms from 
strongest to weakest in their association with periodontal disease (Table 2).
Nevertheless, the presence of a putative pathogen subgingivally does not necessarily 
mean disease initiation and progression. Several studies have demonstrated that a 
combination of factors such as changes in the local environment, presence of virulent 
strains of periodontal pathogens in sufficient numbers, absence of beneficial species and 
host susceptibility contribute to disease progression (Socransky and Haffajee, 1992, 
1993). In another study, it has been shown that although patients were considered 
clinically healthy, they still harboured A. actinomycetemcomitans and P. gingivalis post­
therapy (Nieminen et al. 1995).
It has been shown that alterations in the local environment (temperature, osmolarity, 
iron concentration, pocket depth, inflammatory status) affect the expression of virulence 
factors and the ecology of the subgingival microbiota (Socransky and Haffajee, 1991a). 
Frequently, the suspected periodontal pathogens were present in healthy sites or in sites 
that responded well to treatment. This could be due to several reasons. For example, a 
particular species may not be pathogenic (despite its presence in diseased sites), the host 
may be resistant to a particular pathogen, the levels of this organism have not exceeded
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Table 2. Ranking of suspected periodontal pathogens according to the strength of their 
relationship to periodontal disease.
Very strong Strong Moderate
A. actinomycetemcomitans B. forsythus S. intermedius
Spirochaete o f necrotising 
ulcerative diseases
P. intermedia P. nigrescens
P. gingivalis C. rectus P. micros
E. nodatum F. nucleatum
Treponema species Eubactrerium species
E. corrodens
Table adapted from Haffajee and Socransky (1994).
A. actinomycetemcomitans: Actinobacillus actinomycetemcomitans 
P. gingivalis: Porphyromonas gingivalis
B. forsythus: Bacteroides forsythus 
P. intermedia: Prevotella intermedia
C. rectus : Campylobacter rectus
E. nodatum: Eubacterium nodatum
S. intermedius: Streptococcus intermedius 
P. nigrescens: Prevotella nigrescens 
P. micros: Peptostreptococcus micros
F. nucleatum: Fusobacterium nucleatum 
E. corrodens: Eikenella corrodens
the threshold of the host susceptibility, or local environmental conditions may not 
favour pathogen replication and initiation of disease. Host susceptibility to periodontal 
pathogens is influenced by an impaired immune response related to hereditary and 
environmental factors such as living standards and smoking (Bergstrom and Eliasson, 
1987a, 1987b; Williams et al. 1990; Safkan-Seppala and Ainamo, 1992; Kinane et al. 
2001). However, not all systemically diseased individuals or smokers have an altered 
subgingival microbiota or manifestations of periodontal disease. It appears that the 
simultaneous existence of a susceptible host, presence of pathogens, and an appropriate 
local environment are required in the initiation and progression of periodontal infection.
1.5 Association of the five putative periodontal pathogens with periodontal disease
1.5.1 Actinobacillus actinomycetemcomitans
Actinobacillus actinomycetemcomitans is a small, non-motile, gram-negative, 
saccharolytic, capnophilic, round-ended rod and its primary ecological niche is the 
periodontal pocket (Slots et al. 1980). This organism has been implicated in the 
causation of localised aggressive periodontitis (Mandell and Socransky, 1981; Zambon 
et al. 1983; Komman and Robertson, 1985; Moore et al. 1985) and chronic 
periodontitis (Slots et al. 1980; Skaar et al. 1992; Mombelli et al. 1994a) and it is 
occasionally isolated from healthy subjects (Slots et al. 1980). Some individuals with 
no localised aggressive periodontitis (periodontally healthy subjects, chronic 
periodontitis patients and insulin-dependent diabetics) harbour A. 
actinomycetemcomitans (Zambon et al. 1983), which is in contrast to the findings of 
Mandel and Socransky (1981) who did not identify A. actinomycetemcomitans in 
chronic periodontitis and gingivitis patients. In addition, A. actinomycetemcomitans 
was not detected in four localised aggressive periodontitis patients (Loesche et al. 
1985).
It has been suggested that A. actinomycetemcomitans, P. gingivalis and P. intermedia 
may be useful indicators of disease activity in adult patients with periodontitis (Bragd et 
al. 1987), although the absence rather than the presence of these bacteria has been 
shown to be a predictor of future attachment loss (Wennstrbm et al. 1987c). Indeed, A. 
actinomycetemcomitans was detected significantly more frequently, and at higher levels, 
at sites which showed subsequent disease activity (Ebersole et al. 1995) and also, that 
these organisms are related to disease-active periodontitis lesions more closely than to
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periodontal pocket depth (Slots et al. 1986). In another study, this organism was 
detected more frequently at sites without recession and it increased in sites with 
increasing pocket depth in both localised and widespread disease patients, but mean 
counts of this organism were higher in the localised forms of disease at all recorded 
pocket depths (Socransky et al. 1991b). Slots et al. (1980) pointed to a positive relation 
between A. actinomycetemcomitans and pocket depth, although data from another report 
showed that the mean proportions of this organism were found to be higher at 
intermediate pocket depths between 3 and 5 mm compared to depths above 5 mm 
(Wolff et al. 1985). The subjects in the latter study were not as severely diseased as 
those in the former study. However, there is evidence that there is no association 
between A. actinomycetemcomitans detection and clinical parameters in chronic 
periodontitis patients (Christersson et al. 1992; Doungudomdacha et al. 2001). The 
literature associating A. actinomycetemcomitans with periodontitis is inconsistent and a 
summary of the findings is that A. actinomycetemcomitans can be found both sub- and 
supragingivally. Additional research is required to confirm or deny its association with 
destructive periodontal lesions.
1.5.2 Porphyromonas gingivalis
Porphyromonas gingivalis is a gram-negative, anaerobic, non-motile, asaccharolytic rod 
that is usually seen in coccal or short rod morphologies. It is a member of the widely 
studied black-pigmented Bacteroides group of organisms. A low prevalence of P. 
gingivalis has been found in maintenance patients and in non-progressive chronic 
periodontitis patients (Loesche et al. 1985; Slots et al. 1986; Gmiir et al. 1989). 
Higher frequencies and higher levels of this suspected pathogen were found in 
periodontal sites which were actively breaking down (Dzink et al. 1988). P. gingivalis 
predominates in subgingival plaques during the early stages of disease recurrence (Choi 
et al. 1990) and was found to have a relatively high prevalence in subgingival plaques 
from patients that responded poorly to treatment (refractory periodontitis patients) 
(Listgarten et al. 1993). It has been shown that P. gingivalis is elevated in periodontitis 
lesions and thrives in deep pockets (Gmiir et al. 1989; Socransky et al. 1991b; Kojima 
et al. 1993; Kigure et al. 1995; Haffajee et al. 1998; Socransky et al. 1998; Ximenez- 
Fyvie et al. 2000b; Doungudomdacha et al. 2001) and is more prevalent at suppurating 
sites (Tanner et al. 1979; Socransky et al. 1991b; Hafstrom et al. 1994).
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Gmiir et al. (1989), showed that P. gingivalis was almost always detected in samples 
which harboured Bacteroides forsythus, but the latter organism was detected more 
frequently by itself and was found to colonise shallower pockets than P. gingivalis. 
This observation implies that either B. forsythus colonises earlier or in shallower lesions 
than P. gingivalis. Kojima et al. (1993) showed that as more P. gingivalis was 
identified in subgingival plaque samples, the percentage of deep sites or sites that bled 
on probing increased significantly. Nevertheless, this pathogen was also found in 
clinically healthy sites or it was absent in sites with deep pocket depths or sites with 
bleeding on probing. In addition, other studies showed the presence of this organism in 
dental plaque of children free of periodontitis (Barron et al. 1991; Ashimoto et al. 
1996; Kamma et al. 2000). Ximenez-Fyvie et al. (2000b), demonstrated that the 
prevalence of P. gingivalis did not differ significantly between supra- and subgingival 
plaque deposits in subjects with chronic periodontitis, although counts and proportions 
of this organism were significantly higher subgingivally. Thus, there is a varied 
literature with respect to the relationship of P. gingivalis to periodontal diseases, but 
there appears to be a consistent trend that this species is frequently detected in advanced 
periodontitis lesions.
1.5.3 Prevotella intermedia
Prevotella intermedia is a gram-negative, short, round-ended anaerobic rod. P. 
intermedia is the second black-pigmented Bacteroides whose relationship to periodontal 
disease has been assessed by several studies. This organism has been associated mainly 
with necrotising periodontal diseases (Loesche et al. 1982), gingivitis (Slots et al. 
1978; Ashimoto et al. 1996) and certain other forms of periodontal disease (Tanner et 
al. 1979; Dzink et al. 1983; Loesche et al. 1985). P. intermedia can be isolated from 
dental plaque as well as from the oral mucosa (Lie et al. 2001). P. intermedia was 
found at significantly elevated levels in active periodontal lesions (Dzink et al. 1985; 
1988) and although it was closely related to progressive periodontitis, a high prevalence 
of it was also found in non-progressive sites (Slots et al. 1986). One reason for this 
could be that P. intermedia is associated with gingivitis as well as with periodontitis. 
This organism has been related to deeper periodontal lesions (Socransky et al. 1991b; 
Wolff et al. 1993; Ximenez-Fyvie et al. 2000b). Higher proportions of this organism 
were found in suppurating periodontal pockets (Dzink et al. 1983) and in abscess sites 
(Hafstrom et al. 1994). Nevertheless, there is conflicting evidence which does not
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support an association between P. intermedia and clinical parameters in chronic 
periodontitis patients (Christersson et al. 1992; Doungudomdacha et al. 2001).
1.5.4 Treponema denticola
Treponema denticola is a gram-negative, anaerobic, helical-shaped, highly motile 
microorganism that is common in many periodontal pockets, and is classed as a 
spirochaete. Although T. denticola was found in dental plaque from children with no 
inflammatory periodontal disease (Barron et al. 1991; Ashimoto et al. 1996), this does 
not preclude its pathogenicity. A positive relationship between T. denticola and severe 
periodontitis has been demonstrated (Simonson et al. 1988, 1990). A further study 
confirmed that T. denticola was associated with severe chronic periodontitis and 
suggested that this organism may be useful as a prognostic marker for disease recurrence 
(Simonson et al. 1992). Adults with no periodontal disease were unlikely to harbour 
spirochaetes of any kind in dental plaque, whereas patients with periodontitis had 
spirochaetes in both supragingival and subgingival plaque (Riviere et al. 1992). In this 
study, spirochaetes including T. denticola were more common in diseased sites and in
subgingival plaque than in healthy sites or in supragingival plaque.
Spirochaetes were predominant in plaques from patients with chronic periodontitis 
(Loesche et al. 1985) and T. denticola has been detected more frequently in deeper than 
shallower pockets (Simonson et al. 1988; Kigure et al. 1995; Haffajee et al. 1998; 
Socransky et al. 1998; Ximenez-Fyvie et al. 2000b). Nevertheless, this pathogen has 
also been detected in supragingival deposits, although in lower proportions than 
subgingivally (Ximenez-Fyvie et al. 2000b). The proportion of spirochaetes increases 
in the apical part of pockets in chronic periodontitis patients (Omar et al. 1990). 
However, a high proportion of spirochaetes were found at some coronal levels of the 
pockets and this could be due to the fact that either spirochaetes are inhabitants of this 
part of the pocket or they are translocated passively by the inflammatory exudate. This 
finding is in agreement with that of another study, which showed that most organisms 
isolated from pockets with recent bone loss including spirochaetes failed to show a 
difference between shallow and deep pocket depth (Tanner et al. 1984). A study by
Kigure et al. (1995) found that T. denticola was predominant in the superficial layers of
the subgingival plaque in advanced chronic periodontitis patients. At pocket depths of 2 
to 4 mm and 4 to 6mm, P. gingivalis was located beneath the surface of subgingival
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plaque while T. denticola was found in the surface of the samples. Nevertheless, the 
simultaneous presence of both bacteria was noticed at pocket depths exceeding 6 mm. 
In summary, the literature relating T. denticola to periodontal disease is consistent and 
supports a role for this fastidious anaerobe as a pathogen in periodontitis lesions.
1.5.5 Bacteroides forsythus
Bacteroides forsythus was first described in 1979, as a fusiform Bacteroides species 
(Tanner et al. 1979). This organism is slow-growing and is a gram-negative anaerobic, 
spindle-shaped, highly pleomorphic rod. B. forsythus was detected by 
immunofluorescence in subgingival microbial samples from patients with refractory 
periodontitis and was found to be the most prevalent species from an array of other 
micoorganisms (Listgarten et al. 1993). In addition, this organism was recovered more 
frequently from active than from inactive periodontitis lesions (Dzink et al. 1985; 
Tanner, 1986; Lai et al. 1987; Dzink et al. 1988). Studies have associated B. forsythus 
with untreated periodontal disease as well as recurrent periodontitis in treated patients 
and with relatively high numbers subgingivally (Lai et al. 1987). It has been 
demonstrated in several studies that this organism is more frequently detected in deeper 
than in shallower pockets (Gmiir et al. 1989; Socransky et al. 1991b; Haffajee et al. 
1998; Socransky et al. 1998; Ximenez-Fyvie et al. 2000b). However, B. forsythus was 
found in supragingival deposits although at lower counts and proportions than in 
subgingival plaque (Ximenez-Fyvie et al. 2000b). This species has also been detected 
in dental plaque from children with no periodontitis (Ashimoto et al. 1996; Kamma et 
al. 2000). Thus, although the evidence supporting B. forsythus as a periodontal 
pathogen is strong, more evidence is required to clarify the role of this species in the 
pathogenesis of periodontal diseases.
1.5.6 Coexistence of Porphyromonas gingivalis, Treponema denticola and 
Bacteroides forsythus
Socransky et al. (1998) demonstrated associations among bacterial species at 
periodontal sites using cluster analysis and community ordination techniques. The 
presence and levels of 40 species in subgingival plaque samples were determined using 
the checkerboard DNA-DNA hybridization technique. Five microbial complexes were 
identified and the species that comprise two of these complexes, the “red” and the 
“orange” are depicted in Table 3. The cluster of bacteria which consisted of P.
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gingivalis, T. denticola and B. forsythus was designated as the “red complex” and was 
strongly related to the severity of periodontal disease, in particular to pocket depth and 
bleeding on probing. This finding is in agreement with other investigators who 
examined the relationship between pocket depth and members of the red complex 
(Gmiir et al. 1989; Simonson et al. 1992; Kigure et al. 1995; Haffajee et al. 1998; 
Ximenez-Fyvie et al. 2000b). In the study of Socransky et al. (1998), 64% of sites were 
found to be negative for any of these species, while 10% of sites harboured all three 
microorganisms.
Haffajee et al. (1998) demonstrated that some species of the red complex, {P. gingivalis, 
T. denticola and B. forsythus) were more prevalent and present in higher numbers in 
periodontitis subjects when compared with well-maintained elder and healthy 
individuals. Nevertheless, the shallow sites of the periodontitis patients harboured these 
organisms more frequently than similar sites in subjects in the other two periodontally 
healthier groups. The authors hypothesised that the detection of these pathogens in 
healthy sites of the diseased subjects may be due to infection originating from the 
infected deeper sites or as a result of the initial colonisation by these species.
1.6 Humoral immune response in periodontal disease
The role of microbial plaque in initiating periodontal disease has been demonstrated by 
several studies. In addition, the humoral immune response to periodontal pathogens is 
widely reported in the literature and a summary of these findings is attempted in this 
section. By studying the systemic and local antibody responses to putative periodontal 
pathogens, we hope to be able to detect changes from colonisation to infection or from 
disease to recovery such that they may provide diagnostic utility. The immune response 
consists of the innate response, which has no immunological memory and is not specific 
for any microorganism and the adaptive response, which targets and eliminates specific 
pathogens. The innate response represents the first line of defense and is activated in a 
short period of time after having no previous contact with the pathogen. In contrast, the 
adaptive response is specific and evolves after encountering a specific microorganism. 
Most of the pathogens that challenge the host are dealt with by the innate response. 
However, when this fails to succeed the adaptive response takes over via both the 
cellular and humoral immune responses. The humoral immune response involves 
antibodies that target specific microorganisms and memory cells that boost the response
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Table 3. Microbial members of the “red” and “orange” complexes.
Red complex Orange complex 
Closely related species:
Bacteroides forsythus Fusobacterium nucleatum ss nucleatum 
Fusobacterium nucleatum ss polymorphum 
Fusobacterium nucleatum ss vincentii
Porphyromonas gingivalis Fusobacterium periodonticum
Treponema denticola Prevotella intermedia
Prevotella nigrescens
Peptostreptococcus micros
Associated species:
Eubacterium nodatum
Campylobacter rectus
Campylobacter showae
Streptococcus constellatus
Campylobacter gracilis
Microbial species that comprise the red and orange complexes, as described by Socransky et al. (1998).
to infection with the same pathogen. Both the antigen-binding domain and the constant 
region of the immunoglobulins perform a variety of functions that protect the host from 
oral diseases. Binding of the antibody to the antigen can kill bacteria or viruses and 
reduce toxins. The constant regions of the antibodies can opsonise pathogens for 
increased phagocytosis, activate complement, cause chemotaxis of phagocytes, 
inactivate viruses and cause lysis of some bacteria. However, despite the protective role 
of the antibody responses against infection, microorganisms often trigger defense 
mechanisms that eventually harm the host.
The humoral immune response to periodontal pathogens has a systemic and a local 
aspect, producing antibodies found in serum and GCF, respectively. Three models of 
the host response to periodontopathogens have been proposed that highlight the 
relationship between local and systemic immune responses (Kinane et al. 1999b). The 
antigens in dental plaque challenge the host as they pass through the junctional 
epithelium and spread within the underlying tissues. They are then processed by cells of 
the innate response and antigen presenting cells travel via lymphatics and reach the 
lymph nodes, where the adaptive immune response is activated and B-cells are 
stimulated. Model 1. Stimulated B-cells produce plasma cells, which then secrete 
antibodies. Antibodies leave the lymph nodes and travel via blood vessels back to 
gingiva where they are excreted into the gingival crevice via the dilated blood vessels. 
In the gingival crevice, antibodies cause aggregation, precipitation, detoxification, 
opsonization, phagocytosis and kill the pathogens. Model 2. Activated B-cells, T-cells 
and plasma cells leave the lymph nodes and home to the local gingival tissues via the 
blood vessels. Chemokines and microbial molecules recruit these cell types to the 
inflamed connective tissue where plasma cells produce antibodies. Antibodies are then 
exuded in the GCF to encounter the pathogens. Model 3. Precursor plasma cells leave 
from the lymph nodes and travel via blood vessels and home and lodge in the gingival 
tissues, from where they proliferate and produce specific antibodies to the plaque 
antigens. Specific antibodies are then excreted in the gingival crevice where they 
encounter periodontal pathogens and provide protection against them.
It has been demonstrated that the infiltrating lymphocytes in the inflamed periodontal 
tissues (gingiva and granulation tissue) were more likely to originate through selective 
homing rather than local proliferation (Takahashi et al. 1996; Koulouri et al. 1999).
13
Therefore, these data point towards model two as the most likely mechanism of the 
immune response involved in the local periodontitis lesion.
1.6.1 Antibody function
Antibody avidity is a measure of the net binding strength between multivalent antigens 
and polyclonal antibodies. It reflects the functional activity of the antibodies and as a 
consequence, the maturation of the immune system. It has been shown that antibodies 
of high avidity are protective against disease and the evidence for this statement is 
summarised in this section.
In a cross-sectional study, O’Dell and Ebersole (1995) examined antibody avidity in: 1) 
non-periodontally affected subjects, 2) A. actinomycetemcomitans-infected chronic 
periodontitis patients, 3) A. actinomycetemcomitans-infected localised aggressive 
periodontitis patients, 4) chronic periodontitis patients with various antibody patterns 
and disease presentation. It was shown that although there were significantly higher 
antibody levels in A. actinomycetemcomitans positive patients than in chronic 
periodontitis patients and healthy subjects, there were no significant differences in the 
antibody avidity among them. A trend for avidity to correlate with the number of 
disease active sites (sites with attachment loss) and pocket depth was noted for the 
patient groups. These observations imply that there is a relationship between active 
disease and the presence of antibodies of high avidity. Therefore, antibody avidity to A. 
actinomycetemcomitans could help to explain the relationship between the host response 
and chronic infection with this pathogen.
Similarly, Mooney et al. (1993) showed that IgG antibody avidities to P. gingivalis and 
A. actinomycetemcomitans were not significantly higher in periodontitis patients than in 
control subjects. However, this study did not examine whether these subjects were 
infected with the homologous organisms. The authors suggested that antibody avidity 
could have prognostic value, by demonstrating significantly higher IgM antibody avidity 
to P. gingivalis in patients who did not experience attachment loss during a three month 
study period than in those who did.
In addition, Holbrook et al. (1996) found that antibody avidity to suspected 
periodontopathogens was higher in refractory patients than in age- and sex-matched
14
control subjects. IgG, IgA and IgM avidities to P. gingivalis and IgG to A. 
actinomycetemcomitans were higher in patients than in controls, probably as a result of 
the regular recalls for hygiene therapy before baseline, which may have boosted their 
immune response.
Lopatin et al. (1991) demonstrated that IgG antibody avidity to P. gingivalis was 
significantly elevated in chronic periodontitis patients compared to healthy individuals, 
while no differences existed in IgM antibodies. This could be a result of repeated 
antigenic exposure of periodontitis patients to P. gingivalis during the chronic process 
o f disease, whereas IgM failed to reveal any differences between patient and control 
sera, since this class of antibody is not representative of the maturation of the immune 
system. Although, a significant increase in IgG antibody avidity was seen in the patient 
sera, avidity was extremely low when compared to the avidity levels obtained in rabbits 
after immunisation with P. gingivalis. The authors hypothesised that the reason for 
human antibodies of low avidity might be that when putative periodontal pathogens are 
present at sites, they consume the high avidity antibodies and remove them from the 
circulation. However, this study showed that the control subjects exhibited antibodies 
of lower avidity than the patients. The latter are expected to have a greater potential for 
antibody consumption than the former and therefore, it seems unlikely that this 
occurred. In addition, this potential action of antibodies should have a greater impact on 
the local synthesis of antibodies (in GCF) rather than the systemic (in serum). Other 
explanations for this could be high antigenic load (Adkinson et al. 1979), chronic 
exposure to the antigens (Kuriyama, 1973), or in utero tolerisation to bacterial antigens 
(Fitzgerald et al. 1988).
In contrast, Saito et al. (1993) found that periodontally healthy individuals exhibited 
higher antibody avidity to the fimbria antigen of A. actinomycetemcomitans than did 
chronic periodontitis patients. A statistically significant negative correlation existed 
between titres and avidities in healthy individuals and in A. actinomycetemcomitans 
culture-positive patients, while a positive correlation was found between titres and 
avidities in A. actinomycetemcomitans culture-negative patients. These data suggest 
that the antibodies produced against the fimbria antigen of A. actinomycetemcomitans 
may provide protection against infection with this organism.
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Chen et al. (1991) analysed the sera of generalised aggressive periodontitis patients and 
healthy subjects for IgG antibodies reactive with three antigens of P. gingivalis. It was 
demonstrated that antibody avidity to all antigen preparations to P. gingivalis were 
lower in the sera of patients than in the control sera. This finding indicates that 
individuals who are resistant to generalised aggressive periodontitis are able to elicit an 
immune response that produces lower antibody titres, but antibodies of higher avidity. 
In addition, this study revealed a statistically significant positive correlation between 
antibody titres to whole-cell antigens and both mean pocket depth and bone loss, and a 
significant negative correlation between antibody avidity to whole-cell antigens and 
mean bone loss and pocket depth. These findings implied that as avidity increases the 
severity of periodontal disease decreases. Data from Whitney et al. (1992) demonstrated 
that in generalised aggressive periodontitis patients, IgG antibodies were of low avidity. 
Antibody avidity was higher in the seropositive healthy subjects and it was not different 
between seropositive and seronegative patients. However, no correlation existed 
between antibody avidity and severity of periodontal disease with respect to pocket 
depth or radiographic bone loss in the patient group.
Studies have shown that elevated antibody avidity in healthy controls may reflect 
chronic exposure to putative periodontal pathogens, while other investigations failed to 
show significant differences in antibody avidity between healthy and periodontitis 
subjects. Nevertheless, the majority of the literature consistently points to the protective 
role of high avidity antibodies from infection, by demonstrating antibodies of lower 
avidity in the sera of periodontitis patients than in the healthy controls.
1.6.2 Systemic antibody responses
Increasing IgG antibody levels to A. actinomycetemcomitans have been shown to 
correlate with an increase in the number of infected sites (O'Dell and Ebersole, 1995). 
Saito et al. (1993) demonstrated that patients with no cultivable A. 
actinomycetemcomitans exhibited higher serum IgG titres to the fimbria antigen than 
did those from whom A. actinomycetemcomitans was cultivated. The authors 
speculated that antibodies against the fimbria antigen contributed to the clearing of A. 
actinomycetemcomitans from the periodontal pockets. Mooney et al. (1993) showed 
that IgG and IgA antibody titres to P. gingivalis were higher in periodontitis patients 
than healthy controls, while Holbrook et al. (1996) found that only IgA antibody titres to
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P. gingivalis were higher in refractory patients than in controls. In another study, it was 
demonstrated that mean IgG antibody titres to P. gingivalis were significantly elevated 
in the sera of patients with chronic periodontitis (Lopatin et al. 1991). However, no 
differences were found in IgM antibody titres. Since the antibodies to P. gingivalis 
were of low avidity, it appeared that the presence of elevated antibody titres may have 
reflected the presence of increased levels of microorganisms in the pocket and, thus the 
ineffectiveness of the immune response to clear the periodontal pathogens.
In another study, 36 patients with generalised aggressive periodontitis were recruited, of 
whom 12 showed antibody titres to P. gingivalis whole-cell antigens at least two-fold 
greater than the median of the healthy individuals, and were designated as seropositive, 
while the remaining 24 patients were seronegative (Chen et al. 1991). A significant 
negative correlation was found between antibody titres and avidities for the seropositive, 
but not for the seronegative patients, indicating that while the titres were high for the 
seropositive subjects, the avidities were low. During the course of disease one-third of 
the patients produced high levels of antibodies, but these were of low avidity to P. 
gingivalis, which one may consider unlikely to protect against infection. The remaining 
two-thirds of patients did not seem to raise a biologically functional immune response, 
as levels and avidities of antibodies were lower than those of the healthy controls. In 
addition, mean percentage bone loss was significantly greater for the seropositive than 
the seronegative patients. This observation raises many questions, but it is clear that 
elevated antibody titres and low avidities may not be protective and indicate disease and 
pathogen exposure. In addition, it is possible that seropositive patients could have been 
exposed to disease for a longer period of time, or that disease progression in this group 
might have been more rapid.
It has been shown that serum IgG levels to A. actinomycetemcomitans strain Y4 were 
associated with localised aggressive periodontitis (Ebersole et al. 1982b). Serum and 
salivary IgA and serum IgE antibody levels were related to generalised and localised 
aggressive periodontitis. These responses were specific to the Y4 strain. The authors 
suggested that monitoring the antibody responses may help us diagnose and differentiate 
different types of periodontal disease. Another study reported low levels of antibodies 
to P. gingivalis in periodontally healthy children and adults and higher levels of IgG 
antibodies in sera of patients with chronic and generalised aggressive periodontitis than
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in adult healthy controls (Mouton et al. 1981). However in this study, half of the 
diseased patients showed low antibody levels to P. gingivalis and the authors speculated 
that this could be a result of: 1) pathogenic bacteria other than P. gingivalis that 
predominate in the periodontal pocket and elicit an immune response, 2) fluctuations in 
the subgingival microflora leading to periods with low numbers of P. gingivalis and 
specific antibodies, 3) infecting organisms causing immunosuppression and production 
of low levels of antibodies. Ebersole et al. (1986) found elevated serum IgG antibody 
titres to P. gingivalis in advanced chronic periodontitis patients, which is consistent with 
data from the study by Mouton et al. (1981). In addition, increased IgG antibody levels 
to P. intermedia were shown in the advanced periodontitis patients and elevated 
systemic antibody responses to Bacteroides species were more frequently found in 
periodontitis patients, possibly reflecting colonisation by these organisms.
In contrast, Whitney et al. (1992) assessed the immunological parameters of generalised 
aggressive periodontitis patients and compared them with those of healthy individuals. 
It was found that a proportion of healthy controls had significantly elevated serum IgG 
antibody levels to P. gingivalis. This finding might be due to the fact that these subjects 
were exposed to the bacteria at some time and had elicited an immune response to the 
antigens but did not have detectable clinical signs of disease, or that the antibodies of 
high avidity found in these seropositive controls protected them from clinical disease. A 
significant positive correlation was found between IgG anti -P. gingivalis titres and 
severity of bone loss, but not pocket depth in the seropositive patients, indicating that 
the high levels of antibodies may not be protective. In contrast, another study 
demonstrated that more than 81% of patients with destructive periodontitis exhibited 
elevated antibody to at least one of the 18 microorganisms tested, but no pattern of 
elevated antibody responses could be directly related to the severity of attachment loss 
(Haffajee et al. 1988a).
IgG antibody reactivity to A. actinomycetemcomitans and P. gingivalis has been shown 
to be inversely related to the number of affected teeth, but did not correlate with 
attachment loss in patients with localised and generalised forms of aggressive 
periodontitis (Gunsolley et al. 1987). This finding indicates that the failure to mount an 
increased antibody response to these organisms leads to more widespread periodontal 
disease. Other reports linked only elevated levels of anti- P. gingivalis IgG antibodies
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to the degree of periodontal destruction in chronic periodontitis patients (Naito et al. 
1985; Gmiir et al. 1986). The lack of agreement in the relationship between antibody 
titres and clinical severity among various studies could be explained by differences in 
the disease severity measurements, limitations in detecting clinical changes by 
conventional clinical assessment techniques, high variability among patients who have 
different types of periodontal disease and relatively small sizes of patient groups.
IgG antibody titres to P. gingivalis and B. forsythus in chronic and aggressive 
periodontitis patients have been investigated (Califano et al. 1997). It was shown that 
antibody titres to B. forsythus were quite low with no significant differences between the 
periodontitis groups and the healthy individuals, while levels of antibody to P. 
gingivalis were significantly higher in the periodontitis patients than in the controls. 
Periodontitis patients and healthy controls showed the same percentage of subjects 
seropositive and seronegative to B. forsythus, whereas a higher percentage of P. 
gingivalis seropositive subjects was seen among the periodontitis patients than the 
controls. The low antibody response to B. forsythus, could be explained by the possible 
absence of this organism in many patients or by the inability of this organism to invade 
host tissues and thus provoke a substantial immune response. As the detection 
frequency of B. forsythus is relatively high in chronic periodontitis patients, and since 
this organism is usually found with P. gingivalis, the former explanation seems unlikely. 
The results of this report showed that B. forsythus elicited an antibody response in a 
small percentage of patients and based on these data the authors questioned the 
pathogenic role of B. forsythus in periodontal disease.
It has been shown that among patients exhibiting destructive periodontal disease, 
clinical characteristics, predominant cultivable microorganisms and antibody levels 
differed, suggesting the existence of different patterns of disease in these subjects 
(Haffajee et al. 1988a). Taubman et al. (1992) monitored clinical and immunological 
parameters of subjects with prior periodontal disease over five years. The majority of 
the subjects showed elevated antibody levels to 18 subgingival species and these 
remained fairly constant over time. Fluctuations in the antibody response were noted for 
only a few species. The authors speculated that elevated antibody titres could be a result 
of bacteraemias caused by the pathogens, increases in the antigenic burden in the 
gingival tissues, invasion of the pathogens in host tissues during the destructive process
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or inoculation of the antigens during therapy. Alternatively, a decrease in the antibody 
levels may originate from therapeutic elimination of the bacteria or host-mediated 
reduction of the antigens.
In summary, most studies tend to agree that elevated serum antibody levels reflect 
exposure to periodontal pathogens, since this was a common finding in periodontitis 
patients. In addition, there seems to be agreement that elevated antibody levels in 
conjunction with low antibody avidity reflect a compromised host response to bacterial 
challenge and therefore a susceptibility to disease initiation or progression.
1.6.3 Site-specific antibody responses
Studies have shown that IgG, IgA and IgM antibodies are present in GCF (Brandtzaeg, 
1965) and that serum immunoglobulins infiltrate the interstitial fluid in inflamed 
gingival tissues and are excreted in the gingival crevice (Challacombe et al. 1978). 
Aspects of both systemic and mucosal immune responses are involved in periodontal 
disease. Kinane et al. (1999b) demonstrated that the lesion near the gingival margin 
presented features of a mucosal immune response with predominance of IgA expressing 
plasma cells and the deeper granulation tissue showed elements of a systemic response 
with the presence of plasma cells expressing IgG and IgM antibodies. GCF antibodies 
are both serum derived (Ebersole et al. 1986, 1987) and produced locally by plasma 
cells in the diseased periodontal tissues (Ebersole et al. 1985a, 1985b). Aspects of the 
local immune responses, such as the association of GCF antibodies with the presence of 
homologous bacteria, the specificity of the local responses and the correlation between 
GCF antibody levels and disease activity have been investigated in several studies. 
Their findings are summarized in this section.
An early report revealed site-to-site variations in GCF antibody levels in the oral cavity 
of periodontally diseased patients (Ebersole et al. 1984). At certain sites local antibody 
levels exceeded those of the systemic circulation, indicating synthesis of specific local 
antibody in gingival tissues. Other studies by the same investigators confirmed previous 
findings and suggested that a local host response against microorganisms colonising 
different sites may be detected by monitoring antibody levels in the crevicular fluid 
(Ebersole et al. 1982a, 1985a). In accordance with these data, Tew et al. (1985) found a 
marked site-to-site variability in local antibody synthesis among different sites of similar
20
clinical status. Although antibody titres in GCF to most strains were lower than those in 
serum, local antibodies to P. gingivalis and A. actinomycetemcomitans were often 
markedly higher than systemic antibodies, indicating local synthesis of specific 
antibodies to these organisms.
Local responses seem to be at least as specific as serum responses against the test 
bacteria (Ebersole et al. 1984; Smith et al. 1985). The coexistence of local antibody, 
homologous organism and active disease suggests that GCF antibodies are the result of 
specific local challenges in diseased subjects (Ebersole et al. 1982a). Lally et al. (1980) 
investigated the specificity of the local antibody response in periodontal disease and 
suggested that IgG is the predominant immunoglobulin isotype produced in chronically 
inflamed gingival tissues. In addition to IgG, the synthesis of IgA was also 
demonstrated, but not that of IgM. No immunoglobulin antibody synthesis was detected 
in histologically normal gingival tissue or in fibrotic tissue. These results indicate that 
there is local antibody production in diseased gingival tissues and that this response is 
specific. Additional data confirmed that a significant portion of the antibody found in 
the gingival crevice is locally produced (Smith et al. 1985). The authors also showed 
that there was no evidence of IgM in the gingival homogenates. All the subjects who 
exhibited high GCF antibody levels also demonstrated elevated IgG antibody 
concentration in the corresponding gingival homogenates, but antibodies in the GCF 
were at lower levels than those in the gingival homogenates. This may have been due to 
consumption of local antibodies by the organisms present in the pockets.
It has been suggested that serum antibody levels that exceed certain thresholds indicate 
an increased likelihood of disease activity, which takes place at some site in the oral 
cavity (Taubman et al. 1992). Therefore, it may be beneficial to measure the antibody 
levels to that species at the local sites, so that areas of active disease can be detected. 
Johnson et al. (1993) investigated the relationship between GCF antibody levels and 
local disease status of patients with generalised aggressive periodontitis. It was 
demonstrated that GCF volume and specific local antibody levels were positively 
correlated with probing depth, indicating that deeper pockets gave rise to more GCF and 
to higher levels of antibody to P. gingivalis. Results from previous studies are 
consistent with this finding (Naito et al. 1984; Murray et al. 1989). However, other
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studies have failed to correlate clinical disease status with elevated anti -P. gingivalis 
antibody levels in GCF (Tew et al. 1985; Baranowska et al. 1989).
GCF levels of IgG antibody have been shown to be lower in deep periodontal pockets 
than in gingivitis sites in the same patient (Mooney and Kinane, 1997). Increased 
consumption of locally produced antibody in periodontitis sites may be responsible for 
this difference. Periodontitis sites had lower levels of inflammation, deeper pockets and 
greater GCF volumes than gingivitis sites. Nevertheless, if  levels of GCF antibody were 
related to volume collected, then higher median levels would be expected in 
periodontitis sites than gingivitis sites, but in that study antibody levels were expressed 
as amounts per 30-second sample. Another report from the same laboratory 
demonstrated lower antibody levels to P. gingivalis at sites with deeper pocket depth 
(pocket depth > 4 mm) and greater gingival index (GI > 3) in a group of chronic 
periodontitis patients (Kinane et al. 1993). Moreover, GCF IgG antibody levels against 
A. actinomycetemcomitans did not differ between sites with different pocket depths and 
gingival indices. However, it should be borne in mind that the diseased subjects in this 
study were maintenance patients who had received extensive treatment in the past and 
were therefore not strictly comparable with other groups of periodontitis patients or with 
untreated patients. These findings highlight the protective role of the local immune 
response and suggest that a failure of local antibody production or reduced amounts of 
GCF antibodies due to consumption within the pocket may reflect or contribute to the 
change from a gingivitis to a periodontitis lesion. Having said this, however, the 
increase in plasma cell density in periodontitis lesions is a significant difference from 
gingivitis lesions and more production of antibodies would be expected.
1.6.4 Correlation of antibody titres with the presence of homologous subgingival 
microorganisms
Several studies investigated the relationship between serum antibody titres against 
pathogens and the subgingival detection of the homologous microorganisms. It was 
found that serum antibody levels reflect the subgingival colonisation and infection with 
periodontal pathogens. This could be fundamental in the early diagnosis and prevention 
of subjects suffering from episodes of active disease.
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Kojima et al. (1997) demonstrated that serum anti-P. gingivalis IgG antibody titres 
correlated positively with the detection frequency of P. gingivalis and that the antibody 
titres also correlated with the amount of P. gingivalis detected subgingivally. Although 
higher levels of P. gingivalis were seen in aggressive periodontitis than chronic 
periodontitis patients, no significant differences in the antibody levels existed between 
the two types of periodontal disease. However despite this, the functional properties of 
antibodies may vary between the different forms of periodontal disease. In addition, it 
has been shown that serum IgG antibody levels to P. gingivalis were positively 
correlated with the presence of P. gingivalis subgingivally but this did not apply to the 
other bacteria tested, including A. actinomycetemcomitans and P. intermedia (Nakagawa 
et al. 1990). Choi et al. (1990) found a close relationship between elevated serum 
antibody responses and homologous infection with P. gingivalis in recurrent sites, 
implying that this species might be important in the pathogenesis of the early stages of 
recurrent periodontal disease.
Similarly, another study reported a strong correlation between elevated serum and local 
antibody levels and subgingival colonisation of pathogens (Ebersole et al. 1982a). In a 
later study, the same authors attempted to determine whether elevated serum antibody 
levels to at least one species from a range of 18 oral microorganisms reflected 
homologous bacterial colonisation at active disease sites (Ebersole et al. 1987). The 
results of this study demonstrated that the microorganism to which the subjects 
exhibited elevated serum antibody responses was detected in nearly 55% of the disease 
active sites, while only 18% of the inactive sites harboured this microorganism. These 
results suggest that elevated antibody levels exist as a response to bacterial infection at 
disease active sites. Another study investigated the antibody responses in a distinct 
subset of periodontitis patients infected with A. actinomycetemcomitans (Ebersole et al. 
1995). Active disease patients exhibited a significantly greater frequency of infected 
sites, as well as a significant elevation in the proportions of A. actinomycetemcomitans. 
The IgG antibody levels were significantly elevated in subjects with active disease, 
whereas IgA antibody titres were low in a number of the disease active patients. Plaque 
samples taken from active sites showed an increase in A. actinomycetemcomitans that 
occurred between two and six months prior to the identification of disease activity. 
Approximately 70% of the active disease group showed an increase in IgG antibody 
level between two and four months prior to disease activity. In an earlier study by the
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same authors, the effect of root planing on the humoral immune response to suspected 
periodontal pathogens was assessed and the microbial species to which the elevated 
antibody responses were targetted, were detected in the subgingival plaque of patients 
(Ebersole et al. 1985c).
However, other investigators failed to associate high serum antibody levels with bacteria 
that were found subgingivally in a large family with a high prevalence of aggressive 
periodontitis (Williams et al. 1985). Conversely, putative periodontal pathogens of 
relatively large proportions subgingivally were found in the absence of elevated serum 
antibody titres. It appears that the bacterial colonisation does not necessarily lead to 
infection and production of protective levels of antibodies. This coincides with findings 
of Magnusson et al. (1991), who suggested that the failure to detect the homologous 
microorganisms subgingivally in subjects with refractory periodontal disease could be 
due to the fact that the microorganisms had been successfully eradicated by the intense 
therapy although, the persistence of disease would not support this conclusion.
Similarly, it has been suggested that the lack of association between antibody levels and 
the counts of homologous bacteria in subgingival plaques could be explained as follows: 
either the tested bacteria were eliminated by the host response or they were not 
pathogenic (Haffajee et al. 1995). However, the authors did not consider the possibility 
that the organisms tested may not elicit a host response with the production of specific 
antibodies (i.e. they were not so immunogenic), as an explanation for the lack of relation 
between antibody levels and homologous presence of bacteria. The authors suggested 
that the combination of high antibody titres to a species and the high prevalence of that 
species might be indicative of disease activity and progression. In addition, Whitney et 
al. (1992) failed to find a significant relationship between the presence of P. gingivalis 
and antibody titres of the IgG subclass or total IgG in generalised aggressive 
periodontitis patients, implying that some subjects in this group of patients did not 
respond to homologous infection by producing high levels of antibodies.
Conflicting data exist on whether elevated antibody levels reflect infection with the 
homologous organisms, since cross-reactions are common between gram-negative 
bacilli from both the oral and enteric environment. Several studies have however 
correlated antibody levels with the detection of specific organisms in periodontal
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pockets. Possible explanations for lack of agreement among studies may be that certain 
species are less pathogenic or less immunogenic (able to elicit a substantial immune 
response) than others, or that these species are eliminated or suppressed by the host 
response. Other factors that may contribute to these inconsistent findings are variations 
in the patients’ clinical condition and in the disease duration within the patients.
1.7 Untreated periodontal sites or other intra-oral niches constitute a reservoir of 
infection for periodontal pathogens
1.7.1 One-stage full-mouth disinfection
Non-surgical periodontal treatment typically comprises several consecutive sessions of 
scaling and root planing per quadrant or sextant at one or two-weekly intervals. 
Quirynen et al. (1995) introduced the one-stage full-mouth disinfection programme 
where they compared the clinical and microbiological effects of this treatment strategy 
with the more typical treatment of quadrant scaling and root planing at two-weekly 
intervals. The rationale behind this treatment was to prevent re-infection of the treated 
sites from the remaining untreated pockets and from other intra oral niches. The same 
investigators conducted a series of clinical trials between 1995 and 2000 and an attempt 
is made to give the background of the one-stage full-mouth disinfection treatment in this 
section.
The clinical design of the pilot study of Quirynen et al. (1995) was as follows: the 
control group (five subjects) received quadrant scaling and root planing at two-weekly 
intervals with no use of antiseptics while the test group (five subjects) received full- 
mouth scaling and root planing within 24 hours, together with repeated application of 
chlorhexidine to all intra oral niches. Patients in the test group were treated in two visits 
on consecutive days under local anaesthesia (i.e. teeth in the lower arch were 
consistently root planed in an afternoon session and the upper arch was treated the 
following morning). Shortly after root planing of each jaw, the following measures 
were applied to achieve optimal intra-oral disinfection: 1) the dorsum of the tongue was 
brushed with chlorhexidine 1% gel for 1 min (by the patients), 2) the oral cavity and 
tonsils were rinsed twice with chlorhexidine 0.2% solution for 1 min (the last 10 sec 
patients had to gargle), 3) the periodontal pockets were irrigated (three times within 10 
min) with chlorhexidine 1% gel (using a syringe with a blunt needle) and were 
repeatedly irrigated at day eight. In addition, patients were advised to rinse twice daily
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for 1 min with a 0.2% chlorhexidine mouthwash for the first two weeks after treatment. 
Participants were asked to complete a questionnaire after scaling in order to record any 
adverse effects after scaling such as increases in body temperature, pain score on a scale 
between zero and ten and number of painkillers they took. In addition, occurrence of 
oral ulcers and labial herpes was also recorded. Clinical parameters were measured and 
subgingival plaque samples were collected from the first quadrant only at baseline prior 
to root planing and at one and two months. The results showed a significantly greater 
mean pocket depth reduction of 0.8 mm for the test group compared to the control group 
at the two-month visit, but this was noted only for deep pockets (7 to 8 mm). The test 
group showed higher body temperature and higher occurrence of labial herpes after 
treatment.
In a follow up study, the investigators examined the same group of patients as in the 
pilot study but over a period of eight months (Vandekerckhove et al. 1996). They 
found similar results with those in their previous study. At eight months, the test group 
had a significantly greater mean pocket depth reduction of 1.0 mm and a gain in 
attachment level of 1.8 mm over the control group for the deep pockets only.
Bollen et al. (1998) examined the clinical and microbiological effects of the one-stage 
full-mouth disinfection on 16 patients who were followed over four months. The 
clinical design of the study was similar to that of previous studies except that patients 
were instructed to rinse with chlorhexidine 0.2% solution for two months instead of two 
weeks post-treatment and to spray the tonsils with 0.2% chlorhexidine spray during this 
period. The results showed that the pocket depth reduction and microbiological findings 
post-treatment were more favourable than those in the pilot study (Quirynen et al.
1995). This observation emphasises the beneficial effects of the extended use of 
chlorhexidine on clinical and microbiological parameters. When deep pockets (> 7 mm) 
were considered, the test group had an additional 1.85 mm pocket depth reduction and a 
1.20 mm attachment gain over the control group at four months.
In a subsequent study, a larger group of patients (n=40) were examined over eight 
months to determine the clinical benefits of the one-stage full-mouth disinfection 
(Mongardini et al. 1999). Patients were subdivided into two groups, chronic and 
generalised aggressive periodontitis patients. The clinical design was similar to that of a
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previous study by Bollen et al. (1998). Results showed that the test group had a greater 
1.05 mm pocket depth reduction and an extra 0.90 mm attachment gain over the control 
group for deep pockets at eight months. These improvements were found for all 
subgroups (chronic periodontitis and generalised aggressive periodontitis patients and 
smokers), while the greatest differences were noted for the non-smoking chronic 
periodontitis patients.
In a more recent study, 36 subjects were followed over eight months to evaluate the role 
of chlorhexidine in the one-stage full-mouth disinfection treatment (Quirynen et al. 
2000). The control group (n=12) received quadrant scaling and root planing at two­
weekly intervals with no use of antiseptics and the test group (n=12) received the one- 
stage full-mouth disinfection treatment (Fdis). These two groups also took part and 
were treated in the previous study of Mongardini et al. (1999). A third group of 12 
subjects was added and patients in this group received full-mouth root planing within 24 
hours with no use of chlorhexidine (FRp). At eight months, pocket depth in deep 
pockets was reduced by: 3.35 mm in the Fdis group, 3.10 mm in the FRp group and 1.75 
mm in the control group. The changes in attachment levels of deep pockets were as 
follows: 2.15 mm for the Fdis, 2.45 mm for the FRp group and 0.55 mm for the control 
goup. Similarly, the microbiological findings showed additional improvement for the 
Fdis and FRp over the control group. The differences between Fdis and FRp were 
negligible. The completed questionnaires revealed that on day one both the control and 
the FRp groups scored higher pain rating than the Fdis group, and on day two this was 
significantly higher for the FRp group compared to the Fdis group. This increase 
paralleled an increase in the intake of analgesics. Body temperature increased for 
patients in the test groups at the evening of day two but dropped again the following 
morning. Only one patient in the Fdis group had labial herpes. In conclusion, this study 
showed that the role of chlorhexidine was not critical in the one-stage full-mouth 
disinfection protocol.
1.7.2 Clinical studies that compare full-mouth versus partial-mouth treatment
Mombelli et al. (1996) tested the subgingival application of tetracycline fibres in 
subjects who received treatment at only two tested sites in comparison with individuals 
who had all their teeth treated. The tested sites had pockets deeper than 4 mm, bleeding 
on probing and were positive for P. gingivalis. Periodontal treatment consisted of
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supragingival scaling, subgingival application of tetracycline fibres and subsequent 
scaling and root planing under local anaesthesia after removing the fibres. Only patients 
who received the full-mouth treatment used chlorhexidine mouth rinse for two weeks. 
The results of this study showed that there was a greater pocket depth reduction in the 
full-mouth treatment group (1.74 mm) than in the local treatment group (0.88 mm). 
However, there was no difference in attachment level changes between the groups. This 
could be explained by the fact that the general oral hygiene status in the local treatment 
group was compromised and that there was no adjunctive use of chrohexidine in this 
treatment group. Another possibility may be that the untreated sites acted as bacterial 
reservoirs.
Nowzari et al. (1996) investigated the amount of guided tissue regeneration and 
microbial contamination of expanded polytetrafluroethylene membranes after 
periodontal surgery on two groups of patients. Group A showed no remaining pockets > 
5 mm except for the study sites and low levels of periodontal pathogens, while group B 
had several deep pockets > 5 mm and high levels of periodontal pathogens. Barrier 
membranes from group B had significantly more pathogens than group A. The authors 
were unsure whether the organisms that were recovered from the membranes were true 
colonisers or solely contaminants originating from other periodontal pockets in the oral 
cavity. It was speculated that the source of infection might originate from several areas. 
Pathogens may have been translocated from other deep pockets and contaminated the 
membranes via saliva, and the oral mucosa could have contaminated the membranes via 
sutures. The study site itself may have harboured these pathogens prior to membrane 
placement. In conclusion, this study showed that the group of patients who received 
periodontal osseous surgery and had no remaining pockets > 5 mm except for the study 
sites exhibited the lowest levels of periodontal pathogens in the membranes and the 
highest clinical attachment gains.
The effects of some oral hygiene measures on Streptococcus mutans and interproximal 
dental caries in a group of children who had high salivary levels of S. mutans has been 
investigated (Axelsson et al. 1987). Patients were divided into three groups who 
received prophylactic measures of different intensity. In group one, patients received 
the most meticulous preventive treatment which consisted of a combination of 
professional plaque control, tongue-scraping and chlorhexidine application, while the
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other two groups received less intensive prophylactic measures. Results showed that 
interdental and salivary S. mutans markedly decreased for group one, in the short-term. 
However, after six months and until the completion of the study no differences in S. 
mutans colonisation were detected among the three groups. These results suggest that 
the additional preventive measures that were provided to group one did not enhance the 
elimination of S. mutans as might have been expected. All three groups received a high 
standard of oral hygiene measures, and although in one of the groups the measures were 
more stringent, this appeared to have no clinical effect.
1.7.3 Means of intra-oral bacterial translocation
Numerous studies, in addition to the clinical trials on the one-stage full-mouth 
disinfection, attempted to test the hypothesis that intra-oral transmission of pathogens 
occurs and to define the mechanisms by which this may occur. It has been shown that 
putative periodontal pathogens are frequently detected in supragingival plaque deposits 
(Ximenez-Fyvie et al. 2000b) and there is the potential for them to spread to uninfected 
sites or re-colonise periodontal pockets that have been previously treated (Quirynen et 
al. 1999). A study by Danser et al. (1994) failed to detect certain periodontal pathogens 
such as A. actinomycetemcomitans and P. gingivalis in edentulous patients, suggesting 
that these organisms preferably colonise periodontal pockets rather than other oral 
niches. This is in agreement with other studies, which suggest that the primary 
ecological niche for A. actinomycetemcomitans is the periodontal pocket (Slots et al. 
1980; Kononen et al. 1991). On the contrary, P. intermedia and other Prevotella 
species were recovered from the oral mucous membranes before and after full-mouth 
extractions in patients with severe periodontitis, implying that these organims may be 
commensal microorganims of the oral cavity (Danser et al. 1994). Translocation of 
microorganisms from one site to another may occur via the supragingival plaque 
deposits and also by saliva, oral hygiene aids (toothbrushes, floss, interdental brushes) 
and / or dental instruments (periodontal probes, syringe tips).
The potential of bacterial transmission from periodontally affected teeth to implants in 
partially edentulous patients was investigated by using differential phase contrast 
microscopy (Quirynen et al. 1996). The results of this study confirmed that this occurs 
and showed that higher proportions of spirochaetes and motile organisms were found 
around the implants when teeth and implants were present in the same jaw rather than
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the antagonistic jaw. In addition, pockets around teeth and implants of the same disease 
severity were found to contain a similar subgingival micro flora. The coexistence of A. 
actinomycetemcomitans in stimulated saliva and subgingival sites was demonstarted 
(Asikainen et al. 1991), and similarly, another study showed that P. gingivalis and P. 
intermedia were present in the saliva of untreated chronic periodontitis patients (van 
Winkelhoff et al. 1988). These findings imply that there is a possibility of intra-oral 
transmission of these putative pathogens via saliva.
It has been shown that S. mutans can be transmitted intra-orally with a dental explorer 
(Loesche et al. 1973, 1979) and this finding led many investigators to examine the 
potential of a periodontal probe as a means for intra-oral transmission of pathogens. 
The majority of sampled periodontal probes contained bacteria with morphologic 
characteristics of a pathogenic microflora (Barnett et al. 1981). High numbers of 
bacteria including putative periodontal pathogens were recovered from periodontal 
probes implying that an intra-oral translocation of the adhered bacteria might occur 
during probing (Papaioannou et al. 1996). A study by Preus et al. (1993) revealed that 
tips of syringes used for subgingival application of minocycline in periodontal pockets 
were contaminated with subgingival bacteria resistant to the antibiotic. These bacteria 
were found to survive on the syringe tips for up to eight days after the clinical 
procedures.
Another study showed that toothbrushes and toothpaste were infected with S. mutans 24 
hours after usage (Svanberg, 1978). It has been suggested that although there was no 
clear time of toothbrush contamination, contamination might have occurred between 
one week and one month after use (Glass and Lare, 1986). Muller et al. (1989) 
examined toothbrushes from periodontitis patients harbouring high numbers of A. 
actinomycetemcomitans subgingivally to detect contamination of the toothbrushes with 
this organism. It was shown that immediately after toothbrushing 62% of the 
toothbrushes were contaminated with A. actinomycetemcomitans while this dropped to 
50% after one hour. Significantly higher numbers of A. actinomycetemcomitans could 
be detected on the toothbrushes when the organism was present on the oral mucous 
membranes or in the saliva. Although there is evidence that oral hygiene aids can 
become contaminated with oral bacteria, it is difficult to prove whether this could result
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in inoculation of microorganisms into sites currently free of these organisms (Muller et 
al. 1989).
In conclusion, these studies suggest that dental instruments can result in translocation of 
pathogens from one site to another. However, it still remains unclear whether dental 
procedures can cause inoculation of bacteria and thus infection of new sites. This is 
supported by another study which demonstrated that A. actinomycetemcomitans can be 
transmitted by periodontal probes to healthy periodontal sites in localised aggressive 
periodontitis patients, although the pathogen was eliminated from the recipient sites in 
three weeks (Christersson et al. 1985). The authors speculated that protective 
mechanisms such as mechanical removal, bacterial antagonism, and specific or non­
specific host responses might be responsible for the elimination of the microorganism 
from the recipient gingival sulci.
1.7.4 The significance of supragingival plaque control in the maintenance of stable 
periodontal conditions and in the prevention of intra-oral bacterial transmission
Several investigators demonstrated that effective supragingival plaque control 
significantly affected the composition of the supragingival and subgingival microflora. 
Studies using darkfield microscopy showed that professional supragingival plaque 
control resulted in reduction of the motile organisms and spirochaetes in subgingival 
plaque samples (Smulow et al. 1983; Magnusson et al. 1984; Muller et al. 1986; 
McNabb et al. 1992; Katsanoulas et al. 1992), while culture techniques showed a 
reduction in the levels of bacteria including A. actinomycetemcomitans and P. gingivalis 
(Smulow et al. 1983; Dahlen et al. 1992; McNabb et al. 1992; Hellstrom et al. 1996). 
In addition to microbiological changes, improvement in clinical indices was also 
detected.
In agreement with previous studies, Ximenez-Fyvie et al. (2000a) showed that weekly 
professional supragingival plaque control in maintenance patients reduced counts of 
both supra- and subgingival species at moderately deep pockets for a period of nine 
months using checkerboard DNA-DNA hybridization technique. Haffajee et al. (2001a) 
showed that manual and powered toothbrushing resulted in significant reductions in 
pocket depth, plaque index and bleeding on probing in periodontitis patients that were 
enrolled in a maintenance programme. A follow up study by the same investigators,
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demonstrated that both toothbrushing groups exhibited reduced supra- and subgingival 
counts and prevalence of most species examined (Haffajee et al. 2001b). Nevertheless, 
a clinical study showed that during the first three months of the study plaque control 
measures alone resulted in a limited pocket depth reduction (0.4 to 0.5 mm), despite the 
low plaque scores that were achieved (Badersten et al. 1984a). This improvement was 
primarily due to gingival recession and limited improvement in bleeding scores was also 
noted. These changes were inferior to the enhanced clinical outcome following scaling 
and root planing during the subsequent three months.
It is doubtful whether supragingival plaque control affects the levels of pathogens within 
deep periodontal pockets (Listgarten et al. 1978; Kho et al. 1985; Beltrami et al. 1987; 
Loos et al. 1988). This finding suggests that the periodontal pocket is a separate 
ecological niche independent from the supragingival environment and that the nutrients 
for the subgingival microorganisms are supplied by other members of the microflora or 
by the GCF. Additional data showed no differences in the patterns of subgingival 
bacterial re-colonisation between sites under strict supragingival plaque control and 
control sites (Lavanchy et al. 1987). The authors suggested that the bacteria detected in 
the pockets following instrumentation rather than the meticulous supragingival plaque 
control measures, may play a more important role in the re-establishment of the 
subgingival microbial flora. Supragingival plaque control on its own was not shown to 
be successful in halting the progression of periodontal disease, particularly at sites with 
initial pocket depths exceeding 6 mm (Westfelt et al. 1998). Nevertheless, a reduction 
in the total number of subgingival microorganisms of the sampled sites was observed 
regardless of baseline pocket depth. Another study showed that the clinical outcome of 
supragingival treatment alone was not as favourable as that observed after subgingival 
instrumentation (Kaldahl et al. 1996a). The authors speculated that the clinical 
improvements seen at the sites which were treated only supragingivally may have 
resulted from an alteration in the subgingival microflora or from immunological 
changes caused following subgingival instrumentation in other areas of the same mouth.
In contrast, two studies showed that carefully performed supragingival plaque control 
over a prolonged period of time significantly affected the quantity and composition of 
the subgingival microflora at periodontal sites including deep periodontal pockets 
(Dahlen et al. 1992; Hellstrom et al. 1996). Similarly, it has been shown that the
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numbers of subgingival anaerobes at deep periodontal pockets were influenced by 
supragingival plaque control over 21 days of observation (Smulow et al. 1983). Lack 
of agreement among studies could be explained by differences in the patient populations 
and in the severity of disease; in the sampling frequency and sampling technique; in the 
frequency and nature of application of plaque control measures (professional plaque 
control and intensive programme of oral hygiene instruction against unsupervised self­
performed plaque control). In some of the studies mentioned, root planing was 
performed in addition to supragingival scaling.
Using an animal experimental model, it was shown that subgingival plaque formation 
could be arrested in areas that were accessible to the toothbrush (Waerhaug, 1981). 
However, optimal plaque control could not be achieved solely by toothbrushing, 
particularly at the interdental areas where supragingival deposits are most likely to 
accumulate. Mousques et al. (1980) found marked clinical and microbiological 
improvements after one-day full-mouth scaling and root planing without giving patients 
any oral hygiene instruction. Pocket depth improvement was maintained over the 90 
days of observation. However, in the absence of plaque control, subgingival microflora 
returned to baseline values with spirochaetes taking as long as 42 days to re-populate the 
sites. Similarly, Magnusson et al. (1984) showed that in presence of supragingival 
plaque a subgingival microflora with a predominance of spirochaetes and motile rods 
was soon re-established at four to eight weeks. In another study with a similar clinical 
protocol, therapy consisted of a single course of scaling and root planing and no oral 
hygiene instructions and patients were followed over eight weeks (van Winkelhoff et al. 
1987). This treatment resulted in significant probing pocket depth reduction and gain in 
attachment level. Nevertheless, no further clinical improvement was seen two weeks 
after treatment.
In conclusion, the results of the studies described above showed that optimal 
supragingival plaque control can inhibit the microbial re-population of subgingival 
pockets, which have been periodontally treated. As a result, periodontal deterioration 
can be arrested at a periodontally diseased site by controlling the plaque formation 
supragingivally, despite the presence of subgingival calculus. Nevertheless, it has been 
shown that in the presence of supragingival plaque deposits, it takes approximately 42 
days for the subgingival micro flora to shift back to pre-treatment values.
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1.7.5 The role of chlorhexidine in the treatment of periodontal disease
It has been shown that following surgery, and during the healing period, professional 
tooth cleaning was a slightly more efficacious plaque control measure compared to 
chlorhexidine mouth rinsing (Westfelt et al. 1983). Despite the fact that both 
procedures were equally effective in supragingival plaque control, pocket depth 
reduction and gain in attachment levels were slightly greater in the patients who 
received professional plaque control post-surgery. It was suggested that this may be due 
to the fact that chlorhexidine more likely had no effect on the subgingival plaque 
formation or on the microflora at deep periodontal pockets. This is in agreement with 
the results of another study, in which the effect of chlorhexidine on plaque accumulation 
and gingival conditions in a group of young adults was investigated (Flotra et al. 1972).
In addition, there is evidence that chlorhexidine irrigation (2%) of deep pockets did not 
enhance the beneficial effects of meticulous scaling and root planing and oral hygiene 
instructions (Braatz et al. 1985; MacAlpine et al. 1985). Similarly, periodic 
subgingival irrigation with chlorhexidine (0.2% solution) as a single measure of 
treatment as well as combined with mechanical debridement in patients with moderate 
to severe periodontitis was found to have only limited and temporary effect on the 
subgingival micro flora and clinical parameters in deep periodontal pockets (Wennstrom 
et al. 1987a, 1987b). It is of great interest to see that adjunctive irrigation with 
chlorhexidine or hydrogen peroxide did not improve healing to a greater extent than that 
obtained after mechanical treatment alone or in combination with saline irrigation. 
Additional data showed that the effects of a single professional subgingival irrigation 
with antimicrobial agents (0.12% chlorhexidine, 5% tetracycline) or saline did not result 
in a greater reduction of A. actinomycetemcomitans, P. gingivalis and P. intermedia, 
compared to that achieved by meticulous scaling and root planing (Shiloah and Patters, 
1994). In a follow up study, the adjunctive use of these antimicrobials was not shown to 
affect the rate of re-population of periodontal pockets (> 5 mm) by these species 
(Shiloah and Patters, 1996).
In contrast, chlorhexidine 2% gel was found to significantly reduce the number of black 
pigmented Bacteroides species by 99% within 30 min of application in 5-9 mm deep 
periodontal pockets. However, whether this short-term effect of chlorhexidine on the
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subgingival microflora is significant in the maintenance of periodontitis patients still 
needs clarification (Oosterwaal et al. 1991). The beneficial effect of the use of 
chlorhexidine (0.2% solution) in periodontitis patients who received supragingival 
debridement and no oral hygiene instructions over a two-month period has been 
demonstrated (Soh et al. 1982). Using a similar study design, Haskel et al. (1986) 
demonstrated that the subgingival irrigation with chlorhexidine 0.2% solution in 
moderate chronic periodontitis patients had a transient microbiological effect and 
limited clinical benefit. Another study demonstrated that 2% chlorhexidine irrigation of 
deep pockets (> 6 mm) as a sole therapy was nearly as effective as scaling and root 
planing, in terms of clinical improvement and reduction in the levels of P. gingivalis 
(Southard et al. 1989). However, the combination of these therapies resulted in an 
enhanced attachment gain and a further reduction in the levels of P. gingivalis. It 
should be stressed, however, that the protocol of this study included no reviews or oral 
hygiene instructions throughout the monitoring period (15 weeks).
It has been demonstrated that a single subgingival irrigation with chlorhexidine (0.2% 
gel or solution), as the only measure of treatment in moderately deep pockets, decreased 
the mean percentage of spirochaetes and motile bacteria, with a concomitant increase in 
the mean percentage of cocci and “other” microorganisms (Lander et al. 1986). In 
addition, there was a decrease in the mean percentage of bleeding sites, but not in the 
plaque and gingival index and attachment levels. The suppression of the 
microorganisms remained up to four weeks. In a further study, basic oral hygiene 
instructions were given and the periodontal pockets (> 4 mm) were treated with one 
session of scaling and root planing and the adjunctive use of 0.2% chlorhexidine 
solution or metronidazole (Khoo and Newman, 1983). It was demonstrated that both 
antimicrobial agents yielded greater beneficial changes in subgingival microflora than 
mechanical control alone which lasted up to 84 days. Soskolne et al. (1997) tested a 
degradable subgingivally placed drug delivery system containing 2.5 mg chlorhexidine 
as an adjunct to scaling and root planing in chronic periodontitis patients with pockets 
of 5 to 8 mm depth. The supplementary use of chlorhexidine to scaling and root planing 
provided a greater pocket depth reduction at three and six months. However, it must be 
emphasised that during this clinical trial no oral hygiene instructions were given.
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In conclusion, differences in the plaque control levels during the experimental period 
may have contributed to the conflicting results across the studies. In some clinical trials 
there was a lack of meticulous plaque control and in others no scaling and root planing 
was performed prior to the use of chlorhexidine. Therefore, the studies comparing test 
and control subjects, both of which had inadequate plaque control, gave misleadingly 
promising results for the adjunctive use of chlorhexidine.
1.8 Efficacy of non surgical periodontal therapy
The purpose of scaling and root planing is to: 1) eliminate or suppress the pathogens, 2) 
shift the microflora to one that is less pathogenic to the host, 3) alter the local 
environment to one which does not favour plaque accumulation and multiplication of 
organisms, and 4) develop a more competent host immune response. The effects of 
periodontal therapy on the clinical, immunological and microbiological parameters are 
summarised in the following sections.
1.8.1 Effect of scaling and root planing on clinical parameters
Numerous investigations have documented the efficacy of scaling and root planing in 
the treatment of periodontal disease. Studies have shown that the amount of pocket 
depth reduction after treatment is related directly to the initial pocket depth with the 
greatest reduction for the deepest pockets (Knowles et al. 1979; Pihlstrom et al. 1983; 
Ramfjord et al. 1987). In addition, a relationship is apparent between attachment 
changes and initial pocket depth. Comparisons of before and after treatment data are a 
crucial element of analyses of therapeutic studies. However, it should be taken into 
consideration that statistical errors may arise if these data are used in regression models 
as the baseline and endpoint data are not truly independent and are subject to bias due to 
mathematical coupling. Difficulties or biases may also arise due to the phenomenon of 
regression towards the mean. Therefore, regressing / correlating post-treatment changes 
of variables with their baseline values should be treated with care.
In a thorough review of the literature, the mean probing pocket reduction and mean 
attachment gain following scaling and root planing were determined for shallow, deep 
and moderately deep sites (Cobb, 1996). It was demonstrated that shallow pockets (1-4 
mm) and moderately deep sites (4-7 mm) had a mean pocket reduction of 0.03 mm and 
1.29 mm, respectively, while deep sites (> 6 mm) showed the greatest pocket reduction
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of 2.16 mm. The mean attachment gain for shallow, moderately deep and deep sites 
was -0.34 mm, 0.55 mm and 1.19 mm, respectively. That study also showed a mean 
reduction in bleeding on probing of 57% post-therapy. Lindhe et al. (1982a) 
demonstrated that in a well controlled oral hygiene regimen, meticulous scaling and root 
planing was equally effective when used alone as in combination with the modified 
Widman’s procedure in the treatment of advanced periodontitis. A high frequency of 
probing depth of less than 4 mm was seen following both treatment modalities and the 
authors speculated that the gain of attachment after treatment reflected a reduction in the 
degree of gingival inflammation rather than a true gain of connective tissue attachment. 
The clinical improvements after mechanical debridement remained unchanged during a 
maintenance period of 18 months. During this period recurrence occurred but it was a 
rare finding, and when it did develop it was considered to be related to either ineffective 
prophylactic measures or inadequate debridement during active treatment (Waerhaug, 
1978).
Isidor et al. (1984) demonstrated that periodontal therapy resulted in significant clinical 
improvements in patients with advanced periodontal disease. Root planing resulted in 
marked pocket depth reduction, although more shallow pockets were obtained after 
modified Widman flap and reverse bevel flap surgery. Gain in attachment was obtained 
by all treatments, but root planing resulted in slighty more gain in attachment than the 
other two procedures. Data from another study showed that non-surgical periodontal 
treatment of patients with severely advanced periodontitis resulted in a marked clinical 
improvement in pockets of moderate depth, as well as pockets greater than 12 mm deep 
(Badersten et al. 1984a). Initially, 305 sites demonstrated pocket depth > 7 mm and at 
the 24-month examination this number was reduced to 43. Clinical indices continued to 
improve during the six and nine months following start of instrumentation. This finding 
disagrees with the results of a previous study by the same investigators, where clinical 
improvement reached a plateau at three to four months after initiation of treatment 
(Badersten et al. 1981). This could be due to the fact that patients with less advanced 
disease were examined in the earlier study. Another study by the same investigators 
demonstrated marked clinical improvement in patients with severely advanced 
periodontitis (Badersten et al. 1984b). Mean pocket depth was reduced from 5.5-5.9 
mm to 3.5-3.9 mm and bleeding scores from 80-90% to 15-20% after treatment. 
Clinical improvement reached a peak level at six to nine months after the start of
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instrumentation. Data from this study suggested that a single instrumentation was 
equally effective as repeated episodes of instrumentation.
1.8.2 Effect of scaling and root planing on the systemic and site-specific antibody 
responses
Many studies have sought to determine the changes in antibody titres to putative 
periodontal pathogens following treatment. These changes can provide criteria on 
which to evaluate periodontal treatment and prognosis.
Quirynen et al. (2000) observed that seven out of 11 patients, whose body temperature 
rose above 37°C after the second day of the one-stage full-mouth scaling and root 
planing, with or without the use of chlorhexidine treatment, had an overall pocket depth 
reduction exceeding 3.5 mm, whereas this was noted for only four of the remaining 13 
patients that did not have an increase in temperature. The observation that patients with 
a rise in body temperature the evening after the second day of the full-mouth treatment 
had the more impressive clinical improvements was considered by the authors to be due 
to an increased immunological reaction. However, this was a hypothesis only, since the 
investigators did not investigate the host immune response following this treatment.
Naito et al. (1985) reported a significant reduction in serum antibody titres to P. 
gingivalis, but not in antibody titres to other species such as A. actinomycetemcomitans, 
P. intermedia at 12 to 14 months after initiation of treatment. This is in agreement with 
the findings of another study (Tolo et al. 1982). In this study, a serum sample was 
collected one year after treatment and the results showed that in seven out of 12 patients 
the anti-P. gingivalis antibody levels decreased by 25% post-treatment. Except for P. 
gingivalis, most antibody levels were within the normal range before and after 
treatment. Pre- and post-treatment antibody titres to periodontopathic bacteria by 
ELISA in sera of periodontitis patients have been examined (Horibe et al. 1995). A 
reduction in serum antibody titres to P. gingivalis and P. intermedia at least two months 
(6.9 months on average) after the completion of active treatment was demonstrated. In a 
longitudinal study, Aukhil et al. (1988) demonstrated two distinct types of antibody 
response to P. gingivalis post-treatment. The first was, a significant reduction in the 
antibody titres to P. gingivalis during the early stages post-therapy, i.e., the end of the 
hygiene phase (two months after baseline approximately). The second was a significant
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reduction in the antibody levels to this pathogen at the end of the maintenance phase, 
i.e., two years after the end of the hygiene phase. The authors concluded that 
periodontal treatment reduced the antigenic challenge in the periodontium and 
consequently the antibody titres to these antigens. Local and systemic antibody levels to 
P. gingivalis in patients with treated chronic periodontitis, untreated chronic 
periodontitis and gingivitis have been evaluated (Murray et al. 1989). Antibody levels 
decreased 12 to 16 months after treatment in the treated group, whereas significantly 
higher antibody levels to P. gingivalis were seen in the untreated periodontitis patients 
compared to the treated and gingivitis subjects.
Johnson et al. (1993) found that antibody titres to P. gingivalis in GCF decreased 
significantly as the clinical disease status improved post-treatment, 3 to 12 months after 
the completion of scaling and root planing. In a longitudinal study, a serological 
dichotomy to P. gingivalis in chronic periodontitis patients was observed (Mouton et al.
1987). The first group was characterised by pre-treatment antibody levels similar to 
those of healthy individuals, while the second group showed elevated levels of 
antibodies, indicating infection with P. gingivalis. Treatment resulted in a progressive 
reduction in IgG antibody titres to 55% of the pretreatment levels five to seven months 
after treatment, reaching 41% one year post-therapy for the second subgroup of patients, 
while the low-titre patients maintained their low antibody levels following treatment. 
No peak antibody levels were observed in the immediate post-treatment period, 
suggesting that scaling and root planing may not induce active immunisation with P. 
gingivalis. In addition, no cyclic pattern of antibody levels was observed throughout the 
monitoring period that would reflect the series of exacerbation and remission of disease 
activity, as previously described (Socransky et al. 1984). The reduction of antibody 
levels was attributed to the elimination of bacterial load by the periodontal treatment.
However, the previously reported findings are not consistent with the findings of 
Ebersole et al. (1985c), who demonstrated that scaling and root planing elicited a 
significant increase in circulating antibody levels to various pathogens, due to 
inoculation of bacteria in the host tissues. Peak levels in responses were observed two 
to four months after scaling and levels returned to pre-scaling levels eight to 12 months 
post-treatment. In addition, a significant relationship was found between increased 
antibody levels post-treatment and pre-existing elevated antibody titres in the patients.
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In conclusion, this study supports the concept that scaling can be an effective means of 
active immunisation against periodontopathogens. Sjostrom et al. (1994) determined 
the pre- and post-treatment IgG antibody titres to A. actinomycetemcomitans in the sera 
of generalised aggressive periodontitis patients. The investigators observed that 
antibody titres and polymorphonuclear function as assessed by polymorphonuclear 
leukocyte chemiluminescence assay (CL) increased significantly after treatment, 
whereas pocket depths decreased. When they classified the patients as either 
seropositive (baseline IgG titres greater than twice the median of control subjects) or 
seronegative, they observed that median antibody titres and CL values increased for the 
seronegative group at six and 12 months after the beginning of the treatment, while an 
increase was seen only in the antibody levels for the seropositive patients at 12 months. 
The increase in antibody titres may have resulted from repeated scaling and root planing 
treatments over an extended period of time. The authors concluded that a humoral 
immune response induced by scaling and root planing can be a major factor in the 
clinical improvement seen after therapy.
It has been demonstrated that periodontal therapy affects the quality of the immune 
response to suspected periodontopathogens and that this effect is depended on the initial 
serostatus (Mooney et al. 1995). In this study, initially seropositive patients 
demonstrated a significant increase in IgG avidity to P. gingivalis, whereas seronegative 
patients showed no change in IgG avidity, but had a slight increase in IgG and IgA 
antibody titres. No significant changes were seen in antibody avidity to A. 
actinomycetemcomitans post-treatment, and IgG, IgA and IgM antibody levels to this 
organism increased significantly only for the seronegative subgroup. The seropositive 
patients had a higher chance of clinical improvement after conventional periodontal 
treatment. Chen et al. (1991) investigated the humoral immune response in generalised 
aggressive periodontitis patients and concluded that many patients do not produce 
protective levels of biologically functional antibody of high avidity during the course of 
their natural infection, but treatment may induce the production of such antibodies. 
Whitney et al. (1992) investigated the humoral immune response against a whole cell 
homogenate of P. gingivalis in generalised aggressive periodontitis patients, as well as 
in control subjects. Their data suggest that while the avidity of anti-P. gingivalis IgG 
antibodies in seropositive patients did not significantly differ from the values for 
seronegative patients or seronegative control subjects, the median avidity for
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seropositive control subjects was elevated compared to the other groups. This could 
explain the observation that although some subjects experience P . gingivalis 
colonisation, they do not develop clinical disease. In general, low titre and low avidity 
anti-P. gingivalis IgG antibodies were observed in generalised aggressive periodontitis 
patients, indicating a genetically determined compromise of their humoral immune 
response to certain types of antigens (Whitney et al. 1992).
A recent study from our laboratory showed that conventional periodontal treatment of 
chronic periodontitis patients resulted in significant clinical improvement and 
significant reduction in sites positive by polymerase chain reaction (PCR) for some of 
the test bacteria {P. intermedia, B. forsythus and T. denticola) (Darby et al. 2001). 
There was little change however, in the systemic and local antibody titres post-scaling, 
although there was a significant reduction in the IgG antibody avidity to P. gingivalis 
and P. intermedia. These results indicate complex interactions between the subgingival 
microflora and the host response and also a possible failure of the host response to 
produce adequate levels of biologically functional antibodies to putative periodontal 
pathogens.
There are great discrepancies among studies looking at the humoral immune changes 
following periodontal therapy. There is evidence suggesting that antibody levels decrease 
following treatment probably due to a reduced microbial burden, whereas other studies 
demonstrate increased antibody levels post-treatment which are possibly explained by 
inoculation of bacteria into the host tissues. These conflicting data could be attributed to 
differences in laboratory protocols and clinical study designs, in particular the time of 
testing following therapy. The majority of the literature however agrees that increased 
antibody avidity post-treatment indicates maturation of the immune system and therefore 
successful treatment. Further investigation based on standardised protocols, in terms of 
duration of clinical trials, sampling intervals and laboratory procedures, forms of 
periodontal disease and microbial species examined is required to delineate the effect of 
periodontal treatment on the antibody response.
1.8.3 Effect of scaling and root planing on the subgingival microbial flora
Several studies sought to determine the beneficial effects of scaling and root planing on 
both clinical and microbiological parameters and have consistenly reported marked
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changes in the subgingival microflora and clinical indices following non-surgical 
instrumentation (Slots et al. 1979; Renvert et al. 1990a; Pedrazzoli et al. 1991; Shiloah 
and Patters, 1994; Darby et al. 2001). Nevertheless, it is unlikely that scaling and root 
planing can eradicate and permanently clear all the microorganisms from a site. The 
microbes which re-colonise a subgingival pocket post-therapy could be either residual 
microorganisms following incomplete instrumentation or the extension of a growing 
and maturing supragingival plaque. It has been shown that in the presence of 
supragingival plaque it takes 42 days for organisms to re-colonise a previously scaled 
site (Mousques et al. 1980). In a study by Slots et al. (1979), the microbial shifts 
paralleled clinical improvement of patients with moderate to severe periodontitis. The 
kinetics of the microbial re-population over a six month period after a single course of 
thorough debridement and / or use of antibiotics followed three patterns: 1) rapid 
reduction followed by a slow return, seen for the total subgingival cell counts, including 
spirochaetes, 2) rapid increase in proportions of organisms followed by a slow return, 
observed for coccal forms and Actinomyces viscosus, 3) rapid reduction followed by a 
return which exceeds pre-treatment levels, seen for gram-negative anaerobic organisms 
including Fusobacterium nucleatum, various Bacteroides species, Veillonella parvula 
and gram-negative motile rods.
Scaling and root planing has been shown to have a modest effect on the composition of 
the subgingival microflora in chronic periodontitis patients (Haffajee et al. 1997a). Of 
40 subgingival species examined, only P. gingivalis, B. forsythus and T. denticola 
significantly decreased post-treatment and none of them or any other species was 
undetectable on a patient-basis after therapy. For the majority of patients, most of the 
sites were re-colonised by pre-treatment levels of most test species three months post­
therapy. Another study showed that residual pocket depth per se was not critical in the 
re-colonisation of periodontal pockets by black pigmented Bacteroides species and 
streptococci over a period of 16 weeks (Pedrazzoli et al. 1991). It has been 
demonstrated that scaling and root planing had a lasting suppressive effect on P. 
gingivalis, A. actinomycetemcomitans and P. intermedia for the majority of sites in 
patients with chronic periodontitis that received no supportive maintenance therapy over 
a period of 12 months (Shiloah and Patters, 1996).
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The effects of modified Widman flap surgery and systemic tetracycline on the clinical 
and microbiological parameters at sites with evidence of active periodontal destruction 
have been examined (Haffajee et al. 1988b). Post-treatment sites with loss of 
attachment had high levels of A. actinomycetemcomitans, B. forsythus, P. gingivalis, P. 
intermedia, Peptostreptococcus micros, Streptococcus intermedius and Campylobacter 
rectus while the sites with no change or gain in attachment level had high levels of 
Actinomyces species, Capnocytophaga ochracea, Streptococcus mitis, Streptococcus 
sanguis and V. parvula. Following treatment, A. actinomycetemcomitans and C. rectus 
were less frequently detected, but the black pigmented Bacteroides had the same 
detection frequency as before treatment, although their mean levels decreased. The 
authors suggested three possible effects of periodontal therapy on the subgingival 
micro flora: 1) pathogens remain at the same levels or increase after treatment, resulting 
in a compromised clinical outcome; 2) elimination of all pathogens and establishment of 
a microbiota which is antagonistic to their return; 3) suppression of the pathogens and 
an increase in the proportions of beneficial species to the host. The latter treatment 
outcome would require frequent maintenance procedures in order to maintain this health 
compatible micro flora.
Other investigators have shown that in the majority of chronic periodontitis patients the 
detection frequency of A. actinomycetemcomitans decreased significantly after 
conservative periodontal treatment (Mombelli et al. 1994a). However, in three of ten 
subjects there was a high detection of A. actinomycetemcomitans and many of the sites 
harboured high levels of this organism. After treatment, the highest chance of detecting 
this organism was in residual pockets of approximately 5 mm. In another study by the 
same investigators A. actinomycetemcomitans was detected in all patients after 
treatment, with individual detection frequencies ranging from 2% to 72% (Mombelli et 
al. 1994b). Post-treatment, the presence of this pathogen was significantly correlated 
with its detection frequency before treatment and the baseline mean probing depth. 
There was also a significant relationship between post-treatment levels of A. 
actinomycetemcomitans and probing depth reduction and attachment gain. The authors 
concluded that detection of A. actinomycetemcomitans in multiple sites before therapy 
indicates a higher chance of persistence for this organism after treatment, and this might 
be of more importance than the mere presence or absence of this pathogen at a site.
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It has been reported that in pockets of localised aggressive periodontitis patients, scaling 
and root planing alone could not suppress A. actinomycetemcomitans (Komman and 
Robertson, 1985). In addition, Renvert et al. (1990a) showed that in advanced 
periodontitis patients (28-54 years of age), debridement resulted in significant reduction 
of total viable counts of microorganisms including A. actinomycetemcomitans, P. 
gingivalis and P. intermedia. Only proportions of P. gingivalis and P. intermedia 
decreased after treatment while A. actinomycetemcomitans tended to increase as a 
proportion of the viable flora six months post-treatment. Of the 38 sites that harboured 
A. actinomycetemcomitans at baseline, 28 sites were still positive for this organism after 
treatment, while P. gingivalis was present in 15 of the 52 initially positive sites after 
therapy. Subgingival persistence of A. actinomycetemcomitans appeared to be related to 
a compromised clinical outcome. In a follow up study, those patients who possessed at 
least two separately located sites harbouring A. actinomycetemcomitans, received further 
treatment which consisted of either repeated debridement or surgical excision of the 
gingival tissue (Renvert et al. 1990b). Neither treatment was more effective in 
eliminating A. actinomycetemcomitans than initial debridement, since this organism 
persisted in the majority of infected sites. The authors speculated that the difficulties in 
eliminating A. actinomycetemcomitans could be because this species resides in the 
gingival tissues, or could be due to a re-infection originating from other infected areas in 
the oral cavity. The latter explanation seemed to be more likely.
Moreover, a study by Pedrazzoli et al. (1992) showed that scaling and root planing 
resulted in significantly increased proportions of A. actinomycetemcomitans at the 2-, 
12-, and 24-week examinations. The authors speculated that this could result from a 
relatively higher sensitivity of the other subgingival microflora to the mechanical 
debridement. Slots et al. (1986), showed that refractory periodontitis patients yielded 
predominately A. actinomycetemcomitans. The results reported in these studies show 
that A. actinomycetemcomitans seems to be difficult to eradicate from periodontitis 
lesions, possibly due to the fact that this organism can invade the gingival tissues 
(Saglie et al. 1982; Carranza et al. 1983). Combined mechanical debridement and use 
of antimicrobial therapy succeeded in suppressing A. actinomycetemcomitans over a 
long period of time, and this paralleled a further clinical improvement for up to 24 
months after active treatment (Pavicic et al. 1994).
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Renvert et al. (1996) treated periodontitis patients with the intention of suppressing A. 
actinomycetemcomitans and P. gingivalis to below detection levels and P. intermedia to 
below 5% of the cultivable subgingival microflora. Treatment to eliminate the bacteria 
continued for three years and the total period of observation was five years. Although 
the aim of the study was achieved in all sites, the indicator bacteria recurred in a number 
of sites over a five-year period (3% of sites for A. actinomycetemcomitans, 20% for P. 
gingivalis and 12% for P. intermedia). Patients who either lost attachment or returned 
to pre-treatment levels after an initial gain harboured these bacteria at a higher frequency 
than patients who retained their initial attachment gain.
Hafstrom et al. (1994) showed that, six months following treatment, abscess sites 
demonstrated significant improvements in pocket depth, attachment gain and bleeding 
on probing. Elimination of P. gingivalis and significant reduction in the proportion of 
P. intermedia was also demonstrated. Deep periodontal pockets also followed the same 
pattern. Results from another study showed a positive correlation between pocket depth 
reduction and decrease in P. gingivalis and between attachment gain and reduction in 
the percentage of this organism (van Winkelhoff et al. 1987). However, no correlation 
between these clinical parameters and other test microorganisms was seen, while an 
inverse relationship between P. gingivalis and P. intermedia was shown. Simonson et 
al. (1992) demonstrated that T. denticola and, to a lesser extent, P. gingivalis levels in 
successfully treated sites decreased, while non-responding sites had levels of these 
bacteria equal to or greater than the pre-treatment levels. In accordance with this 
finding are data of another study, which showed that a decrease in T. denticola levels 
was associated with successful clinical outcome following scaling and root planing 
(Haffajee et al. 1997b). Several suspected periodontal pathogens, including P. 
gingivalis, T. denticola and B. forsythus were found at higher levels before than after 
treatment in the subjects or sites that responded well to therapy.
A more recent study investigated the prevalence and counts of P. gingivalis, P. 
intermedia and A. actinomycetemcomitans in chronic periodontitis patients before and 
after treatment by use of a quantitative PCR method (Doungudomdacha et al. 2001). It 
was found that there was a significant decrease in the numbers of the test organisms 
post-scaling but none was completely eradicated, emphasising that the mere presence of 
a suspected pathogen may not indicate the presence of disease.
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1.8.4 Microbiological findings after the one-stage full-mouth disinfection 
treatment
The clinical findings and the study design of the one-stage full-mouth disinfection are 
presented in section 1.7.1. The microbiological findings of this treatment strategy are 
summarised in this section. In a pilot study, Quirynen et al. (1995), collected plaque 
samples from the upper right quadrant of ten patients at baseline and after one and two 
months. At one month, differential phase-contrast microscopy revealed a significantly 
higher reduction in the proportion of potential periodontal pathogens (sum of 
spirochaetes and motiles) in the test group, whereas at two months the differences were 
no longer significant. The culture data showed that there were no differences in the 
relative proportion of aerobic colony forming units (CFUs) for both treatments. 
Nevertheless, when the relative proportion of potential pathogenic and beneficial 
species were compared, the test group showed significantly fewer pathogenic organisms 
at one month and more beneficial species at two months. Post-treatment, P. gingivalis 
was eliminated from the test group although this was not the case for A. 
actinomycetemcomitans, whose proportion increased following treatment, which is 
consistent with poor treatment findings of others (Slots et al. 1986; Pedrazzoli et al. 
1992; Renvert et al. 1990a).
In a follow up study using the same protocol, samples for microbiological analysis were 
collected from ten patients, but patients were followed over eight months (Bollen et al.
1996). The findings from the differential phase-contrast microscopy were similar to 
those of the previous study, except for the eight-month observation where proportions of 
spirochaetes and motile rods remained lower only for the multi-rooted teeth of the test 
group. The culture data showed that at eight months there were no significant 
differences in the reduction of the anaerobic CFUs between the groups. The proportions 
of pathogenic species remained lower for the test group, with the exception of the four- 
month interval when the control group scored slightly better, but these findings were not 
statistically significant. The proportions of the specific species showed that no 
statistically significant differences existed between the two groups, although 
spirochaetes and P. intermedia remained lower in the test group up to eight months. P. 
gingivalis was eliminated in both groups over time and A. actinomycetemcomitans was 
only present in the test group at baseline, but was not detectable at eight months.
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Bollen et al. (1998) examined the effect of the full-mouth disinfection on the micobiota 
of 16 patients with severe periodontitis over four months. The clinical design of this 
study included use of chlorhexidine for an extended period of time post-treatment (two 
months). The results showed that there was a greater reduction in the total amount of 
facultative and strict anaerobic CFU/ml in the test group, especially at two months with 
some relapse around the multi-rooted teeth of the test group at month four. The changes 
in CFU/ml for pathogenic species were negligible in the control group in contrast to the 
test group (with the exception of A. actinomycetemcomitans).
Quirynen et al. (1999) compared the full-mouth disinfection with the more typical 
treatment of four sessions of quadrant root planing on 16 patients with aggressive 
periodontitis and 24 patients with severe chronic periodontitis. The patients were 
followed over eight months and full-mouth disinfection resulted in a significantly 
greater reduction in spirochaetes and motiles for the chronic periodontitis patients in the 
test group at each follow up visit, while this was the case for the aggressive periodontitis 
patients only at one and two months. A significantly additional reduction in total 
CFU/ml and CFU/ml of black-pigmented bacteria in the test group was found for the 
chronic periodontitis patients at each visit, while no significant differences between the 
two groups were seen in the aggressive periodontitis patients at month eight. For the 
chronic periodontitis patients, the test group showed long-term reductions in more 
species of suspected periodontal pathogens (P. intermedia, P. gingivalis, C. rectus, P. 
micros, and F. nucleatum).
In a more recent study from the same laboratory, three groups of 12 patients were 
included and followed over a period of eight months as had been described earlier 
(Quirynen et al. 2000). Full-mouth root planing with and without the use of 
chlorhexidine resulted in a greater reduction of spirochaetes and motile organisms 
compared to the control group, but this was only marginally significant at four and eight 
months. There was a greater reduction in the total number of anaerobic organisms and 
black-pigmented bacteria for the test groups. A more sustained reduction in the number 
of CFU/ml for specific periodontal pathogens was seen for both test groups. 
Differences between the two test groups were negligible.
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A later study compared the effects of the one-stage full-mouth disinfection and quadrant 
scalings on the subgingival microflora by the checkerboard DNA-DNA hybridisation 
technique (De Soete et al. 2001). Two groups of patients were examined, advanced 
chronic periodontitis patients and aggressive periodontitis patients. The results of this 
study showed that both treatments reduced the detection frequency and levels of the 
suspected pathogens for up to eight months. However, the one-stage full-mouth 
disinfection resulted in a greater reduction in the detection frequency and levels of the 
“red” and “orange” complex species (Table 3, section 1.5.6), and in the numbers of 
patients in whom these complexes of species were undetectable. These differences 
existed mainly for the chronic periodontitis patients.
1.9 Smoking and periodontal health
Numerous studies have indicated that smoking is a significant risk factor for the 
development of periodontal disease. It was interesting to see in an early report that none 
of 202 heavy smokers examined was periodontally healthy (Grossi et al. 1994). 
Subjects who smoked more than 30 pack-years (i.e. packs of cigarettes smoked per day 
multiplied by the number of years the subject smoked) were classified as heavy 
smokers. This study also showed that the severity of attachment loss was highly 
correlated with the number of pack-years. The odds for more severe attachment loss in 
smokers compared to non-smokers ranged from 2.05% for light smokers to 4.75% for 
heavy smokers. Similarly, a follow up study revealed that smokers had greater odds for 
more severe bone loss than non-smokers, ranging from 3.25% for light smokers to 
7.28% for heavy smokers, and that the severity of bone loss was positively related to the 
number of pack-years (Grossi et al. 1995).
The prevalence of cigarette smoking was shown to be higher in both chronic 
periodontitis and severe generalised aggressive periodontitis patients compared with 
age- and race-matched periodontally healthy subjects (Schenkein et al. 1995). Another 
study associated the severity of periodontal condition (as determined by clinical 
attachment level, probing pocket depth and bone crest height) with cotinine 
concentrations in serum (Gonzalez et al. 1996). A more recent study confirmed 
previous reports that smoking is a major risk for periodontitis, and suggested that 
smoking cessation may enhance the treatment outcome in adults with periodontitis and 
also reduce the risk for disease progression (Tomar and Asma, 2000). That study
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showed that former smokers were more likely to have periodontitis than subjects who 
had never smoked, and current smokers were about four times as likely as subjects who 
had never smoked to have periodontitis. Among former smokers, the odds for 
periodontitis decreased with the number of years since giving up, while among current 
smokers, there was a dose-response relationship between cigarettes smoked per day and 
the odds for periodontitis.
1.9.1 Effect of smoking on the periodontal tissues
Several studies have shown that smoking can reduce the clinical signs of gingival 
inflammation in periodontitis and experimental gingivitis patients. This could be due to 
the potential of nicotine to cause vasoconstriction in the peripheral blood vessels 
(Clarke et al. 1981). Significantly lower GCF volume was found for smokers than non- 
smokers, in periodontitis patients (Kinane and Radvar, 1997). Holmes et al. (1990) 
compared the gingival crevicular flow between periodontally healthy smokers and non- 
smokers. Smokers tended to exhibit lower GCF volume than did non-smokers and 
lingual readings were not significantly different from buccal readings. These findings 
indicate that the effect of cigarette smoke on clinically healthy gingiva may be a result 
of vasoconstriction rather than a physical irritation.
Smoking was found to suppress overt clinical signs of gingival inflammation, as 
indicated by a reduced bleeding score in the smokers (Preber and Bergstrom, 1985). In 
addition, Darby et al. (2000) examined the periodontal status in chronic periodontitis 
and generalised aggressive periodontitis patients, and found that smokers in both disease 
groups exhibited significantly lower bleeding scores than non-smokers. A more recent 
study has confirmed earlier reports and has shown a suppressed bleeding on probing in 
smokers, by examining the hemorrhagic responsiveness in two populations of subjects, 
one of which were periodontitis patients and the other dental care attenders in general 
(Bergstrom and Bostrom, 2001). Bergstrom et al. (2000) showed that in individuals free 
of periodontal disease the association between smoking and gingival bleeding was 
weak. The authors speculated that the interference of smoking with the inflammatory 
responsiveness of the periodontium may not be attributed solely to the vasoconstriction 
effects of tobacco and its products, but that it may be a result of changes in the vascular 
dynamics and cellular metabolism induced by smoking (Bergstrom and Bostrom, 2001).
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Danielsen et al. (1990) reported findings from a 21-day experimental gingivitis study 
conducted in periodontally healthy smokers and non-smokers. By day 21, both 
subgroups had equivalent amounts of plaque, but smokers developed fewer sites with 
gingivitis assessed clinically than non-smokers, possibly reflecting a reduced capacity of 
the host to induce an effective response to the plaque challenge. Lie et al. (1998b) 
assessed the bleeding tendency in smokers versus non-smokers and demonstrated that at 
the end of 14 days of experimental gingivitis smokers showed less bleeding on probing 
than non-smokers. Differences in bleeding indices between the two subgroups were 
seen for probing the marginal gingiva and to the bottom of the pocket as well. This 
suppressed inflammatory response of smokers to plaque accumulation implies that 
smokers should be studied as a separate group in experimental gingivitis trials. These 
findings indicate that smoking reduces gingival inflammation and thus masks early signs 
and symptoms of periodontal disease.
The harmful effects of cigarette smoking on periodontal health in subjects with 
generally good oral hygiene standards and dental awareness have been demonstrated 
(Bergstrom and Eliasson, 1987b). Both the number of pockets and probing pocket 
depth were significantly greater in smokers than in non-smokers and this finding existed 
even after taking into consideration age and oral hygiene. The same investigators 
demonstrated that the frequency of diseased sites and bone loss was significantly greater 
in current smokers than in non-smokers (Bergstrom et al. 2000). In addition, a dose- 
dependent realtionship was found between periodontal disease and smoking. The 
finding that former smokers exhibited less disease than current smokers, although worse 
than non-smokers, indicates that smoking cessation may be beneficial for the 
periodontium.
These results are in accord with those of Haffajee & Socransky (2001), who showed that 
current smokers had significantly more attachment loss, missing teeth, deeper pockets 
and fewer sites with bleeding on probing, yet similar levels of plaque and gingival 
redness than former smokers or subjects who had never smoked. In agreement with the 
findings of Bergstrom & Eliasson (1987a), this study revealed larger differences in 
pocket depths between smokers and non-smokers for the middle of the pocket depth 
range rather than the ends of the range. Age, pack-years and being a current smoker 
were strongly associated with mean attachment level. Significantly more bone loss was
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observed at maxillary palatal sites and lower anterior teeth suggesting the likelihood of a 
local effect of cigarette smoking. Kamma et al. (1999) evaluated the impact of smoking 
on the clinical status of aggressive periodontitis patients. Smokers exhibited increased 
number of diseased sites and more severe periodontal destruction in terms of pocket 
depth, attachment loss and radiographic bone loss than did non-smokers, and this was 
observed mainly in maxillary anteriors and premolars. In a more recent study, cigarette 
smoking was associated with deeper periodontal pockets and the intra-oral distribution 
of the pockets suggested a local effect (van der Weijden et al. 2001).
Several studies have reported that plaque levels were similar between smokers and non- 
smokers (Kinane and Radvar, 1997; Kamma et al. 1999; Darby et al. 2000; Haffajee 
and Socransky, 2001), implying that the deleterious effects of cigarette smoking on the 
periodontal tissues are less likely to be related to compromised plaque control 
(Bergstrom and Eliasson, 1987a, 1987b).
Another study examined the serum cotinine levels in periodontitis patients and found a 
correlation between the cotinine levels and the severity of chronic periodontal disease 
(Gonzalez et al. 1996). Variations in cotinine levels among “one pack a day” smokers 
were shown, suggesting that self-reporting of smoking status may not be reliable. This 
could result from the fact that some individuals may be untruthful when self-reporting, 
or that individual variations in smoking habits and variations among different cigarettes 
exist.
1.9.2 Subgingival microbial flora in smokers
After matching for age, sex, plaque and calculus in a sample of healthy middle-aged 
adults, one study found that the odds of having posterior proximal probing depth >3.5 
mm were 5.3 times greater for smokers than non-smokers (Stoltenberg et al. 1993). 
The prevalence of five putative periodontal pathogens, as determined by 
immunofluorescence, did not differ between smokers and non-smokers and smoking 
was a stronger risk indicator for the presence of posterior proximal probing depth >3.5 
mm than the detection of any of the five bacteria. The relationship between smoking 
and occurrence of periodontal pathogens was assesssed in 145 patients with severe 
periodontitis by a culture technique (Preber et al. 1992). The results of this study 
showed that there were no differences in the prevalence, counts and occurrence of
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different combinations of A. actinomycetemcomitans, P. gingivalis and P. intermedia 
between smokers and non-smokers.
In accordance with these findings, another study failed to show any differences in the 
prevalence of five putative periodontal pathogens between smokers and non-smokers 
(Darby et al. 2000). The organisms were detected in subgingival plaque using PCR in 
two different groups of patients, one with chronic periodontitis and the other with 
generalised aggressive periodontitis. Utilizing the checkerboard DNA-DNA 
hybridization technique, Bostrom et al. (2001) confirmed the previous data by showing 
that, in chronic periodontitis patients, smoking had little, if any, influence on the 
subgingival presence of several suspected periodontal pathogens. Lie et al. (1998a) 
demonstrated that the phenomenon that smokers presented with less bleeding than non- 
smokers after the induction of experimental gingivitis was not associated with 
microbiological differences between the two subgroups.
Conversely, Zambon et al. (1996) demonstrated by immunofluorescence that higher 
proportions of smokers harboured B. forsythus, P. gingivalis and A. 
actinomycetemcomitans than did non-smokers and they were infected with higher mean 
levels of the majority of the test bacteria than were non-smokers. Controlling for the 
severity of periodontal disease, former and current smokers were 1.5 times more likely 
to be infected with B. forsythus than non-smokers, and the greater risk seen in smokers 
for infection with B. forsythus was dose-related. Similarly, Kamma et al. (1999) 
compared the microbial profiles of smokers and non-smokers in a group of patients with 
aggressive periodontitis using a culture technique. The analysis of the subgingival 
plaques revealed that a variety of suspected periodontal pathogens, including B. 
forsythus and P. gingivalis, were found in significantly higher numbers and more 
frequently in non-smokers than smokers. In addition, another study demonstrated that 
former smokers exhibited a decreased risk of harbouring A. actinomycetemcomitans in 
saliva than non-smokers (odds ratio: 0.23), while current smokers displayed an 
increased risk of harbouring T. denticola in periodontal pockets than non-smokers (odds 
ratio: 4.61) (Umeda et al. 1998).
Differences in the composition of the subgingival microbial flora among various studies 
between smokers and non-smokers could be attributed to sampling techniques, detection
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methods, characteristics of patient populations (such as sample size) and detection of 
different putative pathogens.
1.9.3 Immunological profiles of smokers
Smoking has been shown to have an adverse effect on fibroblast function (Raulin et al.
1988), chemotaxis and phagocytosis by neutrophils (Kenney et al. 1977; Kraal et al. 
1977), and immunoglobulin production (Holt, 1987; Johnson et al. 1990). It has been 
shown that cigarette smoke results in reduced concentration of serum IgG antibodies 
(Andersen et al. 1982). The effects of smoking and tobacco on the immune system are 
summarised in a review, which highlights the deleterious effects of tobacco on the host 
response (Barbour et al. 1997).
Reduced serum antibody titres to P. intermedia and F. nucleatum were found in 
smokers (Haber, 1994). Smoking has been related to depresssed serum IgG2 antibody in 
generalised aggressive periodontitis patients (Quinn et al. 1996). The significance of 
this finding is that antibody responses elicited by carbohydrate antigens, including LPS, 
have high quantities of IgG2 (Scott et al. 1988). These antigens are commonly found on 
oral pathogens. In another study from the same laboratory, IgG2 antibody levels were 
reduced in smoking chronic periodontitis patients and healthy controls of white race, but 
not in black subjects (Quinn et al. 1998). It was interesting to note that there was a 
relation between a smoking-related decrease in serum IgG2 and an increase in 
periodontal destruction in white subjects. In accordance with previous findings, this 
study showed that smoking had an impact on serum immunoglobulin levels, but this 
effect was both race- and serum IgG subclass-specific.
Gunsolley et al. (1997) examined the combined effects of IgG allotype, race, smoking 
and periodontal diagnosis on IgG subclass levels. In black subjects smoking was only 
asssociated with lower concentrations of IgGi in chronic periodontitis patients and 
lower concentrations of IgG2 in subjects with generalised aggressive periodontitis. 
However, in white subjects complex relationships existed between smoking and 
allotypic markers, but no influence of periodontal diagnosis was found. Thus, in 
addition to immunoglobulin allotype, smoking is associated with IgG subclass 
concentrations and, together with periodontal diagnosis and gender, all influence IgG 
subclass concentrations in black subjects. In conclusion, smoking can modify the
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antibody response seen. Tangada et al. (1997) tested the hypothesis that smoking results 
in reduced IgG2 antibody levels to A. actinomycetemcomitans in black generalised 
aggressive periodontitis patients but not in black localised aggressive periodontitis 
patients. The results confirmed the study hypothesis and also indicated that serum IgG2 
reactive with other antigens might not be reduced in this group of periodontitis patients. 
An interesting finding was that no significant differences in the anti-A 
actinomycetemcomitans IgG2 antibody levels existed between non-smoking generalised 
and localised periodontitis patients.
A more recent study examined the effect of smoking on the IgG titres and avidity to a 
panel of five putative periodontal pathogens in two subgroups of aggressive 
periodontitis patients, one group of untreated patients and the other of maintenance 
patients (Mooney et al. 2001). Median antibody titres to A. actinomycetemcomitans, P. 
intermedia and T. denticola were significantly lower in smoking maintenance patients, 
but not in untreated patients. Antibody avidity to P. gingivalis was also lower in the 
former patients but not in the latter. These results indicate that the maturation of the 
humoral immune response during treatment is compromised in smokers.
1.9.4 The effect of smoking on periodontal therapy
Bostrom et al. (1998) showed a predominance of smokers among patients exhibiting 
loss of bone height after five years of maintenance, and an increased level of TNF-a in 
the GCF of smokers. No differences in supragingival plaque and presence of 
periodontopathogens subgingivally were seen between smokers and non-smokers. Over 
the five years of monitoring, the proportion of smokers who dropped out of the study 
was higher, implying that there is lack of motivation in this group of patients. Kaldahl 
et al. (1996c) evaluated the effects of the level of cigarette consumption and a previous 
smoking history on the treatment outcome and on supportive periodontal treatment 
which lasted seven years. Heavy and light smokers demonstrated less pocket depth 
reduction, less gain in clinical attachment level and greater loss of horizontal attachment 
level than previous smokers and non-smokers following active and supportive 
treatment. No differences were seen in bleeding on probing among the groups and 
heavy smokers exhibited a higher percentage of sites with supragingival plaque than the 
other groups. These data suggest that past history of smoking does not have an adverse 
effect on the treatment outcome. The same investigators examined the yearly incidence
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of sites with active periodontal disease losing clinical attachment level during a seven- 
year period of supportive treatment (Kaldahl et al. 1996b). They showed that patients 
with higher breakdown incidences tended to be smokers at the initial examination, 
suggesting that smoking cessation may be a therapeutic consideration in the long-term 
clinical treatment of periodontal patients.
Another study monitored the short-term effects of conventional periodontal treatment on 
the subgingival microbial flora in smokers and non-smokers (Preber et al. 1995). 
Smokers had significantly greater mean pocket depth as well as greater number of 
diseased sites at baseline. The treatment resulted in similar plaque and gingival indices 
for both subgroups, but in a significantly smaller pocket reduction in smokers than non- 
smokers. There were no microbiological differences between the two groups, and the 
authors speculated that the compromised clinical outcome seen in smokers may be due 
to factors related to the host response rather than to microbial infection. A further study 
showed that there were no differences in baseline clinical parameters between smokers 
and non-smokers (Renvert et al. 1998). However, six months after treatment bleeding 
scores were greater and pocket depth reduction was smaller in smokers than non- 
smokers. Although, A. actinomycetemcomitans was more difficult to eradicate among 
smokers than non-smokers, there were no significant differences in the microbiological 
responses between the two groups.
The effect of cigarette smoking on the outcome of scaling and root planing and 
adjunctive antimicrobial treatment has been evaluated (Kinane and Radvar, 1997). 
Non-smokers showed greater pocket depth reduction and a trend for greater gain in 
attachment levels, indicating that a greater degree of recession occurred in smokers 
rather than non-smokers. The percentage of sites with bleeding on probing after 
treatment was not significantly different between the two groups, and this was also the 
case with the plaque scores. No differences in the baseline plaque scores were seen 
between the two groups, suggesting that the compromised clinical outcome in smokers 
could be attributable to factors other than the level of plaque control. Haffajee et al. 
(1997a) reported that pre-treatment P. gingivalis, B. forsythus and T. denticola were 
equally prevalent among current and past smokers and subjects who had never smoked, 
and decreased significantly after periodontal therapy in past smokers and in subjects 
who had never smoked but increased in current smokers. Current smokers had deeper
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pockets and more attachment loss than past smokers or subjects who had never smoked, 
both pre- and post-treatment. In summary, the findings presented in this section 
strongly relate smoking to a compromised clinical outcome and suggest that smoking 
cessation can have beneficial effects on periodontal health and management of 
periodontal diseases.
1.10 Polymerase chain reaction and detection of putative periodontal pathogens
PCR is a rapid and highly sensitive technique which has been used for the detection of 
bacterial DNA sequences. PCR is highly specific and relatively inexpensive. It is not as 
labour-intensive as other methods and it does not rely on viable cells. With these 
characteristics in mind, PCR can be more advantageous than other techniques such as 
culture methods, immunodiagnostic methods and chromosomal and cloned DNA probes 
(Ashimoto et al. 1996; Riggio et al. 1998). Studies from our laboratory showed that 
the sensitivity of PCR for the leukotoxin A and fimbrillin gene was 50 cells of A. 
actinomycetemcomitans and P. gingivalis, respectively (Riggio et al. 1996), and for the 
16S rRNA gene was 100 cells of P. intermedia (Riggio et al. 1998).
Slots et al. (1995) showed that the proportions of subgingival plaque samples positive 
by PCR ranged from 52.8% (A. actinomycetemcomitans) to 91.4% (B. forsythus) in a 
group of patients with advanced periodontitis. Another study from the same laboratory 
found a prevalence of 30% for A. actinomycetemcomitans, 86% for B. forsythus, 70% 
for P. gingivalis, 58% for P. intermedia, and 54% for T. denticola in subginigval plaque 
of advanced periodontitis patients (Ashimoto et al. 1996). A further study detected P. 
gingivalis in 25% of the healthy subjects and in 79% of the periodontitis patients, 
emphasising the possible pathogenic role of this organism in periodontitis (Griffen et al. 
1998). A. actinomycetemcomitans and P. gingivalis were detected in subgingival plaque 
samples of refractory periodontitis patients at frequencies of 44% and 58%, respectively 
(Wahlfors et al. 1995) and B. forsythus was detected in 89.7% of periodontitis patients 
(Meurman et al. 1997). In another study, 78.5% of periodontitis patients were found to 
be positive for the fimbrillin gene of P. gingivalis (Amano et al. 1999).
Investigations from our laboratory revealed that 40% and 28% of chronic periodontitis 
patients harboured A. actinomycetemcomitans and P. gingivalis respectively (Riggio et 
al. 1996), and 52% of the patients possessed P. intermedia (Riggio et al. 1998). More
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recently, the prevalence of five putative periodontal pathogens was compared between 
patients with chronic periodontitis and generalised aggressive periodontitis by PCR 
(Darby et al. 2000). In that study, 54.4% of chronic periodontitis patients harboured P. 
gingivalis, 3% A. actinomycetemcomitans, 72.9% P. intermedia, 54.4% T. denticola, 
and 63.6% B. forsythus. The prevalence of these organisms in generalised aggressive 
periodontitis patients was as follows: 62.5% of patients were positive for P. gingivalis, 
20.8% for A. actinomycetemcomitans, 19.2% for P. intermedia, 45.8% for T. denticola, 
and 91.7% for B. forsythus.
Umeda et al. (1998) showed that risk indicators for harbouring six suspected periodontal 
pathogens as detected by PCR included race / ethnicity, age, gender, time of residency in 
the United States, smoking, frequency of professional dental care and existing 
periodontal disease. The data reported in this study revealed that the prevalence of A. 
actinomycetemcomitans in the advanced periodontitis patients was 35.7% in Caucasians, 
30.8% in African-Americans, 50.0% in Asian-Americans, 58.3% in Hispanics and 
35.7% in all subjects. P. gingivalis was detected in 50.0%, 69.2%, 75.0% and 83.3% of 
the above mentioned ethnic groups respectively, and in 56.3% of all subjects. P. 
intermedia was detected in 71.4%, 38.5%, 87.5% and 91.7% of the four ethnic groups 
respectively, and in 46.2% of all subjects. T. denticola was found in 78.6%, 84.6%, 
87.5% and 100% of the ethnic groups respectively, and in 71.9% of all subjects. B. 
forsythus was prevalent in 85.7%, 84.6%, 87.5% and 100% of the different ethnic 
groups respectively, and in 63.3% of the total number of subjects.
Thus, differences in the detection frequencies of organisms by PCR among various 
studies could be due to variations in the patient populations, but also to differences in 
the sampling methods and in the laboratory analysis performed (primers used, primer 
annealing temperatures, primer sensitivity, sample processing, etc) and to operator 
variability.
1.11 Objectives of the study
The study presented in this thesis examined the efficacy of two treatment strategies, full- 
mouth scaling and root planing performed within 12 hours (FM-SRP) versus quadrant 
scaling and root planing performed over four visits at two-weekly intervals (Q-SRP). 
The primary aim of this study was to determine whether these methods of treatment had
57
different effects at six weeks after the completion of scaling and root planing and six
months after the initiation of therapy, on:
• Clinical parameters (full-mouth and site-specific clinical indices);
• Humoral immune response dynamics (systemic and local antibody titres and 
antibody avidity);
• Subgingival microflora (detection of five suspected periodontal pathogens in 
subgingival plaques);
In addition, the clinical, immunological and microbiological parameters for each
treatment strategy were compared before and after therapy.
Other aims of this study were to:
• Determine the relationship between severity of periodontal disease and 
immunological and microbiological parameters;
• Determine the relationship between clinical improvement and changes in 
immunological and microbiological responses;
• Determine the impact of smoking on clinical and immunological parameters and on 
the detection frequency of five periodontal pathogens in subgingival plaque;
• Determine whether during the period of quadrant scaling and root planing at two­
weekly intervals, treated sites in quadrant one deteriorated clinically and 
microbiologically in the presence of non-scaled sites in the other quadrants;
• Test the hypothesis that each session of quadrant scaling and root planing and oral 
hygiene instructions had a beneficial effect on the clinical indices in the remaining 
untreated quadrants;
• Test the hypothesis that in the short-term, Q-SRP over four visits elicited an immune 
response that reached peak levels more gradually and was sustained at high levels 
for a longer period of time than that elicited by one session of FM-SRP.
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CHAPTER 2 
MATERIALS AND METHODS
2. Materials and methods
2.1 Clinical methodology
2.1.1 Patient selection
This study was approved by the Ethics Committee at Glasgow Dental Hospital and 
School. All participants were fully informed about the nature of the treatment and 
singed a consent form prior to recruitment.
60 patients were recruited from new referrals to the Department of Periodontology at 
Glasgow Dental Hospital between February 1999 and September 2000. These were 
untreated moderate to advanced periodontitits patients with no history of systemic 
disease or antibiotic therapy in the last three months. Each patient, who had at least two 
sites per quadrant with a pocket depth of 5 mm or greater and radiographic evidence of 
bone loss, entered into the study. A history of cigarette smoking was recorded and 
confirmed using the COZART serum cotinine assay kit (Abingdon, U.K.).
2.1.2 Clinical study design
Patients were randomly allocated into two groups:
• Q-SRP group. Received quadrant scaling and root planing (Q-SRP) over four visits 
at two-weekly intervals,
• FM-SRP group. Received full-mouth scaling and root planing (FM-SRP) within 12 
hours.
Patients were randomly allocated into one of the two treatment groups based on a 
predetermined randomisation list made by computer. The Q-SRP group consisted of 20 
patients (13 males and 7 females) with a mean age of 42.3 years (range 31-70) and the 
FM-SRP group consisted of 22 patients (12 males and 10 females) with a mean age of
47.5 years (range 36-67) (Table 4). All participants were of Caucasian ethnic origin 
except for two subjects who were Asians (one subject in the Q-SRP group and one in 
the FM-SRP group). Seven patients in the Q-SRP group and ten in the FM-SRP group 
were smokers. Smokers in the Q-SRP group consumed on average 13.6 cigarettes a day 
(range 5-20) and in the FM-SRP group 16.2 cigarettes a day (range 10-30). The mean 
number of teeth was 27 and 26 for Q-SRP and FM-SRP groups, respectively.
Scaling and root planing was performed under local anaesthesia. In the Q-SRP group, 
root planing started with the upper right quadrant, to be continued clockwise over four
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Table 4. Demographic details for Q-SRP and FM-SRP patients.
No. of subjects No. of  
teeth*
Age* Males Females Smokers
Q-SRP 20
19 Caucasians 
1 Asian
27 (23-31) 42.3 (31-70) 13 7 7
FM-SRP 22
21 Caucasians 
1 Asian
26(18-32) 47.5 (36-67) 12 10 10
* Mean (min-max)
Q-SRP = quadrant scaling and root planing 
FM-SRP = full mouth scaling and root planing.
visits at two-weekly intervals. This order was kept consistent for all patients in the Q- 
SRP group, so that equal healing time was allowed for the treated quadrants. In the FM- 
SRP group, root planing was performed in one lower and one upper quadrant at the 
morning clinical session, to be continued in the other half of the dentition at the 
afternoon session, on the same day. Time spent for scaling each quadrant was 
approximately one hour. FM-SRP was performed over four hours in total, two hours at 
the morning session and two hours at the afternoon session on the same day. Patients in 
both groups were advised not to use antiseptic mouthwash during the course of 
treatment so that plaque control was achieved solely by optimal toothbrushing. No teeth 
were extracted during therapy in order to avoid bias.
The subjects were assessed with conventional full-mouth periodontal pocket charts at 
three time points: 1) baseline (BAS), 2) reassessment one (Rl); six weeks after the last 
session of scaling and root planing, 3) reassessment two (R2); six months after the 
initiation of therapy. Furthermore, one site per quadrant with the deepest pocket depth 
(PD) (not less than 5 mm deep) was selected from each patient at baseline for collection 
of GCF, subgingival plaque samples and clinical data. From these selected sites, clinical 
data and samples were collected at baseline, at R l and R2. In addition, for the Q-SRP 
group site-specific clinical indices were collected at each scaling session during the 
active phase of treatment.
The clinical design of the study was as follows:
Screening visit; the suitability for patient recruitment was confirmed and a signed 
consent form was obtained. Patients were randomly allocated into one of the two 
treatment groups.
Baseline; clinical indices and samples were collected.
Visit 1 (1 week later approximately); quadrant root planing for the Q-SRP group and 
full-mouth root planing for the FM-SRP group were performed under local anaesthesia.
Visit 2 (2 weeks later); sample collection for both groups, Q-SRP and oral hygiene 
instructions (OHI) were given to the Q-SRP group, whereas only OHI were given to the 
FM-SRP group.
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Visit 3 (2 weeks later); same as visit 2.
Visit 4 (2 weeks later); sample collection for both groups, Q-SRP and OHI was given 
to the Q-SRP group whereas clinical reassessment was performed for the FM-SRP 
group.
Visit 5 (6 ± 1 weeks later); sample collection was carried out for both groups. Clinical 
reassessment was performed for the Q-SRP group. At this visit, maintenance scaling 
was performed in both groups.
Visit 6 (12 ± 2 weeks later); sample collection and clinical reassessment were carried 
out for both groups.
Subsequent to the one-day FM-SRP, patients in this treatment group were recalled at 
two-weekly intervals for OHI and blood collection. Effectively, patients in both 
treatment groups were seen at equal time points and received an equal amount of OHI 
and motivation. The timings of clinical interventions are summarised in Table 5.
2.1.3 Site selection
The following criteria for site selection were adopted: non-adjacent sites were selected so 
that there would be no interference between sites during plaque and GCF sampling. 
Mesial sites were preferred to distal sites since they were more accessible, with the deepest 
site being preferred. On the lower teeth, buccal and labial sites were preferred to lingual 
sites, since these sites were less prone to saliva contamination of the GCF sample. Single­
rooted teeth were preferred over multi-rooted teeth. No sites with furcation or endodontic 
involvement were selected. Moreover, sites adjacent to teeth with poor prognosis, such as 
those with deep pockets proximal to the apex or with complications of endodontic or 
periodontic lesions were not included.
2.1.4 Sampling procedures
A blood sample was collected from the ante-cubital vein at each visit. Six blood samples 
in total were taken from patients in both groups.
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Table 5. Timeline for clinical interventions.
Q-SRP GROUP
Baseline Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 (R l) Visit 6 (R2)
A-E F-G/ I A / E - G A / E - G A / E - G A- F / J A-F
0 1 week 3 weeks 5 weeks 7 weeks 13 ± lweeks 25 ± 2 weeks
Q-SRP = quadrant scaling and root planing
FM-SRP GROUP
Baseline Visit 1 Visit 2 Visit 3 Visit 4 (Rl) Visit 5 Visit 6 (R2)
A-E H / F / I A / F A / F A-F A / F / J A-F
0 1 week 3 weeks 5 weeks 7 weeks 13 ± lweeks 25 ± 2 weeks
M-SRP = full mouth scaling and root planing
Key to table: A: Blood sample (3 x 7ml tubes)
B: GCF samples
C: Plaque samples
D: Pocket chart (PD, AL, BOP)
E: Site-specific clinical assessment 
(PD, RAL, MGI, PI, BOP, Sup) 
F: OHI 
G: Q-SRP 
H: FM- SRP 
I: Questionnaire 
J: Maintenance scaling
At baseline, Rl and R2, the following samples were collected from the study sites in the 
order listed:
1. Modified Gingival Index (MGI) and Plaque Index (PI).
2. GCF samples. GCF volume was determined using the Periotron 6000 (Oraflow Inc., 
Plainview U.S.A.).
3. First set of pocket depth (PD) measurements as determined by Florida probe 
(Florida Probe Corporation, Florida, USA), an electronic pressure sensitive probe.
4. Bleeding on probing (BOP) and suppuration (Sup).
5. The second set of PD measurements was recorded.
6. After changing the handpiece of the electronic probe, the first set of relative 
attachment level (RAL) measurements was taken.
7. The second set of RAL measurements was collected.
8. A subgingival plaque sample was collected from each site for PCR analysis.
9. Finally, a 20 ml venous blood sample was collected in order to obtain serum.
After the first session of scaling and root planing an anonymous questionnaire was given 
to participants of both groups to evaluate post-treatment complications (Figure 2). Day 
one was 24 hours after the first session of quadrant or full-mouth scaling and root 
planing, whereas day two was between 24 and 48 hours after the first session of scaling 
and root planing. The discomfort a patient experienced was rated on a 10 cm horizontal 
visual analogue scale with marks every centimetre (cm) (Figure 2). The cross mark 
placed by the patient was scored to the nearest cm, resulting in a score between zero (no 
pain) and ten (extreme pain). The percentage of patients taking analgesics, the number 
of painkillers and body temperature (thermometer placed at the axilla for five minutes) 
were also recorded. The occurrence of cold sores or oral ulcers was reported by the
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Figure 2. Assisted questionnaire.
• Day 1, evening:
no pain extreme pain
I 1---------1---------1---------1---------1---------1--------- 1---------1---------1--------- 1
0 1 2 3 4 5 6 7 8 9  10
Number of painkillers:.......
Body temperature:........
• Day 1, next morning:
no pain extreme pain
I 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1- - - - - - - - - - 1
0 1 2 3 4 5 6 7 8 9  10
Number of painkillers: ........
Body temperature: ........
• Day 2, evening:
Number of painkillers: ... 
Body temperature: ........
• Day 2, next morning:
Number of painkillers: ... 
Body temperature: ........
patient or recorded by the examiner at the following visit, two weeks later. At that visit, 
the completed questionnaire was obtained.
2.1.5 Clinical measurements
Clinical measurements were collected by the same operator (DA) who had no access to 
recordings of previous visits. Full-mouth pocket charts were completed at baseline, Rl 
and R2. Pocket depth (PD) and attachment level (AL) were determined at six sites per 
tooth to the nearest millimetre (mm) using a PC 12 probe (Hu-Friedy Mfg Co, Chicago, 
IL, USA). Bleeding on probing (BOP) was also recorded dichotomously as present or 
absent after PD probing on each arch. PD was determined as the distance between the 
gingival margin and the base of the pocket and AL was measured as the distance 
between the cementoenamel junction (CEJ) and the base of the pocket.
At these visits, clinical data were also collected from the selected sites. The Florida 
Probe was used for PD and RAL recordings (Gibbs et al. 1988). Clinical measurements 
were recorded from the computer screen by an assistant. The operator was unable to 
view these recordings, so that an unbiased collection of measurements was ensured. All 
clinical indices were stored on a specially designed sheet. MGI, PI, BOP, Sup, PD and 
RAL were recorded at each site.
For the Q-SRP group, in addition to clinical assessment at baseline and reassessments 
one and two, clinical measurements were also collected from the selected sites at each 
scaling session at two-weekly intervals. At these visits, clinical recordings were 
collected from the sites in the remaining untreated quadrants only. For example, at 
baseline, clinical parameters were determined at sites in all quadrants; at visit two, in the 
second, third and fourth quadrant; at visit three, in the third and fourth quadrant; at visit 
four, in the fourth quadrant prior to scaling.
2.1.5.1 Clinical indices
2.1.5.1.1 The Modified Gingival Index (MGI)
The modified Gingival Index (MGI) (Lobene et al. 1986) was used to assess gingival 
inflammation and is described below:
0 Absence of inflammation.
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1 Mild inflammation; slight change in colour, little change in texture of any 
portion but not the entire marginal or papillary gingival unit.
2 Mild inflammation; criteria as above but involving the entire marginal or 
papillary gingival unit.
3 Moderate inflammation; glazing, redness, oedema and/or hypertrophy of the 
marginal or papillary unit.
4 Severe inflammation; marked redness, oedema and/or hypertrophy of the 
marginal papillary gingival unit, spontaneous bleeding, congestion or 
ulceration.
MGI was preferred over the Gingival Index (Loe and Silness, 1963) because it permits 
non-invasive evaluation of the severity of gingival inflammation and thus facilitates 
GCF sampling. In addition, it provides greater sensitivity to detecting alterations in the 
signs of gingival inflammation, as the scoring system ranges from zero to four.
2.1.5.1.2 The Plaque Index (PI)
The plaque index (PI) (Silness and Loe, 1964) was used for recording plaque 
accumulation. The scoring system for this index is as follows:
0 No plaque in the gingival area.
1 A film of plaque adhering to the free gingival margin and adjacent area of the 
tooth. The plaque may only be recognised by running a probe across the tooth 
surface.
2 Moderate accumulation of soft deposits within the gingival crevice, on the 
gingival margin and/or adjacent tooth surface, which can be seen by the naked 
eye.
3 Abundance of soft matter within the gingival crevice and/or on the gingival
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margin and adjacent tooth surface.
2.1.5.1.3 Pocket Depth (PD) and Relative Attachment Level (RAL) measurements
PD and RAL were recorded by the Florida Probe to the nearest 0.2 mm. This is an 
electronic pressure sensitive probe set at 25 grams. The system consists of a pocket 
depth and an attachment level handpiece, a foot switch, computer interface and portable 
personal computer (Figure 3). The measurements of PD and RAL were made 
electronically, using the ‘pocket depth’ and ‘attachment level’ handpieces respectively 
(Figure 4), and transferred automatically to the computer when the foot switch was 
pressed. The assistant recorded clinical measurements on paper.
The probe tip has a diameter of 0.4 mm with no visible graduations along its length and 
it reciprocates through a sleeve. The edge of the sleeve is the reference from which 
measurements were recorded. PD was recorded when the probe sleeve was brought into 
contact with the gingival margin of the tooth (Figure 5). The Florida Probe, disc probe 
handpiece has a disc which, during attachment level measurement, touches the biting / 
occlusal surface of the tested tooth. When the tested tooth was not aligned with the rest 
of the teeth in the arch or was proximal to teeth with prominent cusps (canine) then the 
occlusal / biting plane of the adjacent tooth was preferred as a reference point for RAL 
measurement. Thus, attachment level measurements did not rely on the identification of 
CEJ, which is often complicated by its subgingival location or the presence of the 
restorations.
PD and RAL were carefully measured keeping the probe tip parallel to the long axis of 
the tooth. PD measurements were taken at the same points as RAL recordings and 
readings were taken twice to improve accuracy. If there was a discrepancy of more than 
1.0 mm between the two readings, then one more additional recording was taken and the 
mean of these two measurements that had less than a 1.0 mm difference was used (Clark 
et al. 1993). After each probing the probe tip was wiped with isopropyl alcohol.
2.1.5.1.4 Bleeding on Probing (BOP)
Bleeding upon probing (BOP) was scored dichotomously using the Florida Probe. 
Scoring was performed within 30 seconds after the first probing as either one (1: BOP 
present) or zero (0: BOP absent).
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Figure 3. Florida probe monitor, computer interface, and foot switch.
Figure 4. Florida probe attachment level and pocket depth handpieces.
Figure 5. Florida pocket depth probe in use.
2.1.5.1.5 Suppuration (Sup)
Presence (score: 1) or absence (score:0) of suppuration was recorded after applying 
gentle finger pressure on the gingival wall of the pocket at an apico-coronal direction.
2.1.6 GCF sampling
GCF samples were collected using Whatman grade 4 paper strips (2x13 mm) (Whatman 
Labsales Ltd. Maidstone, Kent). The paper strips were cut manually using a steel ruler 
and scalpel. Rubber gloves were worn during their preparation in order to avoid 
contamination of the strips by substances from the operator’s hands. A line was drawn on 
each strip at 8 mm, indicating the length of the paper strip to be inserted between the 
Periotron jaws and that part of the strip to be used for GCF sampling. The strips were then 
placed in glass universal bottles for autoclaving and storage.
In the clinic, GCF was sampled after PI and MGI were determined but prior to any other 
clinical recordings which could cause irritation of the tissues and serum contamination of 
the sample. Such recordings included PD, RAL measurements, BOP and suppuration. 
The site being sampled was gently air-dried in an apico-coronal direction and supra- 
gingival plaque deposits were removed. The area was carefully isolated with cotton rolls 
and a saliva ejector, to prevent samples being contaminated by saliva. The paper strip was 
inserted into the crevice to the bottom of the pocket until mild resistance was felt, taking 
care in order to avoid mechanical injury of the tissues (Mann, 1963). By the 
intracrevicular method of GCF collection, the fluid volume is a reflection of the GCF 
volume and the pocket depth as well. Then, the strip was left in the crevice for 30 seconds 
and was discarded on visual signs of serum contamination (Lamster et al. 1985) (Figure 
6). After GCF collection, the paper strip was transferred to the chairside-located Periotron 
6000 for the quantification of fluid volume (Figure 7). The jaws of the Periotron were 
wiped with pure methanol between each reading. The strips were then stored on ice in 
patient- and site-labelled sterile tubes and stored at -70°C until required.
2.1.7 Blood sampling
Venous blood was collected from the ante-cubital fossa by venipuncture using the 
Vacutainer system (BD Vacutainer™, Plymouth UK). Three tubes of 7 ml of venous 
blood were collected.
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Figure 6. Placement of filter paper strips in the gingival crevice for GCF collection.
Figure 7. Periotron 6000
2.1.8 Plaque sampling
After ensuring that no supragingival plaque deposits were present, the sites were 
isolated with cotton rolls and gently air-dried. Subgingival plaque samples were taken 
with a single vertical stroke, using a sterile hoe for each sample to prevent cross­
contamination. Care was taken to access the most apical part of the pocket with the hoe. 
Samples were stored on ice in sterile micro-centrifuge tubes containing 0.5 ml sterile 
MilliQ grade H2O (Millipore U.K. Limited, Watford, England).
2.2 Experimental Methodology
2.2.1 Calibration of the Periotron 6000
In order to transform the Periotron digital readings for each paper strip into volumes and 
also assess the accuracy of the instrument, a calibration curve was constructed for the 
Periotron 6000. The Periotron was calibrated each time prior to GCF collection in order to 
minimise daily variability in the room’s temperature and humidity. Before the Periotron 
was used the machine’s digital display was adjusted to zero using a blank paper strip. 
GCF volumes were determined from the Periotron readings, using the equation V = a + b 
x p, where V = GCF volume, a= intercept, b = slope and p = the Periotron reading. The 
curve was split into two parts, the upper and the lower as described by Lamster et al. 
(1985) and two lines were fitted by regression as shown in Figure 8. In the graph shown, 
the lower part included volumes of 0.1 to 0.3 pi while the upper part included volumes of
0.3 to 1.0 pi. GCF volumes were determined from the Periotron readings from the 
appropriate part of the Periotron calibration curve using the relevant derived formula.
Serum : phosphate-buffered saline (PBS) (1:1) was selected as the calibrating fluid since 
GCF with the majority of its constituents represents a dilution of serum (Adonogianaki, 
1992). Known volumes of a serum : PBS (1:1) mixture were delivered to Whatman grade 
4 paper strips with a Hamilton (0-1.0 pi) microsyringe (McQuiklin & Co, Glasgow, UK) 
in a range of volumes from 0.1 to 1.0 pi at 0.1 pi increments. Each measurement was 
performed three times and the mean value for each volume was used in a linear regression 
analysis from which the slope and intercept were used to determine the volumes of GCF 
collected. The digital display of the Periotron 6000 was zeroed before each measurement 
and the electrodes of the machine were carefully wiped with pure methanol and dried 
using Whatman grade 1 filter paper (Chappie et al. 1995). The GCF volumes were
67
Figure 8. Calibration curve for the Periotron 6000.
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determined from the calibration curve that was constructed based on Periotron readings 
taken on the same day as the GCF samples. Only two out of the 168 GCF samples that 
were collected displayed volume beyond the measuring range of the Periotron 6000 and 
they were arbitrarily assigned a volume of 1.6 pi.
2.2.2 GCF elution
GCF samples were eluted into 1ml of incubation buffer at room temperature using a rotary 
mixer for one hour. The strips were discarded and the eluates were aliquoted into eight 
tubes and stored at -70°C. The tubes were coded so that the laboratory analysis was 
performed in a blind manner.
2.2.3 Processing of sera samples
Each blood sample was allowed to clot overnight in tubes with no additive and then 
centrifuged at 2000 rpm for 10 minutes. The serum was aliquoted at a volume of 1 ml and 
stored into labelled microcentrifuge tubes at -70°C for further analysis. The aliquots were 
then coded so that the laboratory analysis was performed in a blind manner.
2.2.4 Processing of plaque samples
Plaque samples were vortex mixed for 30 seconds and stored in a coded sterile tube at - 
70°C until required. The PCR analysis was performed blindly. Once thawed the plaque 
sample was vortex mixed for 30 seconds and an aliquot was taken, for subsequent use in 
the PCR analysis. Lysates of plaque samples were prepared by boiling for 10 minutes.
2.2.5 Preparation of microorganisms and coating of plates
A. actinomycetemcomitans, P. gingivalis, P. intermedia, B. forsythus and T. denticola 
were prepared for coating the ELISA plates. A. actinomycetemcomitans strain Y4 was 
grown on blood agar plates and harvested after 24 hours. P. gingivalis strain W50, P. 
intermedia strain ATCC 25611, and B. forsythus strain ATCC 43037 were grown on 
fastidious anaerobe agar and harvested after seven days. The organisms were harvested 
with swabs and dispersed into PBS containing 0.1 mM disodium EDTA (PBSE). They 
were then washed once in PBSE and fixed overnight in 10% formal saline. T. denticola 
strain ATCC 35405 cells were grown, fixed and kindly donated by Dr C. Wyss, Zurich, 
Switzerland. After washing twice with PBSE, the fixed organisms were re-suspended in 
coating buffer (CB). The organisms were further washed once with coating buffer, and
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were used to coat the plates at bacterial concentrations determined by the following 
optical densities (OD6oo)- 0.02 for A. actinomycetemcomitans, 0.05 for P. gingivalis,
0.05.for P. intermedia, 0.02 for B. forsythus, and 0.001 for T. denticola.
These optical densities were determined as optimal after coating the same plate with one 
bacterium at three different bacterial concentrations. In brief, an ELISA was carried out 
after adding control serum serially diluted from 1/100 to 1/25600 in IB. Then the EU 
readings were plotted against the serum dilutions at each coating density and linear 
regression analysis was performed. The coating giving the lowest background and the 
best correlation (R2) was selected.
During the period of ELISA analysis, a new batch of B. forsythus of the same strain as 
previously used was utilised to coat the microtitre plates. In order to standardise the 
conditions of the assay, a plate was divided into two and each half was coated with the 
old and the new batches of the bacterium. Control serum serially diluted from 1/100 to 
1/25600 in IB was then added and the reference line was calibrated with reference to the 
previous dilution factor.
2.2.6 ELISA buffers
The buffers employed in ELISA assays were as follows
1. Coating buffer (CB): 1.59 g Na2CC>3 , 2.93 g NaHCCb was dissolved in 800 ml 
distilled H2O. The pH was adjusted to 9.6 at just under 1L, by adding 0.1M HC1, and 
made up to 1L in a volumetric flask, with distilled H2O. It was stored in sterilised 
bottles at 4°C for no longer than one week.
2. PBS: 8 g NaCl, 1.44 g Na2HP04.2H20 , 0.2 g KH2P 0 4, 0.2 g KC1, was dissolved in 
800 ml of distilled H2O, made up to 1L and stored at room temperature (pH 7.4).
3. Incubation buffer (IB): PBS with the addition of 0.5 g Tween 20 (SIGMA, Poole, 
Dorset) and lg of lyophilised bovine serum albumin (BSA) (SIGMA, St. Louis, USA) 
(pH 7.4). BSA was layered on the surface until dissolved without mixing. It was 
stored at 4°C for maximum of one week.
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4. 10 x Wash buffer (PBST): 10 times the concentration of IB (nil BSA) and stored at 
room temperature. It was diluted 1/10 immediately prior to use.
5. PBSE: PBS with the addition of 0.1 mM disodium EDTA (pH 7.4) and stored at room 
temperature.
2.2.7 Control serum for the ELISA
Standards for the range of ELISA analyses were obtained by initially testing sera from 
33 patients with advanced periodontitis attending Glasgow Dental Hospital and School 
but not participating in the current study. ELISA analyses indicated which sera had high 
titres to the five putative periodontal pathogens. Then, these sera were serially diluted 
and assayed on the same plate by ELISA to test for linearity. The serum that gave the 
highest reading combined with the best linearity was selected as the control serum for 
that particular microorganism and was consistently used in all the experiments.
2.2.8 Enzyme-Linked Immunosorbent Assay (ELISA) of sera
Specific antibody titres were measured by enzyme-linked immunosorbent assay 
(ELISA) as previously described (Ebersole et al. 1980), using formalised whole cells at 
an absorbance that was previously determined as optimal to coat microtitre plates. 
Immulon 1 plates (Dynatech) were used because of their low protein-binding 
characteristics. The plates were manually pre-washed three times with coating buffer 
and coated with 100 pi per well of whole cells. Plates were stored at 4°C overnight. 
Controls for each aspect of the ELISA process were arranged in the wells around the 
outside of the plates.
After coating, the plates were washed five times with 250 pi of wash buffer using an 
automatic washer (Dynex Ultrawash Plus, Ashford, England). Then they were treated 
with 100 pi per  well of incubation buffer (IB) containing 5% skimmed milk (Marvel, 
Premier Beverages, Stafford, UK) for 30 minutes at 37°C to remove background 
binding. The plates were washed again five times before the addition of sera. Serum 
serially diluted from 1/100 to 1/25600 in EB was used as a reference positive control 
serum. Serum derived from the study patients was added at a dilution of 1/200. 50 pi 
of sera was added in each well and was incubated at 37°C for 90 minutes. Following 
incubation with sera, the plates were washed again five times. Subsequently, 100 pi per
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well of biotin-conjugated anti-human IgG (Sigma, St. Louis, MI, USA) at 1/2000 
dilution in IB was added and plates were incubated at 37°C for 60 minutes. The plates 
were then washed five times. Thereafter, they were incubated at 37°C for 60 minutes or 
at 4°C overnight with 100 pi per well extravidin-peroxidase (Sigma) at 1/2000 dilution. 
After washing (five times) the reaction was visualised using 100 pi per well 
tetramethylbenzidine (TMB) (Kirkegaard & Perry Laboratories, Maryland, USA) and 
stopped after 5-10 minutes using 50 pi 0.1 M HC1.
Optical densities were read using a Dynex Technologies MRX II plate reader at 450 ran 
with a 630 nm reference wavelength. All sera samples collected from the same patient 
at different time points (six samples in total) were assayed in duplicate and on the same 
plate. Correction was made for non-specific binding and the averaged duplicate results 
were read from a reference line derived from serial dilutions of the reference positive 
control serum. Results were expressed as ELISA units (EU) (Gmiir et al. 1986; 
Mooney et al. 1993). The ELISA was standardised such that 1/200 dilution of the 
reference control serum gave a value of 1000 EU (Mooney et al. 1993).
2.2.9 ELISA analysis of GCF samples
The same ELISA methodology that was used for analysis of the sera samples was used 
for analysis of the GCF samples. 50 pi of GCF aliquot was used per well instead of sera 
and it was not serially diluted. The samples were also analysed in duplicate and the 
averaged duplicate results were read from a reference line derived from serial dilutions 
of the reference positive control serum. All the GCF samples from the same patient 
were tested together on the same plate. The results were expressed as EU/30sec 
(Mooney and Kinane, 1997).
Since the GCF assay was standardised against a dilution of 1/200 control serum and the 
GCF sample was eluted in 1 ml of buffer (approximately 1/1000 dilution), one should 
multiply the results by 1000/200 i.e. by a factor of five.
2.2.10 Avidity analysis
The dissociation assay to determine antibody avidity was performed in a similar manner 
to the ELISA for the serum analysis described above. After incubation with sera, the 
wells were treated with increasing concentrations of ammonium thiocyanate (0, 0.2, 1.0,
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2.0, 3.0 M). Patient serum was tested in duplicate at a dilution of 1/20, and the 
thiocyanate dilutions were compared to a buffer blank with 100% binding. The plates 
were incubated at 37°C for 60 minutes, washed five times automatically, and then the 
ELISA continued as before. The concentration of thiocyanate as a molarity (M) 
required to dissociate 50% of the bound antibody was calculated by linear regression. 
This concentration was termed the 50% inhibitory dose ( I D 5 0 )  and provided a measure 
of the relative avidity (MacDonald et al. 1988; Pullen et al. 1986). All the samples 
from the same patient were tested together on the same plate.
2.2.11 Polymerase chain reaction (PCR)
Table 6 lists the PCR primers used in the current study. Species-specific primers that 
were previously tested for cross-reactivity with other closely related species targeted the 
16S rRNA of the bacteria. The specificity of the amplified products and therefore of the 
primers was confirmed in previous studies by Ashimoto et al. (1996) for P. gingivalis,
A. actinomycetemcomitans, T. denticola and B. forsythus, and by Riggo et al. (1998) for 
P. intermedia. All primers were obtained from MWG-Bistech (Milton Keynes, UK). 
Primers were supplied in a lyophilised form and were re-suspended in sterile, molecular 
biology grade water at 1 pg/ml (MilliQ grade H2 O).
PCR amplification reactions were carried out in a reaction mixture of 100 pi consisting 
of 10 pi sample lysate and 90 pi of reaction mixture containing lxPCR buffer (lOmM 
Tris-HCl (pH 9.0 at 25°C), 1.5mM MgCl2, 50mM KC1, 0.1%Triton® X-100), 2 units of 
Taq DNA polymerase (Promega, UK), 0.2 mm dNTPs (dATP, dCTP, dGTP, dTTP) and 
50 pmol of each primer. The primers were separated from the other components of the 
reaction mixture by a layer of wax (DyNAwax, Flowgen, Lichfield, UK). The wax layer 
prevented the PCR reaction from starting until the wax had melted upon commencement 
of PCR cycling (“hot start” PCR). PCR cycling was carried out in an OmniGene 
thermal cycler (Hybaid, Teddington, England, UK).
The yield of PCR product for P. intermedia was greater at 55°C compared to 60°C. 
Therefore, 55°C was selected as the annealing temperature for this organism in 
subsequent reactions. The cycling conditions for P. intermedia and A. 
actinomycetemcomitans comprised an initial denaturation step at 94°C for 5 minutes, 40 
amplification cycles of denaturation at 94°C for 1 minute, annealing of primers at 55°C
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Table 6. Sequences, expected product size, target and references for PCR primers.
Primer pairs (5’-3’)
P. gingivalis
AGG CAG CTT GCC ATA CTG CG 
ACT GTT AGC AAC TAC CGA TGT
A. actinomycetemcomitans
ATG CCA ACT TGA CGT TAA AT 
AAA CCC ATC TCT GAG TTC TTC TTC
P. intermedia
CCT AAT ACC CGA TGT TGT CCA CA 
AAG GAG TCA ACA TCT CTG TAT CC
T. denticola
TAA TAC CGA ATG TGC TCA TTT ACA T 
TCA AAG AAG CAT TCC CTC TTC TTC TTA
B. forsythus
GCG TAT GTA ACC TGC CCG CA 
TGC TTC AGT GTC AGT TAT ACC T
Base position Target Reference
Amplicon length
(bp)
729-1,132 (404) 16S rRNA Slots et al.
(1995)
478-1,034 (557) 16S rRNA Ashimoto et al.
(1996)
Riggio et al. 
(1998)
Slots et al. 
(1995)
Slots et al. 
(1995)
1,028-1,006 16S rRNA
(855)
193-508 (316) 16S rRNA
120-760 (641) 16S rRNA
for 1 minute and primer extension at 72°C for 1.5 minutes, followed by a final extension 
step at 72°C for 10 minutes. The cycling conditions for P. gingivalis, T. denticola and
B. forsythus were as follows: initial denaturation at 94°C for 5 minutes, 35 amplification 
cycles of denaturation at 94°C for 1 minute, annealing of primers at 60°C for 1 minute 
and primer extension at 72°C for 1.5 minutes, followed by a final extension step at 72°C 
for 10 minutes as previously described by Ashimoto et al. (1996). The reaction products 
were either stored at -20°C or analysed immediately.
Strict procedures were employed when carrying out PCR. Separate rooms were used for 
sample preparation, setting up of PCR reactions and analysis of PCR products. Filter 
tips were used at all stages of the experiment, except when adding the sample to the 
reaction mixture when a positive displacement pipette was used. Negative and positive 
controls were included in each batch of samples being analysed by PCR. The negative 
control was a 90 pi reaction mixture with the sample replaced by lOpl of sterile water. 
The positive control with the exception of T. denticola, contained 10 ng of genomic 
DNA from the relevant organism in 90 pi of reaction mixture, with sterile water added 
to bring the volume to 100 pi.
Since it was not possible to grow T. denticola at the microbiology laboratory at Glasgow 
Dental Hospital and School, a synthetic T. denticola positive control was constructed. 
A small fragment of the T. denticola 16S rRNA gene (79 bp) was amplified using the 
following nucleotide primers (from 5’-3’): TAA TAC CGA ATG TGC TCA TTT ACA 
TAA AGG TAA ATG AGG AAA GGA GCT (base position from 193 to 244) and T 
CAA AGA AGC ATT CCC TCT TCT TCT TA (base position from 508 to 482).
2.2.12 Analysis of PCR products
10 pi of each reaction product was added to 1.5 pi of gel loading dye (0.25% 
bromophenol blue, 50% glycerol, lOOmM EDTA pH 8.0), electrophoresed on a 2% 
agarose gel containing ethidium bromide (0.5 pg/ml) and visualised and photographed 
using an ImageMaster video documentation system (Pharmacia Biotech, St. Albans, 
UK). A 100 bp DNA ladder (Pharmacia Biotech) was used as a molecular weight 
marker.
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2.3 Statistical analyses
Minitab (release 12.1, Minitab Inc., State College, PA) and SPSS (version 9.0, SPSS Inc., 
Chicago, DL, USA) statistical packages were used for the analyses of the data. After 
treatment positive values denoted a positive change whereas negative values a negative 
change. The level for declaring statistical significance was set at the 95% confidence level 
(p<0.05 for hypothesis testing).
2.3.1 Clinical data
For the full-mouth clinical indices (PD, AL and BOP), a mean score was derived for 
patient at each visit. BOP was expressed as the percentage of sites which bled on probing. 
The number of sites with PD > 5 mm (No. of sites > 5 mm), per patient and per visit was 
also determined. In the assessment of clinical indices at the four specific sites (PD, RAL) 
a mean score per site and per visit was given.
For the comparison between the Q-SRP and FM-SRP groups over the three visits, an 
ANOVA analysis with the General Linear Model (GLM) was applied for the full-mouth 
and the site-specific clinical indices. The average of the clinical indices (PD and RAL) 
collected from the four selected sites per patient was used for this analysis. Treatment 
modality, smoking status and visit number and their interactions were modelled as fixed 
factors and the patient as a random factor. The PD, AL, BOP and No. of sites > 5 mm for 
all the sites or the PD and RAL for the selected sites were used as the response variables 
for each analysis. The initial model included the three main effects of treatment, smoking 
and visit, together with the three-way interaction of these factors. If the three-way 
interaction was not significant, this model would be rejected and the next model would 
consist of the three main effects and the two-way interactions. Similarly, if the two-way 
interactions were not significant, they would be rejected and the model consisting of only 
main effects would be examined. Therefore, the final model included only the main 
effects and any interactions that gave a significant finding.
The full-mouth clinical indices (PD, AL, BOP and No. of sites > 5mm) were compared 
between the two treatments at baseline, R1 and R2, using the two sample t-test. For the 
site-based analysis, the two sample t-test was used to compare the site-specific PD and 
RAL between the two treatment groups at baseline, R1 and R2. Differences in BOP and 
Sup between the groups were analysed using the Chi squared test, except when expected
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counts were less than five where Fisher’s exact test was used. The Mann-Whitney test 
was applied to analyse MGI and PI differences between Q-SRP and FM-SRP groups. The 
changes of the site-specific clinical indices (PD, RAL, BOP, Sup, MGI, PI) at deep 
pockets (mean PD > 7mm) and moderate to deep pockets (mean PD < 7 mm) were 
compared between the two treatments at R1 and R2 from baseline, using the equivalent 
tests mentioned above.
For the analyses of the full-mouth clinical indices (PD, AL and BOP) before and after 
treatment within each group, the paired t-test was used. The No. of sites > 5 mm was also 
analysed in the same manner. The site-specific clinical indices PD and RAL were 
analysed using the paired t-test. The McNemar test was used to analyse BOP and Sup and 
the Wilcoxon signed rank test was used for the analyses of MGI and PI before and after 
treatment. Although, non-parametric statistical analysis was performed for MGI and PI, 
the mean values of these parameters are shown for illustration of effects.
In order to determine whether any clinical deterioration occurred at sites in quadrant one 
(IQ) for the Q-SRP group over a period of six months, the site-specific clinical indices 
(PD, RAL, BOP) of IQ were compared with those of quadrant four (4Q) at baseline and at 
R1 and R2. The two sample t-test was used for the comparison of PD and RAL and the 
differences in BOP between the two quadrants were analysed using the Chi squared test. 
Changes in PD and RAL with treatment (BAS-R1 and BAS-R2) for IQ and 4Q were 
determined using the paired t-test. The changes in BOP within each quadrant were 
analysed using the McNemar test.
For the Q-SRP group, during the active phase of treatment (baseline to each scaling 
session) the changes in site-specific clinical indices of the untreated sites were determined 
using the paired t-test for the analyses of PD and RAL, the Wilcoxon signed rank test for 
MGI and PI and the McNemar test for BOP and Sup.
For the analysis of the completed questionnaires, the Mann-Whitney test and the two 
sample t-test test were used to compare the pain rating and the body temperature between 
Q-SRP and FM-SRP groups, respectively.
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2.3.2 Immunological data
The immunological data were not normally distributed even after transformations were 
performed and therefore parametric statistical tests were not appropriate. The Mann- 
Whitney test was used for the comparison of serum and GCF IgG titres, and IgG avidity 
between the two groups at baseline and after treatment. This test analysed the data for 
detection of differences between the two groups at each visit (BAS, R l, R2) and for 
comparison of changes with treatment (BAS-R1, BAS-R2). Within each group, the 
Wilcoxon signed rank test was used to assess changes before and after treatment. The 
GCF volume data were found to have a skewed distribution throughout all clinical 
assessments. Therefore, GCF volume was analysed in a similar manner as IgG titres and 
avidity. Although, non-parametric statistical analysis was performed for GCF antibody 
titres and GCF volume, the mean values of these parameters are shown for illustration 
of effects. Spearman’s rank correlation coefficient was used to assess the relationship 
between GCF volume and GCF titres before and after treatment.
For the determination and comparison of the humoral immune response dynamics between 
Q-SRP group and FM-SRP group, the Mann-Whitney test analysed and compared the 
changes in the IgG antibody titres and avidities at each visit from baseline (baseline 
against five additional visits). The Wilcoxon signed rank test was used to determine the 
immune response dynamics in each group by comparing baseline with each follow up 
visit.
Spearman’s rank correlation coefficient was used to assess the relationship between 
immunological parameters (serum IgG titres and avidity) and full-mouth clinical indices 
(mean PD and mean No. of sites > 5 mm). In addition, the subjects of this study were 
categorised as moderately and advanced diseased periodontitis patients based on whether 
they had mean PD and mean No. of sites > 5 mm equal to or less than the median and 
greater than the median baseline values, respectively. Then serum IgG titres and antibody 
avidity were compared between these two subgroups of patients using the Mann-Whitney 
test. In a similar way, the changes in antibody titres and avidity were compared between 
patients who yielded moderate and greater clinical improvement using the Mann-Whitney 
test. Patients with mean changes in clinical indices between baseline and R2 equal to or 
less than the median changes were designated as showing moderate improvement while 
those with mean changes greater than the median values were designated as showing large
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clinical improvement. For the site-specific analysis GCF antibody titres and GCF volume 
were compared between sites of deep pocket depth (mean PD > 7mm ) and moderate 
pocket depth (mean PD < 7mm) using the Mann-Whitney test.
2.3.3 Microbiological data
The presence or absence of differences in the prevalence of the microorganisms between 
Q-SRP and FM-SRP groups were analysed using the Chi squared test, except when 
expected counts were less than five where Fisher’s exact test was used. The data were 
analysed for differences at each visit (BAS, R l, R2) and for comparison of changes with 
treatment (BAS-R1, BAS-R2). For each group, the McNemar test was used to compare 
the prevalence of specific organisms before and after treatment. For the patient-based 
analysis the patient was scored positive for one organism if at least one out of the four sites 
harboured this organism.
For the comparison of changes in the dichotomous variables (BOP, Sup and the presence 
or absence of a periodontal pathogen) between the two treatment groups, the Chi squared 
test compared reduction in the detection of a variable (coded as 1) against no change and / 
or increase in the detection of this variable (coded as 0). Sites that showed an increase in 
the presence of BOP, Sup or in the detection of a pathogen after treatment were very few 
and were combined with the sites that showed no change post-treatment to form a no 
improvement category. Although the results are shown as percentages, the raw data were 
used in the statistical analysis.
The Chi squared test was used to compare the microbiological findings of sites in quadrant 
one (IQ) with sites in quadrant four (4Q) before and after Q-SRP and the McNemar test 
was used to compare the prevalence of the organisms at Rl and R2 from baseline for IQ 
and 4Q.
The prevalence of the bacteria at baseline was compared between moderately and 
advanced diseased periodontitis patients and between deep and moderate to deep sites as 
described earlier, using the Chi squared test, with Fisher’s exact test correction. These 
tests were also used to compare the changes in the prevalence of the organisms at R2 from 
baseline between patients with moderate clinical improvement and patients with large 
clinical improvement.
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The patients were divided into two groups according to whether they were positive or 
negative for an organism. Then the full-mouth clinical indices and serum IgG titres and 
avidities were compared between these two groups. For the site-specific analysis the sites 
were divided into two groups based on the presence or absence of a microorganism and 
the site-specific clinical indices and GCF IgG titres were compared between these two 
categories of sites. The clinical and microbiological analyses between the two subgroups 
of sites or subjects that were positive or negative for an organism were performed in a 
similar manner as previously described.
2.3.4 Effect of smoking on clinical, immunological and microbiological parameters
In general, the differences between smokers and non-smokers for Q-SRP and FM-SRP, 
were analysed for clinical, immunological and microbiological parameters after dividing 
the patients into two groups according to their smoking status. These parameters were 
analysed in a similar manner as described above. Smokers were compared against non- 
smokers in all subjects at baseline and in the Q-SRP and FM-SRP groups before and after 
treatment. Finally, smokers in the Q-SRP group were compared against smokers in the 
FM-SRP group to determine if there were differences in the various parameters between 
the two treatments among smokers.
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CHAPTER 3
EFFECT OF SCALING AND ROOT PLANING ON CLINICAL
PARAMETERS
3. Effect of scaling and root planing on clinical parameters
3.1 Results
3.1.1 Demographic details
Initially, 60 patients were recruited. Ten patients were excluded during the course of the 
study because they failed to attend their appointments on two occasions. Seven of them 
belonged to the Q-SRP group and the remainder to the FM-SRP group. Of the ten poor 
attenders, one had a car accident, one emigrated, two subjects failed to attend due to 
work commitments and the remaining six dropped out of the study for unknown 
reasons.
Therefore, 50 participants completed the study but a further eight were excluded at the 
end of the study because they took antibiotics during treatment. Three of them belonged 
to the Q-SRP group and five to the FM-SRP group. One of the participants was 
prescribed antibiotics for a tooth abscess and the others for reasons not related to 
periodontal treatment. Out of the 42 patients who completed the study, three 
participants in total were excluded from R2, but not from the study. The three 
participants were FM-SRP patients, two of whom could not attend R2 due to work 
commitments and one due to antibiotic therapy. In conclusion, the analyses of this study 
were based on 42 subjects ( N q _ s r p = 2 0  and N f m - s r p = 2 2 )  and 168 sites ( N q _ s r p = 8 0  and 
N f m - s r p = 8 8 )  at R l, but at R2 the analysis for the FM-SRP group was limited to 19 
subjects and 76 sites and this should be noted when referring to the tables. No subjects 
were excluded from this investigation due to poor response to therapy.
3.1.2 Clinical findings before and after Q-SRP
Full-mouth and site-specific clinical indices were significantly reduced at R l and R2 
with a further clinical improvement between Rl and R2. Whole-mouth clinical indices 
showed a significant PD reduction of 1.7 mm and 1.8 mm at R l and R2 from baseline, 
respectively (p<0.001) (Table 7). There was a gain in attachment of 1.1 mm at both Rl 
and R2 (p<0.001). A reduction in BOP of 54% was found at R l and of 58% at R2 
(p<0.001). The number of sites with PD > 5mm was significantly reduced by 56% at 
Rl and by 60% at R2 (pO.OOl). Further clinical improvement between Rl and R2 was 
seen for PD (p<0.05), No. of sites > 5mm (p<0.01) and BOP (p=0.057).
79
a>00
-oO
~ao
*? s
C/37*-x)
co=3
1+
CLTO
X3
!*> JT
S>c
r  i'­ll CTOw
3Q.—too
S 1
D333"
CTQ
03O"3
3 to(T)D.5"
CTQO
3XJ’-iOO'5'
CTQ
N
o. sites>5 
m
m
00
o
XJ
0s
AL 
(m
m
)
PD 
(m
m
)
z
IIK)O
69.0±
20.0
71.01 
19.0
5.010.9
4.410.7
B
aseline
13.01 
12.0
17.019.0
3.910.9
2.710.4
2
9.019.0
13.017.0
3.910.9
2.610.3 B
56.0120.0
54.01 
18.0
i+
o
1.710.6
C
hange
(B
A
S-R
1)
AO
©O
AO
©o
AO
oo
AO
Oo
p- 
value 
(B
A
S-R
1)
60.0120.0
On
CO
©
1+
VO
o 9
0+
 
ri 00
1+
o
C
hange
(B
A
S-R
2)
Ao
oo
A©
©o
Ao
oo
Ao
©o
p- 
value 
(B
A
S-R
2)
0.007
o
o
o
4L
o
©
p- 
value 
(R
1-R
2)
Table 
7. 
Changes in 
the 
w
hole-m
outh 
clinical indices for Q-SRP 
at Rl 
and 
R2.
Table 8 shows the changes in the site-specific clinical indices post treatment. PD was 
reduced by 2.7 mm at R l and by 2.9 mm at R2 (p<0.001). RAL improved by 0.8 mm at 
R l and by 1.0 mm at R2 (p<0.001). The improvements between Rl and R2 were 
significant for both PD and RAL (p<0.05).
Of the 80 sites in total, BOP was present at 66 sites (82.5%) at baseline and decreased to 
14 (17.5%) at R l (p<0.001) and 11 (13.8%) at R2 (p<0.001). One site that was initially 
negative for BOP at baseline became positive at R l and four sites at R2. Suppuration 
was present at 49 sites (61.3%) at baseline, at three sites (3.8%) at Rl (p<0.001) and at 
one site (1.3%) at R2 (p<0.001). Nevertheless one site formerly negative for Sup, 
suppurated between BAS and Rl and one site between BAS and R2. Significant 
reductions in MGI and PI were seen at R l and R2 (p<0.001). There was also a 
significant improvement in MGI between Rl and R2 (p<0.001).
3.1.3 Clinical findings before and after FM-SRP
There was a continuous improvement for all clinical parameters at R l and R2. The 
analyses of the whole-mouth clinical indices showed significant PD reduction of 1.6 
mm, and 1.7 mm at Rl and R2, respectively (p<0.001) (Table 9). Attachment levels 
improved after treatment, with a gain of 1.1 mm at Rl and R2 (p<0.001). There was a 
52% reduction in BOP at Rl and 58% at R2 (p<0.001). The mean number of sites with 
PD > 5 mm was reduced by 53% at Rl and by 54% at R2 (p<0.001). Between R l and 
R2 a statistically significant improvement in PD (p=0.001), BOP (p<0.005) and number 
of sites > 5 mm (p<0.005) was also observed.
Clinical data collected from the selected sites showed that mean PD was reduced by 2.1 
mm at R l and by 2.6 mm at R2 (p<0.001) (Table 10). RAL improved by 0.7 mm at Rl 
and by 1.1 mm at R2 (p<0.001). Additional improvements in PD and RAL between Rl 
and R2 were small but statistically significant (p<0.001).
The site-specific clinical analyses showed that BOP was present in 69 sites (78.5%) at 
baseline and decreased to 18 (20.5%) at R l (p<0.001) and nine (11.8%) at R2 
(p<0.001). Between BAS and Rl, five sites initially negative for BOP bled on probing 
and between BAS and R2, one site became positive for BOP. Suppuration was present 
in 57 sites (64.8%) at baseline and was reduced to three (3.4%) at R l (p<0.001) and
80
3a
3Oo? r
2-Cl
CD3
CD>00 00
3
,3csoa.>-«33
3
CTQ
“3O
S
3O.
0J35’
CTQ
03O
3
CD
CD
S'S'
otqo3
Oct;5’<JQ
00c3
C333
o
3oS'S i
3
<’£L
5‘D-
CD
X
3►3C
CD
5‘a.
3 MG
I
Sup*
BO
P*
RAL 
(m
m
)
PD 
(m
m
)
z:ii
o oo
1.9 
±0.7
2.5 
±0.8
OS
L )
00
Isj
U i
14.0 
±2.3
6.2 
± 
1.2
B
aseline
o
b
1+
o
b o
0.5 
±
0.5
UJ
0 0
- 0
u i
13.2 
±2.3
3.5 
± 
1.1
2
o
b
1+
o
b
0.2 
±
0.4
u j
UJ
bo
13.0 
±
2.2
3.3 
±
0.8
S
1+
o
b o
2.1 
± 
1.0
u>
u i
Os
u i
©
o
o o
1+
b
2.7 
± 
1.3
C
hange
(B
A
S-R
1)
Ao
bo
Ao
bo
Ao
bo
A
O
bo
A
©
bo
A
O
bo
p- 
value 
(B
A
S-R
1)
1.2 
±
0.9
2.4 
±
0.9
OSo
b
Osso
b
b
1+
o
b
2.9 
± 
1.3
C
hange
(B
A
S-R
2)
Ao
oo
A
O
Oo
Ao
bo
Ao
bo
A
O
bo
Ao
b©
p- 
value 
(B
A
S-R
2)
oe
ro
Ao
bo
o
u>oo
o
b
OSo
o
bo
u s
o
b
UJ
p- 
value 
(R
1-R
2)
Table 
8. 
Changes in 
the 
site-specific 
clinical indices for Q-SRP 
at Rl and 
R2.
CO>c/3
13CJ
T5O
7?n>
T)
a .a>
13
>
r
s  §.
DOO13
3
CTQ
3
CL
-So
o
3
CTQ
3 R*
3
CTQ
O
3
Oa r
5"
CTQ
N
o. sites>5 
m
m
BOP 
(%
)
AL 
(m
m
)
PD 
(m
m
)
2Ito
to
66.0127.0
69.01 
17.0
5.1 
1 
1.0
4.410.6
B
aseline
13.016.0
-0
b
1+
o
o
4.011.0
2.810.3
2
8.015.0
b
1+
as
b
3.91 
1.0
2.610.2 s
53.0123.0
52.01 
15.0
1.110.4
1.610.5
C
hange
(B
A
S-R
1)
AO
©o
AO
b
o
Ao
b
o
Ao
b
o
p- 
value 
(B
A
S-R
1)
54.0124.0
O)OO
b
1+
oo
b
1.1 
10.5
1.710.6
C
hange
(B
A
S-R
2)
A
o
o
o
Ao
b
o
A
o
b
o
Ao
b
o
p- 
value 
(B
A
S-R
2)
eo
o'
o o
b
oto
o
o
o
o
b
o
p- 
value 
(R
1-R
2)
Table 
9. 
Changes in 
the 
whole-m
outh 
clinical indices for FM
-SRP 
at Rl and 
R2.
”0a
uX3Oo7Tcd
D-ro"a
03>
C/2
111 p -hrc 2» 3 =CD-■ 3
2 §
i+
oxO
"OO
3. 3
<CD
3a3ocr
3CD3
BJ 3
00 3Cco 3
a  CTQ
05
3
CL
>-too
s  sf053
5'
OP
COoT3
I
2
cTCDel­s'OPo3
oa*3'
op
ooc*3
3
T5T33
o
oo-
3 iCDQ-
qp_5'
OP
3a-CDX
3X3
3CD
5'D-CDX
2
O
00
3
T5*
CD
O
13*
RAL 
(m
m
)
PD 
(m
m
)
2
Ioooo
2.0 
±
0.7
to
b
1+
O
b
OS
bo
-0OO
b
u>
b
1+
00
b
1+
b
DO3coCD
3*CD
0.7 
±
0.6
o
b
1+
p
b
u>
b
to
©
b
U5
to
1+
b
u>
bo
1+
o
b
2
o
bp
l+
o
b
O
b
1+
o
b
-3
b bo
to
b
1+
00
UJ
U)
1+
p
00
S
1.3 
±
0.9
to
b
1+
o
oo
Os
b
(Oi
oo
b
©
b
i+
©
b
to
1+
3
>C/3i
2
o3*33OTPCD
Ao
bo
AO
bo
Ao
bo
Ao
b©
AO
bo
AO
bo
3
>C/3i
J50
7
<
CD
b
1+
o
b
to
to
1+
©
bo
so
b
OS00
b 1+
b
to
bs
1+
b
ro
>
oo
S
o3*33OPCD
AO
bo
AO
bo
Ao
bo
Ao
bo
Ao
bo
AO
bo
x—*\
DO
>
001
7
<
£L
w CD
o
bto
to
o
b boo
o
-oo
AO
bo
Ao
bo
2S
7
<
£.3CD
Table 
10. 
Changes in 
the 
site-specific 
clinical indices for FM
-SRP 
at R1 and 
R2.
three (4.0%) at R2 (p<0.001). One site initially negative for suppuration became 
positive between BAS and R2. MGI and PI significantly improved at R1 and at R2 
(p<0.001). A significant further reduction in MGI and PI was noted between R1 and R2 
(p<0.05).
3.1.4 Comparison of clinical indices between Q-SRP and FM-SRP groups
No statistically significant differences in any clinical index were seen between the two 
treatments at baseline. The GLM analysis revealed that there was no significant three- 
way or two-way interaction among the following fixed factors: the treatment strategies 
(Q-SRP and FM-SRP), smoking and visits (BAS, R l, R2), on the full-mouth clinical 
parameters (p>0.05) (data not shown). Similarly, no significant effect of treatment or 
smoking on the full-mouth indices was seen (p>0.05). This series of analyses showed 
that there was a statistically significant visit effect on PD reduction, gain in AL, BOP 
improvement and reduction of No. of sites > 5 mm (p<0.001). There was also a 
significant (random) patient effect on the full-mouth clinical indices (p<0.01). The GLM 
analysis for the selected sites showed that there was a significant three-way interaction 
among the following fixed factors: the treatment strategy, smoking and visits on PD and 
RAL of the selected sites (p<0.001) (data not shown).
Table 11 depicts marked clinical improvement in the whole-mouth clinical indices after 
treatment with no differences in any clinical index between the treatment groups at any 
time point. The differences in the site-specific clinical indices between the two 
treatment strategies over time are shown in Table 12. A significantly greater PD 
reduction of 0.6 mm was seen for the Q-SRP group between BAS and Rl when 
compared to the FM-SRP group (p<0.005). However, no statistically significant 
differences were noted between the two treatment groups between BAS and R2. PD 
was reduced by 2.9 mm for the Q-SRP group and by 2.6 mm for the FM-SRP group at 
R2. When the differences between Rl and R2 were examined, there was an additional 
0.3 mm PD reduction for the FM-SRP group (p<0.05). No significant differences in 
gain of RAL were found between the two groups at Rl and R2 from baseline. RAL gain 
was 0.8 mm and 0.7 mm between BAS and R l, and 1.0 mm and 1.1 mm between BAS 
and R2 for the Q-SRP and FM-SRP groups, respectively.
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When PD and RAL from the selected sites were averaged per patient and then compared 
between the two treatments the same results were found as with the site-specific analysis 
mentioned above (data not shown). The latter analysis was based on the assumption 
that sites are statistically independent units while the former used the patient as the 
experimental unit. In the following sections, in reference to site-specific data, these are 
analysed using the site as the experimental unit.
The analysis of BOP and Sup, showed no significant differences between Q-SRP and 
FM-SRP groups at any time point. Similarly, no significant differences in MGI and PI 
were seen between the treatment groups at BAS, Rl and R2.
When deep pockets (mean PD > 7 mm) and moderate to deep pockets (mean PD < 7 
mm) were considered, a significantly greater PD reduction in moderately deep pockets 
was seen for the Q-SRP group between BAS and R l compared to the FM-SRP group 
(p<0.01) (Table 13). No significant differences in any other site-specific clinical index 
were noted in moderately deep pockets between the two treatments between BAS and 
R l. The analysis of the deep pockets revealed no significant differences in any clinical 
index between the two treatments at this time interval. This finding indicates that the 
greater clinical improvement at a site-specific level seen for the Q-SRP group between 
BAS and Rl was due to differences in PD reductions in the moderately deep pockets 
only between the two treatment groups. No significant differences in any clinical index 
were found for the moderately deep pockets between the two treatment modalities 
between BAS and R2. Nevertheless, the analysis of the deep pockets showed a 
significantly greater gain in RAL for the FM-SRP group compared to the Q-SRP group 
at this time interval (p<0.05). No other significant differences in the other clinical 
indices were found between the two treatment groups at R2 from BAS.
In conclusion, no statistically significant differences in the full-mouth clinical indices 
were seen between the two treatment groups post-therapy. Nevertheless, at a site- 
specific level there was a greater PD reduction for the Q-SRP group between BAS and 
Rl compared to the FM-SRP group, which was seen for moderately deep pockets (PD < 
7 mm). In addition, a significantly greater gain in RAL was found for deep pockets (PD 
> 7 mm) in the FM-SRP group at R2. However, when all the selected sites were
82
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considered regardless of their initial pocket depth, no significant differences in any 
clinical index were detected between the treatment groups at R2 from BAS.
3.1.5 Effect of partial periodontal therapy (plaque control and root planing 
quadrant per quadrant) on the untreated sites in Q-SRP patients
At baseline, clinical indices were collected from the four selected sites. At the 
consecutive sessions of Q-SRP, clinical measurements were taken from the remaining 
not yet scaled quadrants as described earlier, in order to determine the effect of partial 
periodontal therapy on the untreated periodontal sites (Table 14). For sites in 2Q, a 
significant PD reduction of 0.5 mm occurred at visit two, two weeks after the initiation 
of active treatment (p=0.005). MGI and PI significantly improved (p<0.05), but there 
was no significant gain in RAL. BOP decreased from 90% to 75% and Sup from 60% 
to 50%, but these changes did not reach statistical significance.
Sites in 3Q showed a significant PD reduction of 0.4 mm at visits two and three from 
baseline, two and four weeks after the commencement of hygiene phase therapy and 
scaling of IQ (p<0.05). No significant change in RAL was noted, while a significant 
improvement in MGI (p<0.05) and PI (p<0.01) occurred at these visits. BOP improved 
non-significantly from 80% to 55% and 50% (p>0.05) and Sup decreased significantly 
from 60% to 50% and finally to 25% (p<0.05).
Similarly, sites in 4Q showed a significant improvement in all clinical indices except for 
RAL and BOP, over the two, four and six weeks after the initiation of the hygiene phase 
of treatment. PD was reduced by 0.4 mm at visit two (p<0.05) and 0.6 mm at visit four 
from baseline (p=0.01). MGI improved significantly at visits three and four from 
baseline (p<0.01) and PI at all visits from baseline (p<0.01). Sup improved significantly 
at visits three and four from baseline (p<0.01). BOP decreased from 90% at baseline to 
70%, 65% and finally to 70% at visit four, but without reaching statistical significance. 
Very little change in RAL was seen over a period of six weeks.
3.1.6 Patients’ observations post-scaling
51 completed questionnaires were collected, 23 for the Q-SRP group and 28 for the FM- 
SRP group (Table 15). No significant differences in the body temperature or in the 
number of patients who showed elevated body temperature (> 38°C) were detected
83
Table 14. Effect o f partial periodontal therapy on the untreated sites in Q-SRP group.
Baseline Visit 2 p-value
(BAS-2)
Visit 3 p-value
(BAS-3)
Visit 4 p-value
(BAS-4)
PD(mm) 2Q 6.2 ± 0 .9 5.7 ± 0 .8 0.005
3Q 6.1 ± 1.4 5.7 ± 1.2 <0.001 5.7 ± 1.5 0.041
4Q 5.8 ± 1.2 5.4 ± 1.0 0.019 5.4 ± 1.1 0.066 5.2 ± 1.2 0.010
RAL(mm) 2Q 13.8 ± 2.1 13.7 ±2 .3 0.337
3Q 13.6 ± 2 .7 13.5 ± 2 .6 0.496 13.6 ± 2.6 0.727
4Q 13.9 ± 2 .0 13.9 ± 1.8 0.793 14.0 ±2.2 0.534 13.8 ± 1.9 0.469
BOP* 2Q 90.0 75.0 0.453
3Q 80.0 55.0 0.125 50.0 0.070
4Q 90.0 70.0 0.219 65.0 0.125 70.0 0.219
Sup* 2Q 60.0 50.0 0.625
3Q 60.0 50.0 0.625 25.0 0.016
4Q 60.0 50.0 0.625 10.0 0.006 15.0 0.004
MGI 2Q 2.7 ± 0 .9 2.3 ± 0 .9 0.014
3Q 2.6 ± 1.0 2.2 ± 0 .9 0.050 1.8 ± 1.1 0.004
4Q 2.6 ±0 .8 2.3 ± 0 .9 0.070 1.9 ±0.9 0.003 1.8 ± 0 .9 0.004
PI 2Q 1.8 ± 0 .6 1.2 ± 0 .8 0.004
3Q 2.0 ±0.8 1.3 ± 0 .9 0.006 1.0 ±0.6 0.002
4Q 2.1 ±0 .6 1.5 ± 0 .8 0.004 1.4 ±0.8 0.004 1.0 ± 0 .6 <0.001
1Q, 2Q, 3Q, 4Q: quadrants one, two, three and four 
Mean ± sd; *% o f positive sites
PD = pocket depth; RAL = relative attachment level; BOP = bleeding on probing; 
Sup = suppuration; MGI = modified gingival index; PI = plaque index 
P-values are given for changes from baseline.
Table 15. Patients’ observations.
N q_sr p= 2 3
N fm -s r p = 2 8
Q-SRP FM-SRP
Pain rating (0-10)2 
Day 1
2.0 (0.0-5.5) 3.0 (0.0-9.0)
Body temperature (°C)’ 
Day 1
36.7 ± 1.0 36.7 ± 0 .6
Body temperature (°C)' 
Day 2
36.5 ±0 .9 36.6 ± 0 .6
No. patients > 38°C 
Day 1
3.0 (13.0%) 3.0(11.0%)
No. patients > 38°C 
Day 2
2.0 (5.0%) 1.0 (4.0%)
No. patients/analgesics 
Day 1
12.0(52.0%) 24.0 (85.7%)
No. patients/analgesics 
Day 2
2.0 (8.7%) 13.0 (46.5%)
No. analgesics2 
Day 1
1.0 (0.0-6.0) 4.0 (0.0, 10.0)
No. analgesics2 
Day 2
0.0 (0.0-4.0) 0.0 (0.0-8.0)
No. patients/labial herpes 1.0 (4.0%) 2.0 (7.0%)
’Mean ± sd; 2Median (min-max)
between the two treatment groups 24 hours (day one) and 48 hours (day two) after the 
first root planing visit (p>0.05).
FM-SRP patients experienced significantly greater pain than Q-SRP patients on day one 
(p<0.05). A larger number of patients in the FM-SRP group took analgesics on day one 
and day two compared to those in the Q-SRP group. In addition, a larger intake of 
analgesics was seen for the FM-SRP patients compared to the Q-SRP patients on days 
one and two. One patient in the Q-SRP group and two patients in the FM-SRP group 
presented with labial herpes post-SRP. These frequencies are too low to make any 
conclusions, however.
3.2 Discussion
3.2.1 Clinical findings before and after scaling and root planing
Marked improvements in all clinical indices were detected after both treatment 
modalities and the range of improvement in the clinical measurements is consistent with 
results from other studies (Ramfjord et al. 1975; Badersten et al. 1981; Listgarten et al. 
1978; Badersten et al. 1984a, 1984b; Isidor et al. 1984). In the current investigation, 
the six-month analysis of the full-mouth clinical indices revealed a mean of 1.7 mm PD 
reduction, an average of 1.1 mm attachment gain and marked reduction in the number of 
sites with PD > 5 mm and BOP. At the selected sites, PD decreased by 2.9 mm on 
average and RAL improved by 1.1 mm at six months. At this time point a marked 
decrease in BOP, suppuration, MGI and PI also occurred from baseline. These findings 
are relatively consistent with those of Cobb (1996), who demonstrated that following 
non-surgical periodontal therapy moderately deep and deep sites had mean PD 
reductions of 1.29 mm and 2.16 mm, respectively, and clinical attachment gains of 0.55 
mm and 1.29 mm, respectively.
In a cross-sectional study, Quirynen et al. (1995) compared the efficacy of two treatment 
strategies, the one-stage full-mouth disinfection with the more common periodontal 
therapy of consecuitive sessions of Q-SRP. That study demonstrated that Q-SRP 
resulted in PD reductions of 1.7 mm at single-rooted teeth and 2.0 mm at multi-rooted 
teeth at two months. In a more recent study from the same research group, PD 
decreased by 1.2 mm at single-rooted teeth and by 1.0 mm at multi-rooted teeth for the 
Q-SRP group at eight months (Quirynen et al. 2000). The differences between the two
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treatment strategies will be discussed in the following section. The current study 
showed greater PD reductions (2.9 mm) at single-rooted teeth six months after the 
initiation of Q-SRP treatment, compared to the findings of Quirynen et al. (1995, 2000).
The findings presented here exceed those reported by Darby et al. (2001), who showed a 
PD reduction of 1.5 mm and a gain in RAL of 0.4 mm in chronic periodontitis patients 
at approximately four to five months. One possible reason for this could be that in that 
study, subjects were not followed over a longer period of time (i.e. six months as in the 
present study). It should be stressed though that the latter study examined only four 
selected sites per patient with a PD equal to or greater than 5 mm, so comparison of 
clinical improvements with the present study should be made using the site level data 
set. The results reported in the present investigation showed a greater PD reduction and 
gain in AL than those by Haffajee et al. (1997a). One reason for this could be that in the 
mentioned study, plaque control was not optimal and no significant change in the 
percentage of sites exhibiting plaque was noted after treatment, resulting in an overall 
attachment gain of 0.11 mm and a PD reduction of 0.20 mm. In this respect, the present 
study showed marked reductions in plaque scores post-treatment and it has been shown 
that the level of oral hygiene is more critical in the PD and AL changes than the 
treatment modality (Lindhe et al. 1982b). Another reason may be that in the study by 
Haffajee et al. (1997a) the mean baseline PD was lower than that reported in the current 
study (3.3 mm versus 4.3 mm), which might have contributed to the lower levels of 
clinical improvement (Pihlstrom et al. 1983).
The present results indicated a continuous clinical improvement at three and six months. 
Sites were successfully treated with a single episode of mechanical debridement and no 
repeated deep scaling was performed up to the first three months of this study. These 
data confirm previous findings of Badersten et al. (1984b). In addition, a marked 
improvement in plaque, bleeding and suppuration scores seen after both treatment 
approaches paralleled marked improvements in pocket depth and attachment levels. 
This is in agreement with other findings which showed that attachment loss was more 
frequently detected in sites with high scores for plaque, bleeding, residual probing depth 
and suppuration than in site:s with low scores (Badersten et al. 1985).
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3.2.2 Comparison of clinical indices between Q-SRP and FM-SRP groups
A greater PD reduction was seen for the Q-SRP group at R l at a site-specific level but 
not at R2. This could be explained solely by differences in the healing periods between 
the two treatments. Rl corresponded to week 13 for the Q-SRP group, i.e., six weeks 
after root planing the fourth quadrant, but to week seven for the FM-SRP group, i.e. six 
weeks after the one-day full-mouth root planing. This allowed more healing time for the 
sites that received Q-SRP. Patients in both treatment groups were assessed for a second 
time (R2) at equal time points at week 25, when no significant differences in any 
clinical index were evident between the two treatment groups. Indeed, FM-SRP 
appeared to result in a significantly greater PD reduction between Rl and R2, so that by 
the end of the study the FM-SRP group showed similar clinical improvement to the Q- 
SRP group.
When deep pockets were considered (PD > 7 mm), the smaller PD reduction noted for 
the FM-SRP group between BAS and R l compared to the Q-SRP group was due to 
differences in the moderately deep pockets (PD < 7 mm). This means that despite the 
uneven healing periods between the two treatment groups, FM-SRP resulted in similar 
PD reduction to Q-SRP at deep pockets. However at R2, FM-SRP resulted in a similar 
PD reduction but greater gain in RAL for deep pockets than Q-SRP, implying that at six 
months FM-SRP patients had less recession at deep pockets than Q-SRP patients.
Whole-mouth clinical indices did not reveal these differences, probably due to the 
dilution effect of the healthy sites. This is in agreement with Knowles et al. (1979) who 
reported that healing in shallow pockets has a major effect when computing patient 
means for change in pocket depths and masks the effects of treatment on deep pockets 
which are of greatest concern to the therapist.
A series of clinical trials consistently found that the one-stage full-mouth disinfection is 
more efficacious than consecutive sessions of quadrant root planing at two-weekly 
intervals (Quirynen et al. 1995; Vandekerckhove et al. 1996; Bollen et al. 1998; 
Mongardini et al. 1999; Quirynen et al. 2000). Greater PD reductions and attachment 
gains were seen for the FM-SRP group compared to the Q-SRP group, especially for 
deep pockets (Quirynen et al. 1995). Vandekerckhove et al. (1996) showed that for 
pockets > 7 mm, a marked PD reduction of 4 mm and 3 mm and attachment gain of 3.7
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mm and 1.9 mm were seen for the FM-SRP and Q-SRP groups, respectively at month 
eight. The present study showed the same magnitude of PD reduction in deep pockets, 
but the gain in RAL was notably lower for the FM-SRP group. Apart from this, at six 
months the only significant difference between the two treatment groups was the greater 
attachment gain seen only for deep pockets in the FM-SRP group. This finding was 
despite the fact that full-mouth root planing was completed in 12 hours rather than the 
24 hours seen in other studies (Quirynen et al. 1995; Vandekerckhove et al. 1996), and 
that the patients in the FM-SRP group were seen at equal time points and received equal 
amounts of oral hygiene instructions to those that received Q-SRP. This resulted in 
similar plaque indices between the two treatment groups throughout the study, which is 
in disagreement with findings of Vandekerckhove et al. (1996), who showed higher 
plaque indices for the one-stage full-mouth disinfection group after the first month 
possibly due to lack of frequent sessions of oral hygiene reinforcement.
It must be noted, that in the first investigations by Quirynen et al. (1995) and 
Vandekerckhove (1996) the baseline readings collected from the single-rooted teeth 
were not comparable between the two treatment groups, since there was a 0.8 mm 
difference between them, with the deeper pockets seen for the one-stage full-mouth 
disinfection group. In addition, probing depth was recorded immediately after root 
planing, possibly resulting in an overestimation of the disease severity. In a later study 
by Quirynen et al. (2000), three groups of patients were examined, but two of the groups 
participated and received treatment in an earlier trial by the same investigators 
(Quirynen et al. 1999, Mongardini et al. 1999). The third group of patients was 
recruited later and although the assessment of patients in this group started in the middle 
of the previous study, this could have resulted in biased data collection.
Several reasons could account for the differences between the current study and the 
trials described above. In the latter studies clinical measurements were collected from 
quadrant one only, even before Q-SRP therapy was completed. Therefore, the final 
clinical changes seen in the Q-SRP group may not have been revealed at this stage. It 
was interesting to note that no further PD reduction occurred in single-rooted teeth of 
the Q-SRP patients after two months, when root planing of the whole dentition was 
completed (Quirynen et al. 1995). In the current study, patients were reassessed six 
weeks after the completion of active treatment and then six months after the initiation of
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treatment, and a continuous clinical improvement was evident during the monitoring 
period, reaching a plateau at six months. This finding is consistent with previous results 
(Badersten et al. 1984a). The disparity between the present investigation and the 
studies of Quirynen et al. (1995, 2000) is mainly due to differences in the clinical 
outcome seen in the Q-SRP group. In the current study, PD reduction following Q-SRP 
treatment was remarkably greater than that found in the quoted studies.
Another difference in the methodology between the current and the study of Quirynen et 
al. (1995) is that this investigation examined the clinical outcome of conventional 
periodontal therapy consisting of quadrant or full-mouth scaling and root planing and 
oral hygiene instructions with no adjunctive use of antiseptics. The clinical results 
presented in the current study are not inferior to those reported by the other studies that 
used antimicrobial agents adjunctive to mechanical debridement (Listgarten et al. 1978; 
Haffajee et al. 1988b; Mombelli et al. 1996). Data from other studies agree that 
chlorhexidine does not augment the beneficial outcome of periodontal therapy (Braatz et 
al. 1985; MacAlpine et al. 1985; Wennstrom et al. 1987a, 1987b), and when this does 
occur, it is a transient phenomenon rather than a long-term effect (Lander et al. 1986; 
Oosterwaal et al. 1991). Studies where there is lack of meticulous plaque control and 
where the root planing is not thorough, tend to present the most promising results for the 
use of chlorhexidine alone, or in conjunction with root planing.
Bollen et al. (1998) showed that the extended and prolonged use of chlorhexidine in the 
one-stage full-mouth disinfection resulted in additional improvements both clinically 
and microbiologically, to those reported in previous studies (Quirynen et al. 1995). 
Nevertheless, this finding is in disparity with more recent data from the same research 
group, which showed that no significant differences in any clinical index existed 
between patients who received full-mouth root planing, with or without the use of 
chlorhexidine, and that the clinical outcome of these treatments was superior to that of 
quadrant root planing at two-weekly intervals (Quirynen et al. 2000). The authors 
concluded that the role of chlorhexidine in the beneficial effects of the one-stage full- 
mouth root planing is not critical, implying that a host-induced effect could contribute to 
the superior clinical outcome seen after this treatment strategy. These considerations 
will be discussed in Chapter four.
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3.2.3 Effect of partial periodontal therapy on the untreated sites in Q-SRP 
patients
The current study reported that partial periodontal therapy, which occurred in the course 
of quadrant root planing at two-weekly intervals, resulted in improved clinical 
conditions in the remaining untreated quadrants, in terms of pocket depth, suppuration, 
gingival and plaque indices reductions. This finding could be the result of improved 
plaque control in highly motivated periodontitis patients and / or host-induced effects 
during the active phase of treatment and / or a “Hawthorne effect” following 
recruitement into the study. The speculation on host-induced benefits will be discussed 
in detail in Chapter four. The Hawthorne effect was first described in a series of 
experimental studies of employees, at the Western Electric Company’s Hawthorne 
(Illinois) plant between 1927 and 1932 (Roethlisberger and Dickson, 1939). It was 
concluded that the employees’ awareness of their participation in a research study 
affected their behaviour (i.e. to increase production) (Mayo, 1933). It is also possible 
that during the course of active treatment, patients notice improvements in the scaled 
quadrants in contrast to the untreated ones and this reinforces them to practise improved 
oral hygiene measures.
During the monitoring period of six weeks, PD reduction of 0.4-0.6 mm occurred but 
minimum improvement in RAL and bleeding scores occurred, which is in accordance 
with findings of Badersten et al. (1984a). In their study, clinical improvements were 
seen following plaque control measures, but these reductions were limited in 
comparison to those found after instrumentation. The authors suggested that these 
changes were essentially due to gingival recession. The current findings confirm this 
notion, by showing significant reductions in PD and MGI, but not in RAL following the 
initiation of plaque control measures.
Several studies showed that the institution of plaque control measures affects the 
composition of the microbial flora subgingivally, as well as the clinical indices (Smulow 
et al. 1983; Dahlen et al. 1992; Katsanoulas et al. 1992; McNabb et al. 1992; 
Hellstrom et al. 1996; Haffajee et al. 2001a; 2001b). Nevertheless, it is doubtful 
whether supragingival plaque control has an effect on the subgingival microflora in the 
apical aspects of deep pockets (Kho et al. 1985; Beltrami et al. 1987; Loos et al. 
1988). The data presented in the current study are consistent with other findings which
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have shown that the clinical outcome of supragingival control alone is not as favourable 
as that seen after subgingival instrumentation (Badersten et al. 1984a; Kaldahl et al. 
1996a; Westfelt et al. 1998).
3.2.4 Patients’ observations
The completed questionnaires revealed that FM-SRP resulted in significantly higher 
pain rating than Q-SRP. No significant differences in body temperature were seen 
between the two treatment groups 24 and 48 hours after the first scaling session. 
Nevertheless, it was of interest to see that almost the same number of Q-SRP and FM- 
SRP patients had a body temperature > 38°C at 24 hours and 48 hours after 
instrumentation. However, a significantly higher percentage of FM-SRP patients took 
analgesics 24 and 48 hours after debridement and, since some of the analgesics have 
antipyretic properties, this may contribute to the same number of Q-SRP and FM-SRP 
patients having increased body temperature. . One Q-SRP patient and two FM-SRP 
patients presented with labial herpes post-scaling, which could be due to trauma from 
the procedures or to a host-induced effect after thorough and deep root planing. The 
host response to treatment will be discussed with the humoral immunological results 
(Chapter four).
The fact that higher pain scores and higher intake of analgesics was demonstrated for 
the FM-SRP group compared to the Q-SRP group agrees with the findings of another 
study (Quirynen et al. 2000). It should be borne in mind that the FM-SRP treatment 
protocol in the present investigation is more comparable to that of the one-stage full- 
mouth root planing without the use of chlorhexidine in the study of Quirynen et al. 
(2000). Nevertheless, this study showed that no Q-SRP patients had elevated body 
temperature on day one and / or labial herpes, which is in contrast to our findings.
However, body-temperature was self-recorded and although precise instructions for its 
measurement were given, significant individual variability existed with respect to usage 
of different makes of thermometers and differences in the body sites used or the time of 
the day that patients measured their body temperature. Taking into account these 
technical difficulties, as well as an inter-subject variability regarding the following 
factors: pain threshold, tolerance to dental procedures, and the fact that some analgesics 
have anti-pyretic properties, this investigation suggests that the completed
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questionnaires are only indicative of post-treatment complications and therefore no 
attempt was made to relate these data to experimental findings.
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CHAPTER 4
EFFECT OF SCALING AND ROOT PLANING ON 
IMMUNOLOGICAL PARAMETERS
4. Effect of scaling and root planing on immunological parameters
4.1 Results
4.1.1 Immunological responses in Q-SRP patients
4.1.1.1 Serum IgG antibody titres
In general, there was a decrease in serum IgG titres (expressed as EU) against the five 
bacteria following treatment (Table 16). For P. gingivalis, there was a statistically 
significant decrease in the antibody levels at R2 (p<0.005). For P. intermedia and T. 
denticola a reduction in serum antibody titres was noted at R2, but these findings just 
failed to reach statistical significance (p=0.05 for P. intermedia, p=0.052 for T. 
denticola). No significant reductions in antibody levels were noted for A. 
actinomycetemcomitans and B. forsythus following treatment.
4.1.1.2 GCF volume and GCF IgG antibody titres
GCF IgG titres (expressed as EU / 30 sec) decreased significantly post-treatment for A. 
actinomycetemcomitans at R2 (p<0.05) and for T. denticola at Rl (p<0.01) and R2 
(p=0.01) (Table 17). No significant changes were noted after treatment for the other 
suspected periodontal pathogens, although P. gingivalis changes were close to statistical 
significance. Table 18 shows the changes of GCF volume (expressed as pi / 30 sec) 
with treatment. A significant reduction was found at Rl and R2 (p<0.001).
4.1.1.3 IgG antibody avidity
Despite the general trend for IgG avidity (expressed as M at ID50) to increase six months 
post-treatment, changes did not reach statistical significance (Table 19). Therefore, Q- 
SRP resulted in antibodies of similar avidity after treatment.
4.1.2 Immunological responses in FM-SRP patients
4.1.2.1 Serum IgG antibody titres
In a similar way to Q-SRP, one-day FM-SRP resulted in significantly lower serum IgG 
antibody titres (EU) after treatment for the majority of the tested bacteria (Table 20). 
Nevertheless, no significant decreases were noted for P. gingivalis and B. forsythus 
post-treatment. IgG antibody titres to A. actinomycetemcomitans, significantly 
decreased at R2 (p<0.05) and antibody levels to P. intermedia significantly decreased at 
Rl (p=0.005). Median IgG titres against T. denticola, were significantly reduced at Rl 
(p=0.001) and R2 (p<0.01).
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4.1.2.2 GCF volume and GCF IgG antibody titres
In general, GCF IgG titres (EU / 30 sec) appeared to have low values with large subject 
variability (Table 21). A significant decrease in IgG titres against T. denticola was 
noted at Rl (p<0.05) and R2 (p<0.001) and against P. intermedia at R2 (p<0.05). When 
B. forsythus was examined, a small but statistically significant increase was noted at Rl 
(p<0.005). Table 18 shows that GCF volume (pi / 30 sec) significantly decreased at Rl 
and R2 (p<0.001).
4.1.2.3 IgG antibody avidity
IgG avidity (M at ID50) tended to increase post-treatment for the majority of the 
organisms but this observation was statistically significant for antibodies against A. 
actinomycetemcomitans only (Table 22). For A. actinomycetemcomitans there was an 
increase from 0.44 (0.36, 0.60) M at baseline to 0.55 (0.36, 0.80) M at R2 (p<0.02).
4.1.3 Comparison of immunological parameters in Q-SRP and FM-SRP groups
Tables 23 and 24 show that there were no statistically significant differences in serum 
IgG antibody titres (EU) and avidity (M at I D 5 0 )  between the two treatments at BAS and 
at Rl and R2. However, when the changes at R l and R2 from BAS were examined, 
there was a significantly greater reduction in serum IgG titres against P. intermedia and 
T. denticola at Rl for the FM-SRP group (p<0.05) (Table 23). No significant 
differences in changes of IgG avidity with treatment were seen between Q-SRP and FM- 
SRP groups (Table 24).
Table 25 shows that no significant differences were detected in GCF IgG titres (EU / 30 
sec) between the treatment groups at baseline. However, higher GCF IgG titres against 
A. actinomycetemcomitans and P. intermedia were noted at R2 for the FM-SRP group 
compared to the Q-SRP group (p=0.05 for A. actinomycetemcomitans, p<0.01 for P. 
intermedia). In addition, GGF antibody levels against T. denticola were higher at Rl for 
the FM-SRP group compared to the Q-SRP group (p<0.05). No significant differences 
in GCF volume (pi / 30 sec) were detected between the Q-SRP and FM-SRP groups at 
baseline and following treatment (Table 18).
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4.1.4 Correlation between GCF antibody titres and GCF volume
At baseline, GCF IgG titres (EU / 30 sec) were positively correlated with GCF volume 
(pi / 30 sec), indicating that the higher the GCF volume, the higher the GCF IgG 
antibody levels are (data not shown). This finding was statistically significant for A. 
actinomycetemcomitans, T. denticola, and B. forsythus. Correlation coefficient and p- 
value for each of the bacteria tested were as follows: 0.070 and 0.330 for P. gingivalis; 
0.220 and 0.004 for A. actinomycetemcomitans; 0.080 and 0.300 for P. intermedia', 
0.220 and 0.004 for T. denticola', 0.162 and 0.036 for B. forsythus.
At six months (R2), GCF volume was positively correlated with GCF antibody levels to 
A. actinomycetemcomitans (R=0.13, p=0.10), T. denticola (R=0.11, p=0.17), and B. 
forsythus (R=0.08, p=0.35), but this observation failed to reach statistical significance. 
However, GCF volume was negatively correlated with GCF antibody titres to P. 
gingivalis (R=-0.2, p<0.02) and to P. intermedia (R=-0.04, p=0.60) at R2, and this 
finding was statistically significant for the former organism.
4.1.5 Serum IgG antibody dynamics following periodontal treatment
The dynamics of the systemic IgG antibody response over the course of treatment (six 
visits in total) was determined by analysing the changes in serum IgG titres and avidity 
from baseline to each follow up visit i.e. BAS to visit two, BAS to visit three, BAS to 
visit four, BAS to visit five and BAS to visit six. These visits were carried out at equal 
time points for both treatment groups. In order to determine differences in the 
immunological parameters (titres and avidity) between the Q-SRP group and the FM- 
SRP group over the course of treatment, the changes between BAS and each follow up 
visit, and also the findings of each visit with no reference to baseline were compared.
4.1.5.1 Effect of Q-SRP on the humoral immune response dynamics
The median serum IgG antibody levels (EU) at each visit and the p-values of the 
changes from baseline are shown in Table 26. In general, serum IgG antibody titres did 
not appear to increase during the active phase of Q-SRP treatment with reference to 
baseline. A significant reduction in IgG titres to P. gingivalis was found between BAS 
and visit six (p<0.005). Serum IgG titres to A. actinomycetemcomitans showed a 
significant reduction between BAS and visit three (p<0.05). Similarly, serum antibody 
titres to P. intermedia, decreased between BAS and visit six, but this finding just failed
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to reach statistical significance (p=0.05). For T. denticola, serum antibody levels 
decreased at visit three (p<0.05) and visit six from baseline (p=0.052).
The analysis of the IgG avidity (M at ED50) over the six visits for the Q-SRP group 
found that for P. gingivalis, a significant increase was noted between BAS and visit four 
(p<0.05) and for A. actinomycetemcomitans between BAS and visits three and four 
(p<0.05) (Table 27). IgG avidity to T. denticola increased between BAS and each 
session of Q-SRP, significantly at visits two (p<0.005), three (p<0.05) and four (p<0.01) 
from BAS.
4.1.5.2 Effect of FM-SRP on the humoral immune response dynamics
Table 26 shows the serum IgG antibody levels (EU) at each visit during treatment and 
also depicts the p-values of the changes in the serum antibody titres at each visit from 
baseline. A significant decrease in IgG titres to P. gingivalis was noted between BAS 
and visit five (p<0.05) and to A. actinomycetemcomitans at visits two (p<0.005) and six 
(p<0.05) from BAS. The IgG levels to P. intermedia decreased at visits four (p=0.005) 
and five (p<0.05) from BAS, and a significant decrease at visits three, four, five and six 
from BAS was found for T. denticola (p<0.05).
IgG avidity (M at ID50) and the p-values of the changes from baseline are shown in 
Table 27. An increase in IgG avidity to A. actinomycetemcomitans was found at visits 
two (p<0.05), three (p<0.005) and visit six (p<0.05) from BAS, and to B. forsythus at 
visit three from BAS (p<0.01).
4.1.5.3 Humoral immune response dynamics after Q-SRP and FM-SRP
No significant differences were detected in the changes of serum IgG antibody titres 
(EU) against P. gingivalis, between Q-SRP and FM-SRP groups at any of the five time 
points from baseline (Table 28). This was a consistent finding with A. 
actinomycetemcomitans, P. intermedia, and B. forsythus. However, when T. denticola 
was examined, a significant difference was seen in the changes of IgG antibody levels 
between BAS and visit four (p=0.01), with a greater reduction in the IgG antibody levels 
for the FM-SRP group compared to the Q-SRP group. When IgG antibody levels were 
compared between the two treatment groups at each visit with no reference to baseline, 
no significant differences were detected against any of the tested bacteria (Table 28).
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28. 
P-values for the 
com
parison 
of serum 
IgG 
titres at each 
visit and 
the 
changes of IgG 
titres from 
baseline 
for Q-SRP 
and 
FM
-SRP 
groups.
The comparison of the changes in IgG avidity (M at ID50) between Q-SRP and FM-SRP 
groups over the six visits showed a significantly greater increase in IgG avidity to T. 
denticola for the Q-SRP group between BAS and visit two (p<0.01) (Table 29). When 
IgG avidity was compared between the two treatment groups at each visit with no 
reference to baseline, no significant differences were found for any organism (Table 29).
4.2 Discussion
4.2.1 Immunological responses after SRP
4.2.1.1 Serum IgG antibody titres
In general, decreases in serum IgG antibody titres to all putative pathogens were seen at 
six months. These results agree with data reported by other investigators (Tolo et al. 
1982; Naito et al. 1985; Mouton et al. 1987; Aukhil et al. 1988; Murray et al. 1989; 
Horibe et al. 1995). However, significant variation exists among studies with respect to 
the duration of the treatment and the sampling intervals. In the current study, scaling 
and root planing was completed within six weeks for the Q-SRP group and within a day 
for the FM-SRP group. Both treatments resulted in decreased serum antibody titres, 
with the more marked reductions seen at six months. Most of the studies mentioned 
showed reductions in the antibody titres over a period of 1 2  months, but it has to be 
taken into account that the active phase of treatment in these studies lasted notably 
longer than that in the present study. However, other studies have demonstrated 
decreases in serum antibody levels in the immediate post-treatment period (Aukhil et al. 
1988; Horibe et al. 1995).
Significant reductions in serum antibody levels against P. gingivalis and not for the 
other test bacteria have been demonstrated (Tolo etal. 1982; Naito et al. 1985). Horibe 
et al. (1995) showed significant reductions against P. gingivalis and P. intermedia from 
a large range of other putative periodontal pathogens. In contrast, the current study 
showed a significant reduction in the median antibody titres to the majority of the 
organisms tested and a concomitant decrease in the mean clinical parameters at six 
months.
Nevertheless, the present findings are inconsistent with those of Ebersole et al. (1985c), 
who showed that antibody titres increased two to four months post-scaling and returned
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to pre-scaling levels eight to 12 months after treatment. In the current study, no 
increases in IgG titres to any of the organisms tested were detected post-scaling to 
support the inoculation effect of root planing on the host tissues as suggested by 
Ebersole et al. (1985c). However, since the participants in this study were followed 
over a period of approximately six months, no long-term comparisons can be made 
between the present findings and those of Ebersole et al. (1985c). Similarly, increases 
in serum IgG antibody titres to A. actinomycetemcomitans with decreases in pocket 
depths post-treatment have been demonstrated (Sjostrom et al. 1994). The main 
difference between that study and the current study is that the former investigation 
examined a group with generalised aggressive periodontitis patients who required 
extensive and repeated treatment over a period of time and this may have boosted their 
humoral immune response. Mooney et al. (1995) showed elevated antibody titres to A. 
actinomycetemcomitans six weeks after the completion of therapy. Their results, in 
addition to those of Chen et al. (1991), showed increased antibody titres to A. 
actinomycetemcomitans and P. gingivalis, respectively, for the seronegative patients 
after treatment. However, the current study did not examine the immune responses 
based on the initial serostatus of the patients.
In conclusion, data reported here confirm those by Mouton et al. (1987) who showed a 
progressive reduction in antibody titres to P. gingivalis five to seven months post­
treatment, implying that root planing does not cause active immunisation with P. 
gingivalis. Periodontal therapy appears to decrease the antigenic load post-treatment 
resulting in lower levels of antibodies.
4.2.1.2 GCF IgG antibody titres
In general, the present study revealed low values of GCF titres with a wide site-to-site 
variability among sites of similar periodontal status. This is in accordance with results 
from other studies (Ebersole et al. 1984; Tew et al. 1985). Antibody titres were much 
lower in GCF than in serum and this finding confirms previous results (Ebersole et al. 
1985a; Baranowska et al. 1989). A recent study demonstrated little change in the local 
and systemic antibody levels after treatment, emphasising the wide variation in the 
subjects’ response to treatment (Darby et al. 2001).
97
Results from the present study showed a significant reduction in GCF volume after 
therapy. In addition, at six months there was a significant decrease in GCF antibody 
titres to A. actinomycetemcomitans and T. denticola for the Q-SRP group and to P. 
intermedia and T. denticola for the FM-SRP group. It should be noted that serum IgG 
titres to these organisms decreased after treatment, albeit not significantly for all species 
and that the presence of these pathogens in subgingival plaque was markedly reduced 
post-therapy (these findings will be discussed in Chapter five). These data indicate that 
a reduction in the bacterial burden coincides with a reduction in the local and systemic 
antibody levels.
Of great interest was the finding that GCF volume was significantly negatively 
correlated with GCF antibody titres to P. gingivalis at six months, indicating that 
although GCF volume decreased after treatment, there were still high antibody titres to 
this organism in the GCF. It must be stressed that although GCF antibody titres 
decreased for some of the bacteria post-therapy, there was a tendency for antibody 
concentration in GCF to increase. This was due to the fact that GCF volume 
significantly decreased following treatment and this compensated for the reduction in 
GCF antibody titres. One possible reason for this could be that the organisms still 
stimulated and mounted a local immune response, even though their presence in the 
sampled pockets was not detected. This may reflect the potential of a pathogen (i.e. P. 
gingivalis) to invade the gingival tissues (Dzink et al. 1989; Duncan et al. 1993), from 
where it generates a local immune response with the production of specific antibodies. 
Alternatively, organisms at other oral sites and niches that were not sampled may have 
induced the elevated antibody levels. Another possibility is that the microbiota is in a 
state of dynamic flux and that a single sampling does not accurately reflect the flora.
It has been shown that there is local antibody production in diseased gingival tissues and 
that this response is specific (Lally et al. 1980). Therefore, elevated antibody titres in 
GCF may reflect changes in disease activity at specific sites that are not detectable by 
conventional clinical measurements, or by changes in the systemic immune responses. 
Conversely, the tendency for the concentration of GCF antibodies to increase post­
treatment, despite the decrease in homologous serum antibody titres could be explained 
by the fact that the organisms that were formerly present in large numbers in the pockets 
pre-treatment decreased dramatically after scaling, resulting in less antibody
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consumption locally and therefore excess of free antibodies in the gingival crevice. It 
has been demonstrated that GCF IgG levels were lower in periodontitis sites than in 
gingivitis sites in the same patient, implying that increased consumption of locally 
produced antibody in periodontitis sites may be responsible for this difference (Mooney 
and Kinane, 1997). In addition, Smith et al. (1985) showed lower antibody levels in the 
GCF than in the gingival homogenates, possibly due to consumption of local antibodies 
by organisms present in the crevice.
4.2.1.3 IgG antibody avidity
During infection, high levels of antibodies are produced that are of low specificity or 
avidity (O'Dell and Ebersole, 1995). Numerous studies compared the antibody levels 
and avidity between subjects with periodontitis and healthy controls. Antibodies of 
higher avidity in the healthy individuals than the diseased were demonstrated suggesting 
that antibodies of high avidity are protective against disease (Chen et al. 1991; Whitney 
et al. 1992; Saito et al. 1993). However, conflicting data exist that show no significant 
differences in IgG antibody avidities between periodontitis patients and healthy subjects 
(Mooney et al. 1993; O'Dell and Ebersole, 1995). Another study has demonstrated 
increased antibody avidity of the IgG class in periodontitis patients compared to healthy 
controls possibly as a result of repeated antigenic challenge with the same pathogens 
(Lopatin et al. 1991).
Successful treatment results in the elimination of the aetiological agents and maturation 
of the immune system to produce antibodies of high avidity (Chen et al. 1991). 
Mooney et al. (1995) found an increase in IgG avidity to P. gingivalis (p=0.05) six 
weeks after hygiene phase therapy. In the present study, IgG avidity showed a trend 
towards increasing post-treatment for the majority of the organisms tested, but generally 
this finding did not reach statistical significance for most of the test bacteria. It has been 
confirmed in other studies that antibody avidity is independent of the antibody levels 
(O'Dell and Ebersole, 1995). Data reported here show that treatment resulted in lower 
levels of antibodies to all the bacteria tested, but avidity remained the same for the 
majority of the organisms tested. Another study from our laboratory showed that 
despite the clinical improvement seen post-therapy, there were no significant post­
treatment effects on the humoral immune response other than a reduction in the avidity 
of antibodies to P. gingivalis and P. intermedia (Darby et al. 2001). This finding may
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indicate a failure of the host response to produce adequate levels of biologically 
functional antibodies after treatment. It is possible that this poor host response makes 
patients susceptible to future disease progression.
The present findings imply that antibody avidity may be a very dynamic process, with 
fluctuations that are difficult to detect with conventional laboratory techniques, or that a 
period of time longer than the monitoring period of this study (six months) is required to 
document the maturation of the immune system. Lopatin et al. (1991) demonstrated that 
human IgG antibodies were of extremely low avidity compared to the avidity levels in 
rabbits immunised with P. gingivalis. These results suggest that the minimal immune 
maturation seen in human IgG antibodies to P. gingivalis could be a result of an in utero 
tolerization to bacterial antigens or of chronic exposure to oral bacteria after birth. 
Bearing this in mind, although the reduction in the antibody levels noted in the present 
study possibly reflects the reduction in the antigenic load, the immune system may still 
be challenged with antigens that consume the higher avidity antibodies and remove 
them from the circulation. However this seems unlikely, as it has been demonstrated 
that healthy individuals had IgG antibodies of lower avidity than did periodontitis 
patients, who are expected to have a greater potential for antibody consumption than the 
former subjects (Lopatin et al. 1991). Therefore, it is possible that due to repeated 
antigenic exposure during the chronic process of periodontal disease the antibody 
avidity of patients in the current study was elevated pre-treatment, and it reached a 
threshold that could not be surpassed after treatment. Another hypothesis is that the 
chronic exposure to periodontopathogens may inhibit the maturation of the immune 
system. However, these pathogenetic mechanisms still need clarification and more 
evidence is required to support these concepts.
4.2.2 Comparison of immunological parameters in Q-SRP and FM-SRP groups
The present study showed that there were no significant differences in IgG avidity 
between the two treatments. Although antibody titres were similar for both groups at 
baseline, R1 and R2, a significantly greater reduction in the antibody levels to P. 
intermedia and T. denticola was seen between BAS and R1 for the FM-SRP group than 
the Q-SRP group. When the changes in the serum antibody response with treatment 
were considered within each group, significant reductions in the antibody levels to P. 
intermedia and T. denticola were seen between BAS and R1 for the FM-SRP group, but
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this was not seen against any of the tested organisms for the Q-SRP group. These 
findings imply that FM-SRP seems to have a stronger short-term effect on the systemic 
antibody response compared to the classical therapy of quadrant root planing at two­
weekly intervals. However, the clinical significance of this finding is difficult to assess.
The analysis of the local antibody responses revealed that the FM-SRP group had higher 
GCF antibody titres to T. denticola at R1 and to P. intermedia at R2 than did the Q-SRP 
group. Given the fact that selected sites of the FM-SRP patients showed higher PD 
indices at R1 than did the Q-SRP patients, this finding may reflect that there is an 
ongoing healing process at the former sites with higher levels of specific local 
antibodies.
4.2.3 Dynamics of antibody response after Q-SRP and FM-SRP
There is evidence of a short-term effect of treatment on the antibody response. Horibe 
et al. (1995) found a significant reduction in the antibody levels at least two months 
after the completion of treatment. Aukhil et al. (1988) showed significantly lower 
antibody levels by the end of the hygiene phase of treatment, i.e. approximately two 
months after baseline. The current study is the first that has attempted to determine the 
dynamics of the antibody response during the active phase of treatment, i.e. at two­
weekly intervals over a period of three months. Data reported here failed to show that 
each session of root planing resulted in increased antibody levels due to an inoculation 
effect of bacteria in the host tissues as suggested by Ebersole et al (1985c). Each 
session of root planing seemed to result in antibodies of either similar or significantly 
lower levels compared to baseline values. These results agree with those of Mouton et 
al. (1987), who demonstrated a gradual reduction in antibody levels five to seven 
months after treatment with no peak antibody levels seen in the immediate post-scaling 
period. In addition, in the short-term no cyclic pattern of antibody levels was seen to 
justify the series of exacerbation and remission of disease activity as has been suggested 
previously by Socransky et al. (1984).
Antibody avidity appeared to increase during the active phase of treatment for both 
treatment groups and this reached statistical significance even after the first scaling 
visits, reflecting the production of high avidity antibodies as a result of antigenic 
elimination and / or immune maturation. However, of great interest was the observation
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that antibody avidity significantly increased in the immediate post-scaling period rather 
than at later stages (R1 and R2). This finding, if upheld by further studies, would 
contradict the hypothesis that the baseline values of antibody avidity in periodontitis 
patients exceed a threshold beyond which no significant increases can be noted. 
However, it is difficult to interpret these results given the variations within and between 
individuals and over time. It should be borne in mind that this study did not compare 
the antibody response between healthy subjects and treated periodontitis patients. 
Therefore, any fluctuations in the antibody avidity that may be caused by factors not 
related to the periodontal therapy (i.e. Hawthorne effect or other environmental 
influences except for cigarette smoking) were not disclosed.
No significant differences in serum antibody levels and avidity were seen between the 
two treatment groups at each visit during the active phase of treatment (baseline and 
three additional visits). However, comparison of changes in serum antibody levels and 
avidity with treatment between Q-SRP and FM-SRP groups revealed a significantly 
greater reduction in serum antibody levels to T. denticola for the FM-SRP group 
between BAS and visit four, and a significantly lower increase in antibody avidity to T. 
denticola for the FM-SRP group between BAS and visit two. It must be stressed 
however, that visit four corresponded to R1 for the FM-SRP group and to the last 
session of quadrant root planing for the Q-SRP group. This means that the assessment 
of the systemic immunological parameters at this time point was made before treatment 
was completed in the Q-SRP group. These differences in the changes of antibody levels 
and avidity between the two treatment groups would appear to be of doubtful clinical 
significance.
The present findings do not confirm the hypothesis that the beneficial effects of FM- 
SRP with and without the use of chlorhexidine are due to an acute immunological 
reaction caused by the inoculation of bacteria into the host tissues (Quirynen et al. 
2000). These authors speculated that this reaction occurs one to two days after the FM- 
SRP treatment and is reflected by an increase in the patients’ body temperature. 
However, they did not examine the dynamics of the antibody response after FM-SRP or 
whether this treatment induced bacteraemia. Results from the current study did not 
reveal elevated antibody levels during the course of treatment to support the hypothesis 
that one-day FM-SRP caused bacteraemia. Q-SRP also has the potential to stimulate an
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elevated immune response, by repeatedly inoculating bacteria into the tissues over 
consecutive sessions of root planing. However, even though these immunological 
inoculations may occur, the present study was unable to confirm this for a variety of 
reasons, which may include inter- and intra-subject variability in response to therapy, 
extent and severity of disease, timing effects and differences in oral hygiene standards. 
Other enviromental and host response factors, which can not be estimated easily may 
also account for that.
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CHAPTER 5
EFFECT OF SCALING AND ROOT PLANING ON 
MICROBIOLOGICAL PARAMETERS
5. Effect of scaling and root planing on microbiological parameters
5.1 Results
5.1.1 PCR prevalence of putative periodontal pathogens
PCR analysis revealed that at a site-specific level (n=159) the baseline detection 
frequencies of the specific organisms were: 32.7% for P. gingivalis; 22.6% for A. 
actinomycetemcomitans; 36.4% for P. intermedia; 44.7% for T. denticola', and 80.5% 
for B. forsythus. On a subject-basis (n=42), (i.e. whether a subject harboured the 
organism at any site) the baseline prevalence of the bacteria was: 38.0% for P. 
gingivalis', 33.3% for A actinomycetemcomitans', 59.5% for P. intermedia’, 76.2% for T. 
denticola; and 92.9% for B. forsythus (data not shown). Figures 9-13 depict the results 
of the PCR assay to detect the five putative periodontal pathogens in subgingival plaque 
samples.
5.1.2 Bacterial combinations
Figure 14, shows the bacterial combinations in selected sites at baseline. A high 
percentage of sites were positive for the combination of P. gingivalis and B. forsythus 
(30%), P. intermedia and B. forsythus (36%) and T. denticola and B. forsythus (42%). 
9% of the sites (n=159) were negative for any of the five putative pathogens or their 
combinations.
5.1.3 Subgingival microflora before and after Q-SRP
Microbiological data from 80 sites were analysed for Q-SRP. There was a marked 
reduction in the presence of all five putative periodontal pathogens at selected sites 
following Q-SRP. This altered microbiota was maintained at R2 (Table 30). The 
percentage of sites positive for P. gingivalis was significantly reduced at R1 and R2 
(p<0.001). Breakdown refers to the sites that were negative for a pathogen at baseline 
and became positive for the same organism post-treatment. One site that was negative 
for P. gingivalis at baseline turned positive at R1 but none at R2. The detection 
frequency of A. actinomycetemcomitans at selected sites was significantly reduced at R1 
and R2 (p<0.005). Two sites initially free for A. actinomycetemcomitans became 
positive for this organism between BAS and R1 and between BAS and R2. The 
detection frequencies of P. intermedia, T. denticola and B. forsythus significantly 
decreased at R1 (p<0.001) and R2 (p<0.001). Four sites that were formerly negative for 
P. intermedia became positive at R1 and two sites at R2 from BAS. One site that was
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Figure 9. P. gingivalis PCR product analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Lane 1: 100-bp DNA ladder; lanes 2-18: plaque samples; lane 19: positive control; lane 
20: negative control.
Figure 10. A. actinomycetemcomitans PCR product analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
U*r,
Upper and lower panels: lane 1: 100-bp DNA ladder; lanes 2-18: plaque samples; lane 
19: positive control; lane 20: negative control.
Figure 11. P.intermedia PCR product analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Upper and lower panels: lane 1: 100-bp DNA ladder; lanes 2-18: plaque samples; lane 
19: positive control; lane 20: negative control.
Figure 12. T. denticola PCR product analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Upper panel: lanes 1-19: plaque samples; lane 20: 100-bp DNA ladder;
Lowerpanel: lanes 1-17: plaque samples; lane 18: 100-bp DNA ladder; lane 19: positive 
control; lane 20: negative control.
The positive control used was a small fragment of the T. denticola 16S rRNA gene which 
was 79 bp in length. This comprised the first 52 bp of the full-length PCR product and the 
downstream primer sequence.
Figure 13. B. forsythus PCR product analysis.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Upper and lower panels: lanes 1-17: plaque samples; lane 18: 100-bp DNA ladder; lane 
19: positive control; lane 20: negative control.
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Figure 14. Bacterial combinations.
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periodontal pathogens before 
and 
after Q
-SRP.
negative for T. denticola at BAS became positive for this pathogen at R l, and no sites at 
R2 from BAS. B. forsythus colonised one site that was formerly negative for this 
species at Rl and one site at R2 from BAS.
When the analysis was made on a patient basis (n=20), a marked reduction in the 
percentage of patients that were positive for the five periodontal pathogens post­
treatment was also demonstrated (Table 31). The percentage of subjects that harboured 
P. gingivalis significantly decreased at Rl (p<0.05) and R2 (p<0.01). One patient who 
was initially negative for P. gingivalis became positive between BAS and R l. In 
addition, T. denticola was significantly reduced at R l (p<0.05) and R2 (p<0.005) and 
this was the case with B. forsythus (p<0.005). One subject formerly negative for B. 
forsythus turned positive for this organism after treatment and one patient became 
positive for T. denticola at Rl from BAS. No statistically significant decreases in the 
prevalence of A. actinomycetemcomitans and P. intermedia were noted following 
treatment. One patient who was negative for A. actinomycetemcomitans at BAS, turned 
positive for this pathogen at Rl and one at R2 from BAS. Two patients were colonised 
with P. intermedia between BAS and Rl and two between BAS and R2.
5.1.4 Subgingival microflora before and after FM-SRP
Due to technical difficulties, three patients in the FM-SRP group had incomplete sets of 
plaque samples at baseline, although they finished the study. Therefore, the analysis of 
the microbiological data for this treatment group was performed on 79 subgingival 
plaque samples at baseline and R l and on 76 at R2.
Table 32 shows the prevalence of the five periodontal pathogens before and after FM- 
SRP on a site-based analysis. The percentage of sites positive for P. gingivalis was 
significantly reduced at Rl and R2 (p<0.001). No colonisation of P. gingivalis at 
initially negative sites occurred post-treatment. Similarly, the detection frequency of A. 
actinomycetemcomitans significantly decreased at R l (p<0.05) and R2 (p<0.001). 
Three sites negative for A. actinomycetemcomitans at baseline were colonised by this 
microorganism between BAS and Rl and BAS and R2. P. intermedia, T. denticola and
B. forsythus showed significant reductions in their detection frequencies at the selected 
sites at Rl (p<0.001) and R2 (p<0.001). Two sites initially negative for P. intermedia 
were colonised by this species between BAS and R2. At R2, T. denticola colonised one
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periodontal pathogens before 
and 
after FM
-SRP.
site formerly free of this pathogen and one site that was initially negative for B. 
forsythus turned positive between BAS and R2.
The patient-based analysis demonstrated that there was a statistically significant 
reduction in the percentage of patients positive for all putative pathogens post-treatment 
(Table 33). The percentage of patients positive for P. gingivalis significantly decreased 
at R l (p<0.05) and R2 (p<0.05) and the percentage of patients that harboured A. 
actinomycetemcomitans significantly decreased at R2 only (p<0.05). Significantly 
fewer patients possessed P. intermedia at R l (p=0.001) and R2 (p<0.05). Similarly, the 
detection frequencies of T. denticola and B. forsythus were significantly reduced at Rl 
(pO.OOl) and R2 (p=0.001). Post-treatment, B. forsythus colonised one subject that 
was free of this species at baseline, while this was not seen for the other bacteria.
5.1.5 Comparison of microbiological responses between Q-SRP and FM-SRP 
groups
At baseline, there were no significant differences for any of the test bacteria between Q- 
SRP and FM-SRP on a site-based analysis (Table 34). A comparison between the two 
treatments at each visit showed a significantly higher percentage of sites positive for P. 
intermedia at R l for the Q-SRP group than the FM-SRP group (p<0.01). However, 
when the changes with treatment were compared, no significant differences were seen 
between the two groups. These seemed to be similar for both treatments.
Table 35, shows the patient-based analysis of the PCR data. At baseline, a significantly 
lower percentage of Q-SRP patients (55.0%) was positive for T. denticola while 95.5% 
of patients in FM-SRP group harboured this pathogen (p<0.01). At R l, P. intermedia 
was more prevalent in Q-SRP patients than FM-SRP patients (p<0.05). At R2, P. 
gingivalis was not detected in the Q-SRP group, while 5.2% of the FM-SRP patients 
were positive for this pathogen. T. denticola was present in 15% of the Q-SRP patients 
at Rl but was not detected in the FM-SRP group. However, these differences between 
the groups were not statistically significant. When the changes with treatment were 
analysed, a significantly greater reduction in the proportion of patients positive for T. 
denticola was seen in the FM-SRP group at both Rl (p<0.01) and R2 (p=0.01), but any 
conclusion from this comparison between the two treatment groups is unclear given 
their significant baseline differences.
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and 
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ent 
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5.1.6 Investigation of possible re-colonisation of treated sites by pathogens from 
the remaining untreated periodontal pockets
An attempt was made to test whether the scaled sites were re-colonised by pathogens 
from the remaining untreated periodontal pockets or whether root planing the first 
quadrant gave a host-induced benefit to the other quadrants. Therefore, the clinical and 
microbiological parameters of sites in quadrant one (IQ) were compared with those of 
sites in quadrant four (4Q) following Q-SRP therapy. It should be stressed that IQ was 
always root planed first (upper right quadrant), while 4Q (lower right quadrant) was 
treated last.
The comparison of the clinical indices between sites in IQ and 4Q demonstrated an 
unfortunate chance bias in that IQ on average had significantly deeper pockets at 
baseline than 4Q, 6.8 mm versus 5.8 mm (p<0.05) (Table 36). In addition, sites in IQ 
remained deeper at Rl and R2 in comparison to 4Q but this was not statistically 
significant and is an unfair comparison given the significant difference in the baseline 
values. No significant differences in PD reduction were noted between the two 
quadrants after treatment. There was no significant difference in RAL between IQ and 
4Q before and after treatment. In addition, no significant difference in gain of RAL was 
found between IQ and 4Q at Rl and R2 from BAS. BOP was similar for IQ and 4Q at 
BAS and at R l and R2. Despite the greater BOP reduction between BAS and R2 for 
4Q, this was not statistically significant. Sites in both quadrants showed a continuous 
clinical improvement three and six months post-therapy.
No significant differences in the prevalence of putative periodontal pathogens were 
found between sites in IQ and 4Q at baseline and following Q-SRP (Table 37). In 
addition, the changes in the prevalence of bacteria at R l and R2 from BAS were not 
significantly different between IQ and 4Q.
The changes in the prevalence of pathogens in IQ following therapy showed significant 
reductions for P. gingivalis between BAS and R2 (p<0.05), for T. denticola at Rl 
(p<0.05) and R2 (p<0.01) from BAS, and for B. forsythus at R l (p=0.001) and R2 
(p<0.001) from BAS. From this Table it is clear that, the percentage of sites in IQ 
positive for the test pathogens was maintained at low levels at Rl and R2.
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5.1.7 Effect of the presence and absence of putative periodontal pathogens on 
clinical and immunological parameters
A comparison of site-specific clinical indices between sites that were positive and sites 
that were negative for the test bacteria found no significant differences in PD, RAL and 
BOP at baseline (Table 38). Nevertheless, sites that were positive for B. forsythus and 
A. actinomycetemcomitans had a higher frequency of suppuration. 67% of sites that 
harboured B. forsythus suppurated while this was the case for only 42% of the sites that 
were free of this organism (p<0.01). Suppuration was present in 78% of sites that were 
positive for A. actinomycetemcomitans versus 58% of sites that were negative for this 
pathogen (p<0.05).
The comparison of the full-mouth clinical indices of patients that were positive and 
negative for a pathogen yielded significant differences at baseline (Table 39). Patients 
that harboured A. actinomycetemcomitans had significantly lower PD, AL and No. of 
sites > 5mm than those who were free of this pathogen. PD was 4.1 mm for positive 
patients versus 4.5 mm for negative patients (p<0.05), AL was 4.5 mm versus 5.3 mm 
(p<0.005), and the No. of sites > 5mm was 55 versus 74 (p<0.005). On the contrary, 
patients positive for T. denticola had higher AL (5.2 mm) than negative patients (4.5 
mm) (p<0.05) and those who were positive for B. forsythus had deeper pockets, (4.4 
mm versus 3.6 mm) (p=0.01), and more pockets with PD > 5mm than negative patients 
(70 versus 44) (p<0.005).
GCF IgG titres (EU / 30 sec) were compared between sites that were positive and 
negative for a pathogen at baseline (Table 40). Antibody levels in GCF were 
significantly higher at sites positive for A. actinomycetemcomitans than at sites negative 
for this microorganism (p<0.001). GCF antibody titres tended to be higher at sites that 
harboured P. gingivalis, T. denticola and B. forsythus compared to those that were free 
of these pathogens, but this observation failed to reach statistical significance.
In a similar manner, serum IgG titres (EU) and IgG avidity (M at rD50) were compared 
between patients who were positive and negative for a pathogen at baseline (Table 41). 
It appeared that serum IgG titres to a pathogen were higher for patients who were 
positive rather than negative to this pathogen. This was statistically significant for P.
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Table 38. Comparison o f site-specific clinical indices between sites positive and negative
for each pathogen at baseline.
N = 159 PD* (mm) P-
value
RAL* (mm) P-
value
BOP* P-
value
Sup* P-
value
P g- absent(107) 
present (52)
6.1 ± 1.2 
6.0 ± 1.0
0.61 14.0 ±2.1
14.0 ± 1.9
0.95 80.0
79.0
0.82 64.5
57.6
0.41
A. a. absent(123) 
present (36)
6.0 ± 1.1 
6.3 ± 1.3
0.15 14.0 ±2.1  
13.9 ± 1.9
0.79 77.0
89.0
0.12 58.0
78.0
0.03
P.L absent(98) 
present(61)
6.1 ± 1.2 
6.0 ± 1.0
0.33 14.1 ±2.1  
13.8 ± 1.9
0.33 82.0
77.0
0.48 63.0
60.7
0.74
T.d. absent(88) 
present(71)
6.0 ± 1.1 
6.1 ± 1.1
0.75 13.8 ± 2.1 
14.2 ± 1.9
0.18 82.0
77.0
0.49 62.5
62.0
0.95
B.f. absent(31) 
present (128)
6.1 ± 1.2 
6.0 ± 1.1
0.81 13.9 ± 2 .5  
14.0 ± 1.9
0.73 84.0
79.0
0.54 42.0
67.0
<0.01
Table 39. Comparison of full-mouth clinical indices between patients positive and 
negative for each pathogen at baseline.
N = 42 PD*
(mm)
P-
value
AL*
(mm)
P-
value
BOP*
(%)
P-
value
Sites>5mm* P-
value
P.g. absent (26) 
present (16)
4.4 ± 0 .7  
4.3 ±0 .5
0.450 5.1 ± 1.0 
4.9 ± 0 .9
0.350 72.0 ± 16.0
66.0 ± 20.0
0.300 69.0 ± 27.0
65.0 ± 18.0
0.580
A.a. absent(28) 
present (14)
4.5 ± 0 .6  
4.1 ±0.5
0.020 5.3 ± 0 .9  
4.5 ± 0 .7
0.003 74.0 ± 14.0
62.0 ±21.0
0.055 74.0 ± 24.0
55.0 ± 16.0
0.005
P.L absent(17) 
present(25)
4.3 ± 0 .7
4.4 ± 0 .6
0.760 5.1 ± 1.0 
5.0 ± 0 .9
0.630 69.0 ± 18.0
71.0 ± 18.0
0.720 63.0 ± 24.0
71.0 ± 2 3 .0
0.240
T.d. absent (10) 
present(32)
4.2 ± 0 .7  
4.4 ± 0 .6
0.300 4.5 ± 0 .7  
5.2 ± 0 .9
0.020 74.0 ±23.0
69.0 ± 16.0
0.560 61.0 ± 19.0
70.0 ± 25 .0
0.220
B.f. absent (3) 
present (39)
3.6 ± 0 .2  
4.4 ± 0 .6
0.010 4.8 ± 1.2 
5.1 ± 0 .9
0.740 67.0 ± 15.0
70.0 ± 18.0
0.760 44.0 ± 6.0
70.0 ± 23 .0
0.004
Footnote for Tables 38 & 39
§M ean±sd; *% of sites; BAS = baseline; Rl = reassessment 1; R2 = reassessment 2 
P-values compare (i) sites and (ii) patients being either negative or positive for a pathogen 
P.g.: P. gingivalis; A.a.: A. .actinomycetemcomitans', P .i.: P. intermedia', T.d.: T. denticola', 
B .f : B. forsythus.
Table 40. GCF IgG antibody titres in patients positive and negative for each pathogen at 
baseline.
N =  159 GCF IgG titres5 p-value
P.g. absent (107) 14.2 ± 9 .0 0.670
present (52) 28.0 ± 2 2
A.a. absent(123) 876.0 ± 873.0 <0.001
present (36) 9705.0 ± 7992.0
P.L absent(98) 4.4 ± 2.0 0.800
present (61) 2.4 ±0 .5
T.d. absent (88) 2.6 ± 0 .4 0.290
present(71) 10.6 ± 4 .0
B.f. absent (31) 1.2 ±0 .4 0.770
present (128) 2.1 ± 0 .7
GCF IgG titres are expressed as EU/30sec 
^Mean ± SEM;
P-values compare sites being either negative or positive for a pathogen
P.g.: P. gingivalis; A.a.'.A. .actinomycetemcomitans; P.i.: P. intermedia; T.d.'. T. denticola;
B.f.: B. forsythus.
Table 41. Serum IgG titres and IgG avidity in patients positive and negative for each
pathogen at baseline.
N = 42 Serum IgG titres5 p-value IgG avidity5 p-value
P.g. absent (26) 
present (16)
70 (20, 321) 
163 (71,4990)
0.048 0.40 (0.30, 0.56) 
0.56 (0.50, 0.65)
0.054
A.a. absent (28) 
present(14)
34(12, 89) 
582 (66, 9378)
<0.005 0.39 (0.30, 0.55) 
0.46 (0.40, 0.78)
0.090
P.L absent(17) 
present(25)
138 (29, 459) 
232(106, 821)
0.180 0.69 (0.60, 1.00) 
0.92 (0.70, 1.00)
0.250
T.d. absent (10) 
present (32)
10 (6, 74) 
18(7, 64)
0.337 0.29 (0.20, 0.36) 
0.32 (0.20, 0.51)
0.275
B.f. absent (3) 
present (39)
14(12,23) 
38 (15, 1067)
0.143 0.33 (0.30, 0.80) 
0.42 (0.30, 0.60)
1.000
Serum IgG titres are expressed as ELISA units (EU)
IgG avidity is expressed as molarity (M) at IDS0 
^Median (Ql, Q3);
P-values compare subjects being either negative or positive for a pathogen
P.g.: P. gingivalis; A.a.: A. .actinomycetemcomitans', P.i.: P. intermedia', T.d.: T. denticola',
B.f. \ B. forsythus.
gingivalis (p<0.05) and for A. actinomycetemcomitans (p<0.005). In addition, IgG 
avidity seemed to be higher for the individuals who harboured the microorganisms than 
for those who had no detectable microorganisms. Nevertheless, this observation failed 
to reach statistical significance for any of the bacteria, (p=0.054 for P. gingivalis and 
p=0.09 for A  actinomycetemcomitans).
Table 42 compares the changes in site-specific clinical indices and changes in site 
microflora irrespective of the two treatment strategies (Q-SRP and FM-SRP) between 
BAS and R2. At R2, sites where A. actinomycetemcomitans was not detected (coded as 
1) showed significantly greater reduction in all clinical indices than sites that had an 
increase or no change in the prevalence of this pathogen (coded as 0) (p<0.005 for APD, 
p<0.001 for ARAL, p<0.05 for ABOP and pO.Ol for ASup). A greater reduction in 
suppuration was also seen for sites that became negative for B. forsythus at R2 than 
those that did not change or became positive for this species (p<0.05).
There were no significant differences in the changes of GCF IgG titres between sites 
that turned negative to an organism post-treatment and those that had no change or 
increase in the prevalence of that pathogen after therapy (data not shown). Despite the 
trend for a greater reduction in GCF antibody titres to A. actinomycetemcomitans at sites 
where this organism was no longer detected at R2, this was not statistically significant 
(p>0.05).
The changes in clinical, immunological and microbiological parameters of all subjects 
irrespective of the treatment groups were compared between BAS and R2. The 
comparison of the changes in full-mouth clinical indices and the changes in patient 
prevalence of the pathogens demonstrated that there was a significantly greater 
reduction in the No. of sites > 5mm for the subjects who became negative for T. 
denticola (p<0.05) (Table 43). Interestingly, patients who were no longer positive to a 
pathogen at R2 tended to have a greater reduction in serum IgG antibody titres to that 
pathogen than patients who had no change or increase in the prevalence of this pathogen 
(Table 44). This was statistically significant for A actinomycetemcomitans (p<0.05) but 
did not reach significance for the other pathogens. Also, IgG avidity seemed to be 
higher for the patients that turned negative to A. actinomycetemcomitans at R2, but this 
was not statistically significant.
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Table 43. Comparison between changes in full-mouth clinical indices and changes in the 
microflora of patients.
N=39 APDS) (mm) 
(BAS-R2)
P-
value
AAL§ (mm) 
(BAS-R2)
P-
value
ABOPS (%) 
(BAS-R2)
P-
value
ASites>5mm§
(BAS-R2)
P-
value
P.g. 0(25)
1(14)
1.7 ± 0.7
1.7 ±0.5
0.850 1.1 ±0.6 
1.2 ±0.4
0.490 60.0 ± 17.0
54.0 ±21.0
0.360 56.0 ±24.0
59.0 ±18.0
0.730
A. a. 0(28)
1(11)
1.8 ±0.7 
1.6 ±0.5
0.390 1.1 ±0.5
1.1 ±0.4
0.940 61.0 ± 18.0 
51.0 ± 19.0
0.150 61.0±  23.0 
48.0 ± 17.0
0.056
P.L 0(25)
1(14)
1.7 ±0.5
1.7 ±0.8
0.970 1.2 ±0.5 
1.0 ±0.5
0.230 56.0 ± 18.0
61.0 ±20.0
0.370 55.0 ± 18.0
61.0 ±28.0
0.500
T.d 0(14)
1(25)
1.5 ±0.6 
1.9 ±0.6
0.065 1.1 ±0.7
1.2 ±0.4
0.610 55.0 ±22.0
59.0 ± 16.0
0.540 48.0 ±15.0
62.0 ± 24.0
0.037
B.f 0(13)
1(26)
1.5 ± 0.8 
1.8 ± 0.5
0.230 1.0 ± 0.7 
1.2 ±0.4
0.550 55.0 ± 17.0
59.0 ± 19.0
0.440 52.0 ±24.0
60.0 ±21.0
0.300
Table 44. Comparison between changes in serum IgG titres and avidity and changes in the 
microflora of patients.
N=39 IgG titres* 
Change (BAS-R2)
p-value IgG avidity* 
Change (BAS-R2)
p-value
P.g. 0(25) 
1(14)
14 (-21, 237) 
96 (25,3318)
0.07 -0.030 (-0.250, 0.050) 
-0.025 (-0.150,0.180)
0.36
A.a. 0 (28) 
1(11)
5 (-9, 36) 
34 (10, 2650)
0.03 -0.040 (-0.160,0.040) 
-0.290 (-0.450, 0.030)
0.08
P.L 0 (25) 
1(14)
19 (-42, 93) 
35 (-2, 593)
0.21 0.030 (-0.220, 0.120) 
0.035 (-0.030,0.120)
0.84
T.d. 0 (14) 
1(25)
3 (0.0, 35) 
5 (0 .5 ,31 )
0.63 0.000 (-0.080, 0.070) 
-0.030 (-0.100, 0.040)
0.36
B .f  0(13) 
1(26)
2 (-4, 898) 
6 (-2, 70)
0.75 -0.070 (-0.200, 0.090) 
0.000 (-0.150, 0.040)
0.93
Footnote for Tables 43 & 44
sM ean±sd; *median (Q l, Q3); BAS = baseline; R2 = reassessment 2
1 = reduction and 0 = no change or increase in the detection frequency of a pathogen at BAS-R2 
P-values compare patients showing reduction (1) with patients showing no change or increase (0) in the 
detection frequency of a species.
5.2 Discussion
5.2.1 PCR prevalence of putative periodontal pathogens
The prevalence of the five putative periodontal pathogens presented here is relatively 
consistent with the range of values reported by other studies (Ashimoto et al. 1996; 
Riggio et al. 1996; Meurman et al. 1997; Riggio et al. 1998; Umeda et al. 1998). 
However, the present findings show a lower detection frequency for P. gingivalis 
compared to other studies (Wahlfors et al. 1995; Ashimoto et al. 1996; Griffen et al. 
1998; Umeda et al. 1998) and disagree with results of other reports (Darby et al. 2001).
Despite the fact that the above quoted studies utilised PCR as a method for detecting the 
organisms, several reasons could account for the differences in the detection frequencies 
of the bacteria. The reasons for these variations are not clear. Variations in the clinical 
and laboratory procedures with respect to sampling techniques, primers used, primer 
annealing temperatures and processing of the samples prior to PCR analysis may 
contribute to conflicting results. Differences due to patients’ racial or geographical 
characteristics may exist (Umeda et al. 1998), and it is likely that the subgingival 
microbial flora is in a state of dynamic flux and therefore, a single sampling may not 
accurately reflect the flora.
Darby et al. (2001) examined a group of patients from the same population as in the 
present study, who had moderate to advanced chronic periodontitis. In the current study 
and in those of Darby et al. (2001) and Riggio et al. (1996, 1998) the PCR analysis of 
the plaque samples was carried out in the same laboratory, thus reducing laboratory 
variations among studies. In the present investigation the primers targeted the 16S 
rRNA nucleotide region of all bacteria tested, while in the studies of Darby et al. (2001) 
and Riggio et al. (1996, 1998) the primers targeted the leukotoxin gene of A. 
actinomycetemcomitans, the fimbrillin gene of P. gingivalis, and the 16S rRNA 
nucleotide region of the other bacteria. It must be emphasised however, that since the 
present data agree generally with the results reported by Riggio et al. (1996, 1998), 
operator variability may be an important source of variation in the collection and 
processing the plaque samples for PCR analysis.
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5.2.2 Bacterial combinations
The site-based analysis gave a detection frequency of 30.2% for the combination of 
P.gingivalis and B. forsythus and 42.0% for the combination of T. denticola and B. 
forsythus. The three bacteria together, P. gingivalis, T. denticola and B. forsythus, were 
present in 13.8% of the sites. The prevalence of each organism on its own at a site- 
specific level was 32.7% for P. gingivalis, 44.7% for T. denticola and 80.5% for B. 
forsythus. Socransky et al. (1998) found that 10% of sites were positive for the 
coexistence of P. gingivalis, T. denticola and B. forsythus, which is similar to the 
present finding (13.8%). In addition, present data agree with findings by Gmiir et al. 
(1989) who showed that P.gingivalis was almost always detected in samples which 
harboured B. forsythus, although the latter organism was detected more frequently on its 
own. It is obvious, however, that since B. forsythus has been found to be one of the 
most prevalent organisms in subgingival plaque of periodontitis patients (Ashimoto et 
al. 1996; Meurman et al. 1997; Umeda et al. 1998; Darby et al. 2000), this species 
will be statistically more likely to cluster with other bacteria that have a lower detection 
frequency.
5.2.3 Subgingival microflora before and after scaling and root planing
The present study detected all five putative periodontal pathogens at a relatively high 
frequency pre-treatment, confirming previous reports that these organisms are related to 
periodontal disease (Slots et al. 1980; Dzink et al. 1983; Loesche et al. 1985; Lai et al. 
1987; Simonson et al. 1992).
Both treatment modalities resulted in marked reductions in the percentage of sites and 
the subjects positive for the five putative periodontal pathogens and this paralleled 
significant improvements in all clinical indices, confirming the findings of previous 
reports (Simonson et al. 1992; Hafstrom et al. 1994; Shiloah and Patters 1994; 
Haffajee et al. 1997b). The site-based analysis revealed that all tested microorganisms 
were significantly reduced at Rl and R2. In addition, significant reductions in the 
percentage of patients positive for most of the bacteria tested were seen after therapy. 
However, the majority of the organisms were still detected post-scaling but in 
significantly lower frequencies than baseline. This is in agreement with other reports 
which showed that scaling and root planing lowers the numbers of selected periodontal
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pathogens, but is unlikely to eliminate these species from any subject (Cugini et al. 
2000; Haffajee et al. 1997a).
Data presented here showed that the microbial benefits of both treatment strategies were 
maintained over a six-month period in a group of highly motivated patients with optimal 
plaque control. The percentage of sites that were initially free of a pathogen but which 
subsequently became positive for that organism after treatment was negligible for both 
treatment groups, and although this percentage was higher on a patient-based analysis, it 
was still considered to be low. Whether this finding reflects deterioration and infection 
of sites or patients with a pathogen at a later stage is debatable since, the selected 
organisms may have been present at levels below the detection threshold pre-treatment.
It has been shown that the improvement of the subgingival microflora after mechanical 
periodontal treatment is not dramatic and requires supportive periodontal therapy for its 
maintenance (Haffajee et al. 1997a). This finding disagrees with the present study, 
which shows that conservative periodontal therapy results in marked microbiological 
and clinical improvements. Reductions in the detection of the tested organisms 
presented here exceed those reported by Darby et al. (2001) who found significant 
reductions in P. gingivalis, P. intermedia and B. forsythus on a site-basis and little 
change in the micro flora on a subject-basis. However, differences in the clinical and 
immunological procedures and parameters between the two studies also need to be 
considered in order to explain the inconsistency in the microbiological findings.
The results of the current study do not agree with the models of microbial re-population, 
proposed by Slots et al. (1979). The current study revealed that scaling and root planing 
resulted in a rapid reduction of the gram-negative anaerobic microorganisms, including 
Bacteroides species but in contrast to the findings of Slots et al. (1979), this 
improvement was not followed by a return that exceeded pre-treatment levels. 
However, it must be emphasised that the present study compared the detection 
frequencies of the tested organisms before and after treatment, while the study of Slots 
et al. (1979) compared the bacterial proportions and counts. On the other hand, the 
current data support the findings of another study which demonstrated a decrease in the 
prevalence of P. gingivalis, A. actinomycetemcomitans and P. intermedia 12 months 
after scaling and root planing in the absence of supportive periodontal therapy (Shiloah
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and Patters, 1996). It has been shown in another report, that the greatest clinical 
improvement and greatest reductions in selected subgingival organisms occurred within 
the first six months post-scaling which agrees with the findings of the current study, and 
that both clinical and microbiological parameters remained stable or improved 
moderately afterwards (Cugini et al. 2000).
Several studies have shown that conventional periodontal therapy is ineffective at 
reducing the levels of A. actinomycetemcomitans (Komman and Robertson, 1985; 
Mombelli et al. 1994b), and there is evidence that its presence post-treatment is related 
to a compromised clinical outcome (Slots et al. 1986; Renvert et al. 1990a). In 
addition, there are data demonstrating that the proportions of this organism increase 
after treatment (Renvert et al. 1990a; Pedrazzoli et al. 1992), possibly as a result of 
higher sensitivity of the other subgingival species to debridement. The present study 
showed a marked decrease in the prevalence of this organism at a site-specific level, but 
despite the reduction in the percentage of patients that possessed this pathogen after 
treatment, this was not found to be statistically significant.
It was interesting to note that patients who were still positive for any of the tested 
organisms at six months did not appear to have higher indices for pocket depth, 
attachment level or bleeding score than those who did not. This finding is not consistent 
with findings of Renvert et al. (1996), who showed that patients who lost attachment or 
returned to pre-treatment levels after an initial gain harboured P. gingivalis, A. 
actinomycetemcomitans and P. intermedia more frequently than those who maintained 
their initial attachment gain. It should be noted, that the current study followed the 
patients over a six-month period of time, whereas the previous investigation was a 
longer-term study that lasted for five years. Present results agree with those by 
Doungudomdacha et al. (2001), who showed a significant decrease but not eradication 
of the tested organisms post-treatment. The presence of organisms at sites that were 
considered clinically healthy implied that the mere presence of a putative pathogen is 
not indicative of presence or recurrence of disease.
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5.2.4 Comparison of microbiological responses between Q-SRP and FM-SRP 
groups
T. denticola was more prevalent in the FM-SRP patients at baseline. The patient-based 
analysis showed that although there were no significant differences in the detection of T. 
denticola between the two treatment groups at R l and R2, a greater reduction for this 
organism was seen in the FM-SRP group than in the Q-SRP group between BAS and Rl 
and BAS and R2. However, it is difficult to interpret this finding, given the unbalanced 
distribution of T. denticola between the two treatment groups at baseline.
FM-SRP resulted in significantly lower percentages of sites positive for P. intermedia at 
Rl than did Q-SRP. This was also the case on a subject-based analysis. The lower 
prevalence of FM-SRP patients positive for P. intermedia and T. denticola at R l , albeit 
statistically significant only for P. intermedia, paralleled the significantly greater 
reduction in serum antibody levels to these pathogens between BAS and Rl for the FM- 
SRP group compared to the Q-SRP group. This is in agreement with other studies 
showing that reductions in the serum antibody levels post-treatment reflect reductions in 
the antigenic load (Mouton et al. 1987; Aukhil et al. 1988; Murray et al. 1989).
In addition, selected sites of FM-SRP patients showed less PD reduction between BAS 
and R l than those of Q-SRP patients, indicating that at six weeks, post-scaling healing 
is still occurring and that the immunological and microbiological improvements may 
precede clinical changes. These results show that in the short-term (BAS-Rl), 
significant differences in clinical, immunological and microbiological parameters were 
found between the two treatment groups, but these differences seemed to disappear at 
six months.
In the present study, marked microbiological improvements for all tested organisms 
were seen after both treatments. Nevertheless, except for the short-term differences 
between the two treatment groups at R l, there were no significant differences in the 
detection of any organism at R2. Therefore, these data do not confirm the previous 
findings of Quirynen et al. (2000), which showed that over a period of eight months 
FM-SRP with and without the use of chlorhexidine resulted in a less pathogenic 
microflora compared to the common therapy of consecutive sessions of Q-SRP. That 
study also showed that at eight months the number of CFU/ml of specific periodontal
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pathogens returned to pre-treatment values only for the Q-SRP group. Although the 
present results are based on detection frequencies of selected pathogens, no such 
deterioration was noted for the Q-SRP group at six months. A later study by the same 
investigators showed a greater reduction in the prevalence and levels of the “red” and 
“orange” complex species (Table 3, section 1.5.6), but only for the chronic periodontitis 
patients who received the one-stage full-mouth disinfection treatment (De Soete et al. 
2001). The present microbiological data were analysed differently and therefore no 
comparisons can be made between the two studies in this respect.
5.2.5 Re-colonisation of treated sites by pathogens from the remaining untreated 
periodontal pockets
The rationale behind the one-stage full-mouth disinfection was to prevent re­
colonisation of the treated sites by periodontal pathogens from the remaining untreated 
pockets and other intra-oral niches and therefore prevent any recurrence of disease 
(Quirynen et al. 2001). The one-stage full-mouth scaling and root planing with no use 
of chlorhexidine was shown to be equally efficacious with the one-stage full-mouth 
disinfection therapy, and more beneficial than the classical treatment of consecutive 
sessions of scaling and root planing in terms of clinical and microbiological responses 
(Quirynen et al. 2000). These findings indicate that the primary source of bacterial 
translocation are the periodontal pockets. The authors suggest that these considerations 
should be taken into account when split-mouth clinical trials are designed. Another 
study from the same laboratory demonstrated that the composition of the microflora 
around teeth significantly influenced the formation of the subgingival flora around 
implants, and this was more pronounced when teeth and implants were in the same jaw 
(Quirynen et al. 1996). This finding highlights the role of the periodontal pockets as 
bacterial reservoirs.
The clinical design of the present study consisted of consecutive sessions of scaling and 
root planing at two-weekly intervals for the Q-SRP group, with no use of antiseptics 
during or after treatment. Q-SRP consistently started with quadrant one and continued 
clockwise with quadrant two, three and four every second week. The comparison of 
clinical and microbiological effects of Q-SRP on quadrants one and four showed that 
the clinical outcome and improvements in the microbial flora were similar for both 
quadrants post-treatment. These findings imply that there was no recurrence of disease
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or re-colonisation of the already treated sites (IQ) by specific periodontal pathogens 
during a healing period of six months.
However, there is evidence for enhanced clinical outcome after full-mouth versus 
partial-mouth periodontal therapy (Mombelli et al. 1996; Nowzari et al. 1996), which 
supports the hypothesis posed by Quirynen et al. (1995). Mombelli et al. (1996) showed 
that patients who received local treatment at the test sites only, had less pocket depth 
reduction than those who received full-mouth treatment. However, the former group of 
patients received no oral hygiene instructions and had plaque indices higher than the 
latter group of patients. Therefore, the compromised clinical outcome seen in these 
patients could be a result of ineffective plaque control.
Nowzari et al. (1996) showed that patients who had no pockets > 5 mm (other than the 
study sites), and low levels of periodontopathogens, had lower levels of pathogens in 
membranes used for guided tissue regeneration and higher clinical attachment gains 
compared to patients with multiple deep sites and high levels of pathogens. 
Nevertheless, it is unclear whether the recovered organisms from the membranes were 
true contaminants transmitted from other periodontal pockets. One supposition is that 
the microbial contamination of the membranes occurred during membrane manipulation 
prior to application, and originated from the skin or from other areas in the mouth. In 
addition, the recovered pathogens from the membranes may originate from the test sites 
themselves, a possibility which was not assessed by the investigators since, prior to 
regenerative therapy, microbial sampling was performed at sites other than the test 
pockets.
In contrast, in a cariology study, Axelsson et al. (1987) examined the full-mouth 
disinfection treatment compared to another two treatment approaches which consisted of 
less intensive prophylactic measures. This study showed that no long-term differences 
in the reduction of S. mutans and caries existed between the various treatments, 
implying that the additional full-mouth preventive measures used were no more 
successful in preventing caries progression than the less intensive prophylactic 
measures.
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Translocation of microorganisms from one site to another may occur via saliva (van 
Winkelhoff et al. 1988), oral hygiene aids (Svanberg, 1978; Glass and Lare, 1986; 
Muller et al. 1989), and dental instruments (Loesche et al. 1973, 1979; Barnett et al. 
1981; Preus et al. 1993; Papaioannou et al. 1996). Suspected periodontal pathogens 
were also found in supragingival plaque deposits (Riviere et al. 1992; Ximenez-Fyvie et 
al. 2000b; Haffajee et al. 2001b), indicating the possibility that they may be 
translocated to other intra-oral areas. Although, pathogens were recovered following the 
transmission processes mentioned above, it remains debatable whether inoculation of 
microorganisms takes place into sites currently free of these species. It is unlikely that 
inoculation of organisms occurs via saliva since, the constant outflow of GCF from the 
pockets prevents this from happening. Christersson et al. (1985) demonstrated that 
despite the fact that periodontal probes could transmit A. actinomycetemcomitans from 
infected to uninfected sites in localised aggressive periodontitis patients, this organism 
was eliminated from the recipient sites within three weeks. It has been shown that a 
combination of factors such as changes in the local environment, presence of virulent 
strains of periodontal pathogens in sufficient numbers, absence of beneficial species and 
host susceptibility contribute to disease initiation or recurrence (Socransky and Haffajee, 
1992, 1993). In agreement with this are findings from other studies which detected 
suspected periodontal pathogens in sites that were considered clinically healthy, 
suggesting that mere colonisation does not necessarily mean induction of clinical signs 
of disease (Nieminen et al. 1995; Doungudomdacha et al. 2001).
In conclusion, the current study does not provide evidence of microbiological and 
clinical deterioration at sites that were root planed six weeks before the completion of 
the Q-SRP treatment or at sites that received Q-SRP treatment over several visits 
compared to those that were treated with one-day FM-SRP. In the present study, FM- 
SRP was completed in 12 hours instead of 24 hours as described by Quirynen et al. 
(1995). Although the time interval between initiation and completion of treatment was 
lessened, and therefore the chances for bacterial re-colonisation were also reduced, no 
microbiological or clinical differences were found between the two treatment groups six 
months post-scaling to support the hypothesis of Quirynen et al. (1995). It must be 
stressed, however, that the participants in this study were highly motivated patients and 
practised a high standard of plaque control measures. Several studies showed that 
meticulous plaque control can affect the clinical and microbiological parameters in
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moderate (McNabb et al. 1992; Ximenez-Fyvie et al. 2000a), and deep pockets 
(Smulow et al. 1983; Dahlen et al. 1992; Hellstrom et al. 1996). These data 
emphasise the magnitude of oral hygiene measures on the subgingival environment. 
Haffajee et al. (2001b) suggested that the beneficial effects of supragingival plaque 
control on the composition of the supra- and subgingival microflora decreased the risk 
o f disease initiation or recurrence in maintenance periodontitis patients.
Taking these factors into consideration, although there is a potential for translocation of 
periodontal pathogens from one pocket to another, carefully performed plaque control 
measures and changes in the subgingival environment and the host response induced by 
treatment, may prevent re-infection of sites, and thus induction or relapse of periodontal 
disease.
5.2.6 Effect of the presence and absence of putative periodontal pathogens on 
clinical and immunological parameters
The data reported in the current study showed that suppuration was significantly higher 
at sites positive for A. actinomycetemcomitans and B. forsythus than sites negative for 
these pathogens. Sites positive or negative for a pathogen had similar pocket depths, 
relative attachment levels and bleeding scores. This could be due to the fact that the 
selected sites were all relatively deep (mean PD >6.0 mm) and were unable to show any 
differences in clinical and immunological parameters based on the presence or absence 
of an organism. However to confirm this, the microbiological and immunological 
parameters of selected sites were analysed based on pocket depth. The results of this 
analysis will be discussed in Chapter seven.
The subject-based analysis showed lower pocket depths and attachment levels and fewer 
pockets with PD > 5 mm in subjects positive for A. actinomycetemcomitans, while 
subjects positive for T. denticola had higher attachment levels and those positive for B. 
forsythus had deeper pockets and more pockets with PD > 5mm. These findings may 
reflect the fact that A. actinomycetemcomitans is a facultative anaerobe, whereas T. 
denticola and B. forsythus are fastidious anaerobes, thriving in more advanced 
periodontal lesions (Simonson et al. 1988; Gmur et al. 1989; Kigure et al. 1995; 
Socransky et al. 1998; Ximenez-Fyvie et al. 2000b). The data presented in the current 
study confirm the findings of Wolff et al. (1985), who showed that the proportions of A.
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actinomycetemcomitans were higher in pockets of moderate depth and disagreed with 
the findings of Slots et al. (1980), who demonstrated that this pathogen was positively 
related to pocket depth. One possible explanation for this disagreement could be that 
the present study and the study by Wolff et al. (1985) examined patients with moderate 
to advanced periodontitis, in contrast to the study of Slots et al. (1980). The present 
study does not confirm previous findings that P. gingivalis is elevated in deep pockets 
(Gmiir et al. 1989; Socransky et al. 1991b; Kigure et al. 1995; Ximenez-Fyvie et al. 
2000b), and that this organism is more prevalent at suppurating sites (Tanner et al. 
1979; Socransky et al. 1991b).
GCF antibody titres were significantly higher at sites positive for A. 
actinomycetemcomitans and tended to be elevated at sites that harboured P. gingivalis. 
Serum IgG titres and avidities followed the same pattern of elevated levels in the 
subjects that harboured the tested organisms. However, this was statistically significant 
for serum IgG titres in patients positive for P. gingivalis and A. actinomycetemcomitans. 
These findings support earlier reports that the presence of elevated antibody titres in 
periodontitis patients is related to bacterial infection (Ebersole et al. 1982a; Choi et al. 
1990; Nakagawa et al. 1990; Kojima et al. 1997), and imply that the production of 
antibodies of elevated avidity is a result of repeated antigenic exposure (Lopatin et al. 
1991), as has been discussed in Chapter four.
Patients were subdivided into two groups, those who became negative for a bacterial 
species at R2 and those who remained the same or became positive for this species. 
Then the changes in clinical and immunological parameters between BAS and R2 were 
compared between these two groups of patients. A greater decrease in the number of 
sites > 5 mm was found in subjects who became negative for T. denticola than those 
who showed no change or became colonised by this organism. These results highlight 
that a reduction in prevalence of specific periodontal pathogens with treatment parallels 
an improved clinical outcome (Slots et al. 1979; Simonson et al. 1992; Mombelli et al. 
1994b). On a site-based analysis, sites that became negative for A. 
actinomycetemcomitans after treatment were found to have a greater reduction in all 
clinical indices than sites that demonstrated no change or an increase in the prevalence 
of this pathogen. A trend for greater gain in RAL which was close to statistical
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significance was seen at sites that were no longer positive for P. gingivalis and T. 
denticola following treatment.
A greater reduction in serum IgG antibody titres to A. actinomycetemcomitans was 
found in subjects who became negative for A. actinomycetemcomitans at R2 than those 
who showed no change or became colonised by this pathogen. Although, the other 
organisms followed the same trend, this observation failed to show statistical 
significance. This finding is consistent with other reports that associated post-scaling 
reductions in antibody titres with reductions in the microbial burden (Mouton et al. 
1987; Aukhil et al. 1988; Murray et al. 1989; Choi et al. 1990). The local antibody 
responses failed to show significant differences in GCF antibody titres between sites 
that became negative for an organism and those that showed no change or became 
positive for that species.
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CHAPTER 6
IMPACT OF SMOKING ON PERIODONTAL PARAMETERS
6. Impact of smoking on periodontal parameters
6.1 Results
6.1.1 Effect of smoking on all subjects (n=42). Comparison of baseline clinical, 
immunological and microbiological parameters between non-smokers and smokers
Table 45, compares the clinical indices in 17 smokers and 25 non-smokers at baseline. 
Clinical indices collected from the selected sites of smokers showed significantly lower 
PD (p<0.05) and MGI (p=0.005) at baseline compared to sites of non-smokers. 
Smokers tended to have greater RAL and lower BOP, but this failed to reach statistical 
significance. In addition, no significant differences were noted in PI and in the whole- 
mouth clinical indices between the two subgroups at baseline.
Although serum IgG titres (EU) to all putative pathogens were lower for smokers at 
baseline, this observation failed to reach statistical significance (Table 46). No 
significant differences in IgG avidity (M at ID5o) were seen between non-smokers and 
smokers (Table 47). Table 48 compares the GCF IgG titres (EU / 30 sec) and GCF 
volume (pi / 30 sec) between smokers and non-smokers at baseline and shows 
significantly lower GCF volume for smokers (p<0.01). In general, GCF IgG titres were 
lower for smokers than non-smokers at baseline and this was significant for A. 
actinomycetemcomitans (p<0.005) and P. intermedia (p<0.01) and just failed to reach 
statistical significant for P. gingivalis (p=0.057).
Despite the differences between smokers and non-smokers in the proportions of patients 
and sites positive for the five putative periodontal pathogens, none of these differences 
reached statistical significance (Table 49).
Cigarette smoking status was self-reported by the patients. A retrospective serum 
cotinine enzyme inhibition assay confirmed this self-reporting to be reliable (Figure 15). 
Subjects were considered to be smokers if they smoked five or more cigarettes per day. 
Since, no participants smoked less than five cigarettes per day, less than five cigarettes 
per day seemed to be a useful gap in the diagnostic differentiation of smokers versus 
non-smokers. Three patients (one in Q-SRP group and two in FM-SRP group) reported 
that they had given up smoking after the initiation of periodontal therapy, but these 
subjects were included in the smoking subgroup.
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The assay was performed using the COZART serum cotinine assay kit (Abingdon, U.K.), following the 
manufacturer’s instructions. In brief, all reagents were warmed to room temperature. 10 pi dilutions of  
cotinine standards and serum (neat and 1/5 dilution) were added to micro-plate wells in duplicate. Then 100 
pi o f cotinine enzyme was added to each well and the reaction was incubated for 30 min at room 
temperature. The plate was washed four times with wash buffer and 100 pi o f substrate reagent was added to 
each well and the plate was incubated for 30 min at room temperature. The reaction was terminated with 100 
pi o f stop solution and optical densities were read using a Dynex Technologies MRX II plate reader at 450 
nm with a 630 nm reference wavelength. Sample readings were compared with a reference line derived from 
serial dilutions o f the cotinine standards. The median concentration o f cotinine was significantly lower in 
non-smokers (11.2 ng/ml; range: 3.2-28.6) than smokers (1848.0 ng/ml; range: 43.0-3267.0); Mann Whitney 
test p<0.001. Therefore, self-reported smoking status was confirmed.
In the following sections the clinical, immunological and microbiological parameters 
and their change with treatment will be examined for smokers and non-smokers in each 
treatment group.
6.1.2 Effect of smoking on clinical, immunological and microbiological parameters 
in the Q-SRP group
Seven smokers and 13 non-smokers were included in the Q-SRP group. Table 50, 
summarises the analysis of the whole-mouth clinical indices and it shows significantly 
greater BOP reduction for non-smokers at R1 and R2 from BAS compared to smokers 
(p<0.05).
The site-specific clinical indices between non-smokers and smokers before and after Q- 
SRP were also determined (Table 51). Selected sites of smokers showed significantly 
lower gingival inflammation (BOP and MGI) and a trend for lower PD and greater RAL 
at baseline. BOP was present in 64% of sites in smokers versus 92% in non-smokers 
(p<0.005) and mean MGI was 2.2 in smokers versus 2.7 in non-smokers (p=0.005). No 
significant differences in PI and suppuration were found between the two subgroups. 
The analysis of the changes in site-specific clinical indices with treatment showed 
significantly less clinical improvement for smokers (APD, ARAL, ABOP). There was a 
greater PD reduction of approximately 1.2 mm for non-smokers at R1 and R2 from BAS 
(p<0.001). A greater gain in RAL of 0.6 mm was found for non-smokers at R1 and R2 
from BAS compared to smokers (p<0.01). Similarly, there was a greater reduction in 
BOP by approximately 30% and 51% for non-smokers than smokers at R1 and R2 from 
BAS, respectively (p<0.01). 14% of sites in smokers that were negative for BOP at 
baseline turned positive at R2, but no sites in non-smokers did so. Despite the fact that 
smokers had less clinical improvement in comparison with non-smokers, they still had a 
significant reduction in all clinical indices following treatment (p<0.05).
The serum IgG titres (EU) and IgG avidity (M at ID50) were compared between smokers 
and non-smokers in the Q-SRP group and the results are shown in Tables 52 and 53. At 
baseline, serum IgG titres tended to be lower for smokers (Table 52). This was 
statistically significant for P. intermedia (p<0.05), and just failed to reach statistical 
significance for A. actinomycetemcomitans (p=0.052). After treatment, despite the 
lower levels of IgG antibody for smokers at R1 and R2 (significantly for A.
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Serum 
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and 
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actinomycetemcomitans, p<0.05 and close to statistical significance for P. intermedia 
p=0.057 and for T. denticola p=0.052), the comparison of the changes in antibody titres 
between BAS and R1 and BAS and R2 were not significantly different between smokers 
and non-smokers. IgG avidity was similar for smokers and non-smokers at baseline, 
and no significant differences in antibody avidity to any microorganism were noted at 
R1 and R2 (Table 53). When the changes in IgG avidity were examined, no significant 
differences in IgG avidity for any microorganism were noted between smokers and non- 
smokers at R1 and R2 from BAS.
The levels of statistical significance for the changes in the serum immunological 
parameters in non-smokers and smokers post Q-SRP are summarised in Table 54. The 
comparison of changes in serum IgG titres before and after Q-SRP for the two 
subgroups showed significant decrease in antibody titres to P. gingivalis for non- 
smokers (p<0.05) and smokers (p<0.05) after treatment. The decrease in serum 
antibody titres to B. forsythus found at R2 for smokers was close to statistical 
significance (p=0.06). No significant changes in IgG avidity were noted for each 
subgroup after treatment.
The analysis of GCF volume (pi / 30 sec) between non-smokers and smokers is shown 
in Table 55. It is evident that non-smokers had significantly higher GCF volume at 
baseline (p<0.05). In addition, a significantly greater reduction in GCF volume was 
seen for non-smokers between BAS and R2 (p=0.01). However, both non-smokers and 
smokers showed significant reductions in GCF volume after treatment (p<0.05). At 
baseline, GCF IgG titres (EU / 30 sec) were lower in the smokers compared with the 
non-smokers (Table 56). This finding was significant for P. gingivalis (p=0.01), A. 
actinomycetemcomitans (p<0.005), P. intermedia (p<0.005) and T. denticola (p<0.05). 
When the changes in GCF IgG titres with treatment were examined there was a trend for 
a greater reduction in non-smokers and this finding was statistically significant for T. 
denticola at R1 (p<0.05) and R2 (p<0.005) from baseline.
The prevalence of the five putative periodontopathogens between non-smokers and 
smokers before and after Q-SRP is depicted in Tables 57 and 58. Despite the 
differences in the prevalence of pathogens between the two subgroups before and after 
treatment, no statistically significant differences were found for any microorganism on a
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Table 54. P-values for changes in serum IgG titres and IgG avidity in non-smokers and 
smokers after Q-SRP.
IgG titres p-value
(BAS-R1)
p-value
(BAS-R2)
IgG avidity p-value
(BAS-R1)
p-value
(BAS-R2)
P.g. non-smokers 1.00 0.04 P.g. non-smokers 0.2 0.1
smokers 0.09 0.02 smokers 0.3 0.5
A.a. non-smokers 0.36 0.33 A.a. non-smokers 0.5 0.2
smokers 0.40 0.53 smokers 0.6 0.3
P.i. non-smokers 0.83 0.14 P.L non-smokers 0.2 1.0
smokers 0.67 0.35 smokers 0.7 0.9
T.d. non-smokers 0.72 0.18 T.d. non-smokers 0.1 0.3
smokers 0.60 0.10 smokers 0.4 0.6
B.f. non-smokers 0.65 0.59 B.f. non-smokers 0.4 0.6
smokers 0.53 0.06 smokers 0.1 0.1
P.g.: P. gingivalis; A.a.: A. .actinomycetemcomitans; P.i.: P. intermedia', T.d.: T. denticola', 
B.f. : B. forsythus
Q-SRP = quadrant scaling and root planing
BAS = baseline; R1 = reassessment 1; R2 = reassessment 2.
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site- and a patient-based analysis. The site-based analysis revealed that there were 
significant reductions in the prevalence of the bacteria after treatment for each subgroup, 
except for A. actinomycetemcomitans in smokers (Table 57). On a patient-based 
analysis, the only statistically significant microbiological changes folowing treatment 
for each subgroup were found in non-smokers for T. denticola at R2 (p<0.05) and for B. 
forsythus at R1 and R2  (p<0.05) (Table 58).
6.1.3 Effect of smoking on clinical, immunological and microbiological parameters 
in the FM-SRP group
Ten smokers and 12 non-smokers were included in this group and the whole-mouth 
clinical indices between non-smokers and smokers before and after FM-SRP were 
analysed (Table 59). No significant differences were seen in any clinical index between 
non-smokers and smokers before and after treatment indicating that smokers and non- 
smokers had similar clinical improvement after FM-SRP.
Table 60 shows the site-specific clinical indices and their change with treatment in 
relation to smoking status for the FM-SRP group. Non-smokers tended to have slightly 
deeper pockets by 0.3 mm, lower RAL by 0.2 mm and greater MGI than smokers at 
baseline, but these observations were not statistically significant. No significant 
differences in BOP, PI and suppuration were seen between non-smokers and smokers at 
baseline. Following FM-SRP, there was a significantly greater clinical improvement for 
non-smokers, in terms of PD reduction and RAL gain. Non-smokers had an additional 
PD reduction of 0.5 mm and 0.8 mm over smokers at R1 (p<0.05) and R2 (p<0.01) from 
BAS, respectively. Similarly, an increase of approximately 0.7 mm and 0.8 mm gain in 
RAL was noted for non-smokers over smokers at R1 (p<0.005) and R2 (p<0.01) from 
BAS, respectively. However, when the changes in BOP were examined, smokers had a 
greater BOP reduction over the non-smokers between BAS and R2, although this failed 
to reach statistical significance (p=0.051). This observation is in contrast with findings 
in the Q-SRP group. 4.0% of sites that were initially negative for BOP turned positive 
at R1 for non-smokers. This value was 7.5% for smokers. Nevertheless, non-smokers 
and smokers had a significant improvement for all clinical parameters following 
treatment (p<0.05).
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59. 
Com
parison 
of whole-m
outh 
clinical indices between 
sm
okers and 
non-sm
okers before 
and 
after FM
-SRP.
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baseline; 
R1 
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ent 
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ent 2
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ent level; 
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on 
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and 
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Table 
60. 
Com
parison 
of site-specific 
clinical indices between 
sm
okers and 
non-sm
okers before 
and 
after FM
-SRP.
The analyses of serum IgG titres (EU) showed that there were no statistically significant 
differences between non-smokers and smokers before and after FM-SRP (Table 61). 
Table 62 summarises the statistical significance of the changes in serum IgG titres after 
FM-SRP for each subgroup. For non-smokers, there was a significant decrease in IgG 
levels to T. denticola between BAS and R1 (p<0.01), and for smokers antibody titres to 
A. actinomycetemcomitans and P. intermedia significantly decreased at this time point 
(p<0.05).
No significant differences in IgG avidity (M at ID5 0) were detected between the two 
subgroups at BAS or at R1 and R2 (Table 63). Nevertheless, when the changes with 
treatment were examined, a greater increase in antibody avidity against P. gingivalis 
was found for smokers compared to non-smokers between BAS-R1 and BAS-R2 
(p<0.05). Table 62 summarises the levels of significance for the changes in IgG avidity 
in each subgroup following FM-SRP. For non-smokers, no statistically significant
increase in IgG avidity was found after treatment. Antibody avidity to P. gingivalis
significantly increased between BAS and R1 for smokers (p<0.05).
Table 55 (section 6.1.2) compares the GCF volume (pi / 30 sec) between non-smokers 
and smokers before and after FM-SRP. No significant differences were found between 
the two subgroups at baseline and after treatment. Both subgroups had a significant 
reduction in GCF volume following FM-SRP (p<0.01). At baseline, GCF antibody 
titres (EU / 30 sec) were found to be significantly lower in smokers than non-smokers 
for A. actinomycetemcomitans (p<0.05) and P. intermedia (p<0.05) (Table 64). The 
post-treatment changes revealed that non-smokers had a significantly greater reduction 
in GCF antibody titres to P. gingivalis between BAS and R2 (p<0.05) and to T.
denticola between BAS and R1 (p<0.05).
The prevalence in subgingival plaque of the five suspected periodontal pathogens 
between non-smokers and smokers before and after FM-SRP was analysed and the 
results showed no significant differences for any pathogen on a patient-based analysis 
(Table 65). The comparison of the percentage of patients positive for the bacteria before 
and after SRP for each subgroup revealed statistically significant reductions after 
treatment only for T. denticola and B. forsythus in non-smokers (p<0.01) and smokers 
(p<0.05). Table 66 shows that on a site-based analysis a significantly higher proportion
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Table 
61. 
Serum 
IgG 
titres in 
sm
okers and 
non-sm
okers before 
and 
after FM
-SRP.
Table 62. P-values for changes in serum IgG titres and IgG avidity in non-smokers and 
smokers after FM-SRP.
IgG titres p-value
(BAS-R1)
p-value
(BAS-R2)
IgG avidity p-value
(BAS-R1)
p-value
(BAS-R2)
P.g. non-smokers 0.260 0.180 P.g. non-smokers 0.150 0.500
smokers 0.520 0.720 smokers <0.030 0.100
A. a. non-smokers 0.780 0.090 A. a. non-smokers 0.080 0.100
smokers 0.028 0.240 smokers 0.600 0.080
P.i. non-smokers 0.078 0.760 P.i. non-smokers 0.300 1.000
smokers 0.028 0.120 smokers 0.290 0.200
T.d. non-smokers 0.006 0.060 T.d. non-smokers 0.080 0.200
smokers 0.074 0.070 smokers 0.540 0.600
B.f. non-smokers 0.160 0.220 B.f. non-smokers 0.410 0.100
smokers 0.680 0.310 smokers 0.440 0.600
Median (Q l, Q3)
P.g.: P. gingivalis; A.a.:A. .actinomycetemcomitans; P.i.: P. intermedia, T.d. \ T. denticola, 
B .f: B. forsythus
FM-SRP = full mouth scaling and root planing
BAS = baseline; R1 = reassessment 1; R2 = reassessment 2.
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63. 
IgG 
avidity 
in 
sm
okers and 
non-sm
okers before 
and 
after FM
-SRP.
BAS 
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baseline; R1 
= 
reassessm
ent 
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reassessm
ent 2 
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full m
outh 
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root planing
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edia', 
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64. 
GCF 
antibody 
titres in 
non-sm
okers and 
sm
okers before 
and 
after FM
-SRP.
BAS 
= 
baseline; 
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= 
reassessm
ent 
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reassessm
ent 2
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for changes 
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P
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differences 
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and 
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Table 
65. 
Percentage 
of patients positive 
for the 
five 
putative 
periodontal pathogens in 
non-sm
okers and 
sm
okers before 
and 
after FM
-SRP.
BAS 
= 
baseline; 
R1 
= 
reassessm
ent 
1; 
R2 
= 
reassessm
ent 2
'P-value 
is 
given 
for changes 
before/after FM
-SR
P
2P-value 
is 
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for differences 
between 
non-sm
okers 
and 
sm
okers.
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Table 
66. 
Percentage 
of sites positive 
for the 
five 
putative 
periodontal pathogens in 
non-sm
okers and 
sm
okers before 
and 
after FM
-SRP.
of sites of non-smokers harboured A. actinomycetemcomitans at baseline (p<0.05) and 
at R1 (p<0.005) and a greater reduction of this pathogen was seen for non-smokers than 
smokers at R2 from baseline (p<0.05). For P. intermedia, a significantly higher 
percentage of sites of non-smokers was positive for this pathogen at baseline (p<0.05). 
When each subgroup was analysed on a site-basis for changes following FM-SRP, 
statistically significant reductions were noted for all pathogens (p<0.05), except for A. 
actinomycetemcomitans in sites of smokers.
6.1.4 Comparison of smokers before and after Q-SRP and FM-SRP
To investigate whether the differences in clinical and immunological parameters 
between smokers in Q-SRP and FM-SRP groups were the result of therapy or due to 
differences in the frequency of cigarette usage within smokers, a comparison of the 
periodontal parameters was made between smokers in the Q-SRP and FM-SRP groups.
Table 67, shows the differences of the whole-mouth clinical indices between smokers in 
Q-SRP group (n=7) and in FM-SRP group (n=10). No differences in any clinical index 
were detected between therapy groups at baseline. The changes in PD, AL and No. of 
sites > 5 mm with treatment were similar for both groups. However, a significantly 
greater BOP reduction was noted for smokers in the FM-SRP group between BAS and 
R2 (p<0.05).
Tables 50 and 51 (section 6.1.2) and Tables 59 and 60 (section 6.1.3) depict the changes 
in the whole-mouth and the site-specific clinical indices for Q-SRP and FM-SRP 
groups, respectively, based on smoking status. The GLM analysis demonstrated that 
there was a significant three-way interaction of smoking and treatment approach (Q- 
SRP and FM-SRP) and visit effect on PD and RAL of the selected sites. This finding is 
difficult to assess, but it seems that smoking is the predominant factor in this three-way 
interaction. It is apparent from these Tables that Q-SRP non-smokers showed the 
greater PD reduction between BAS and R1 compared to Q-SRP smokers and FM-SRP 
non-smokers and smokers. The analysis of the site-specific clinical indices between 
smokers in the Q-SRP group and smokers in the FM-SRP group showed that there were 
no significant differences in site-specific clinical indices between the two subgroups at 
baseline, despite the greater BOP and Sup seen for FM-SRP smokers (Table 68). The 
analysis of the changes in local clinical parameters with treatment showed that FM-SRP
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resulted in significantly greater BOP reduction than Q-SRP between BAS and R2
(p=0 .0 1 ).
The immunological data were analysed and no differences in serum IgG titres (EU) 
against any bacteria were found between the two subgroups at baseline (Table 69). 
However, at R2 significantly higher serum antibody levels were detected against P. 
intermedia for FM-SRP smokers than Q-SRP smokers (p<0.05). In addition, between 
BAS and R1 there was a significantly greater reduction in serum antibody levels to this 
pathogen for FM-SRP smokers compared to Q-SRP smokers (p<0.05).
Table 70 compares the IgG avidity (M at ID50) in smokers before and after Q-SRP and 
FM-SRP. At baseline, IgG avidity to B. forsythus was significantly higher for FM-SRP 
smokers than Q-SRP smokers (p<0.05), but there was no significant difference between 
the two groups at R1 and R2. FM-SRP smokers showed a significantly greater increase 
in antibody avidity to P. gingivalis between BAS and R1 than did Q-SRP smokers 
(p<0.05).
Table 71 compares the differences of GCF volume (pi / 30 sec) between smokers in Q- 
SRP and smokers in FM-SRP groups. No significant differences in GCF volume were 
found between smokers of the two treatment groups before and after treatment. The 
comparison of GCF IgG titres (EU / 30 sec) between smokers of Q-SRP and FM-SRP 
groups demonstrated a significantly greater reduction in GCF IgG titres to T. denticola 
between BAS and R2 for FM-SRP smokers than Q-SRP smokers (p=0.01) (Table 72).
The prevalence of the putative periodontal pathogens at sites of smokers between the Q- 
SRP and FM-SRP groups is depicted in Table 73, and it shows a significantly higher 
prevalence of P. gingivalis for the Q-SRP group at baseline (p<0.05). At R l, P. 
gingivalis was not detected at the selected sites of smokers in both groups, but between 
BAS and Rl the decrease of this pathogen was greater for Q-SRP smokers than FM- 
SRP smokers (p<0.05). No significant differences in the prevalence of the other 
bacteria were noted before and after SRP. Table 74 shows the patient-based analysis of 
the PCR data between smokers in the two treatment groups. Smokers in the FM-SRP 
group showed significantly a higher prevalence of T. denticola at baseline compared to 
Q-SRP group (p<0.05) and a significantly greater reduction of this pathogen between
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Table 72. GCF IgG titres in smokers before and after Q-SRP and FM-SRP.
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GCF IgG titres are expressed as EU/30sec 
Mean ± SEM
P-values compare sites o f Q-SRP smokers and FM-SRP smokers
Q-SRP = quadrant scaling and root planing; FM-SRP = full mouth scaling and root planing 
BAS = baseline; Rl = reassessment 1; R2 = reassessment 2
P.g.: P. gingivalis; A.a.: A. .actinomycetemcomitans; P.i/. P. intermedia; T.d. : T. denticola; 
B.f. \ B. forsythus.
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BAS and Rl (p<0.005), and BAS and R2 (p<0.05). No significant differences in the 
prevalence of the other bacteria were found before and after treatment on a subject- 
based analysis.
6.2 Discussion
6.2.1 Comparison of baseline clinical, immunological and microbiological 
parameters between non-smokers and smokers
At a site-specific level, smokers showed significantly lower PD, MGI and GCF volume 
and a trend towards lower bleeding scores at baseline compared to sites of non-smokers. 
The lower GCF volume found in smokers confirms the results of previous investigations 
(Holmes, 1990; Kinane and Radvar, 1997). On the other hand, the present data disagree 
with the findings of other studies that showed deeper pockets in smokers than non- 
smokers (Bergstrom and Eliasson, 1987b; Kamma et al. 1999; Haffajee and Socransky, 
2001), but it should be noted that the sample size in the current study was smaller than 
in the quoted studies.
No differences in plaque levels were found between smokers and non-smokers, which is 
consistent with other reports (Kinane and Radvar, 1997; Kamma et al. 1999; Darby et 
al. 2000; Haffajee and Socransky, 2001). Therefore, the harmful effects of smoking on 
periodontal health may not be associated with plaque accumulation and poor oral 
hygiene (Bergstrom and Eliasson, 1987a, 1987b). The finding that smoking suppresses 
the inflammatory response to plaque challenge, and therefore masks clinical signs of 
gingival inflammation, confirms previous observations in periodontitis patients (Preber 
and Bergstrom, 1985; Darby et al. 2000; Bergstrom and Bostrom, 2001) and in 
experimental gingivitis-induced patients (Lie et al. 1998a; Danielsen et al. 1990). 
However, Bergstrom et al. (2000) showed that in individuals free of periodontal disease 
the association between smoking and gingival bleeding was weak.
The present data demonstrated that there were no statistically significant differences in 
the prevalence of organisms between the two subgroups of patients, on either a site- or a 
subject-basis. This finding is in agreement with other studies that failed to show an 
altered subgingival microbiota in smokers (Stoltenberg et al. 1993; Darby et al. 2000; 
Bostrom et al. 2001). Lie et al. (1998a) did not attribute the lower bleeding scores seen 
in smokers after the induction of experimental gingivitis to microbiological differences
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between smokers and non-smokers. Nevertheless, there are conflicting data that 
smokers harbour specific pathogens at higher levels and frequencies than non-smokers 
(Zambon et al. 1996; Kamma et al. 1999), and that they are at increased risk for 
bacterial infection (Zambon et al. 1996; Umeda et al. 1998). Disagreement in the 
subgingival microbial composition between smokers and non-smokers among various 
studies could be explained by differences in patient populations, in microbial sampling 
techniques and in detection methods of putative pathogens.
There is evidence that smoking has a systemic effect on the immune response (Andersen 
et al. 1982; Holt, 1987; Kenney et al. 1977). Present data showed lower serum 
antibody titres against all microorganisms in smokers than non-smokers, although this 
observation did not reach statistical significance. This pattern of decreased levels of 
antibodies was less clear when antibody avidities were considered, showing small 
differences between the two subgroups of patients. However, GCF antibody titres were 
lower in smokers than non-smokers and this observation reached significance for some 
of the tested organisms. Therefore, it appears that smoking can modify the host 
response and this agrees with previous observations (Haber, 1994). It has been shown 
in other studies that smoking has an impact on serum immunoglobulin levels, but this 
effect seems to be both race and serum IgG subclass specific (Quinn et al. 1996; 
Gunsolley et al. 1997; Tangada et al. 1997; Quinn et al. 1998).
6.2.2 Effect of smoking on clinical, immunological and microbiological parameters 
in the Q-SRP and FM-SRP groups
At baseline, the whole-mouth clinical indices were similar between smokers and non- 
smokers in the Q-SRP group. However, on a site-specific basis smokers in the Q-SRP 
group had less BOP, MGI and GCF volume at baseline confirming previous findings 
(Preber and Bergstrom, 1985; Holmes, 1990; Kinane and Radvar, 1997; Darby et al. 
2000; Bergstrom and Bostrom, 2001). In agreement with previous observations (Haber, 
1994), the current study showed that smokers in the Q-SRP group had lower levels of 
serum IgG antibodies to all tested organisms (p<0.05 for A. actinomycetemcomitans and 
P. intermedia) and a tendency for lower antibody avidities to most of them. GCF 
volume was found to be significantly lower for smokers compared to non-smokers and 
GCF antibody titres against the majority of the organisms were significantly lower for 
smokers. No significant differences in the prevalence of specific pathogens were seen
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on a site- and a subject-basis (Stoltenberg et al. 1993; Darby et al. 2000; Bostrom et al. 
2001). These findings are discussed in the previous section and highlight the notion that 
smokers have a suppressed inflammatory response and an altered host response to 
antigenic challenge. In contrast, the subgingival microflora of smokers appears similar 
to that of non-smokers.
The analysis of the whole-mouth clinical indices showed that following Q-SRP, 
smokers exhibited significantly less reduction in BOP compared to non-smokers. This 
finding emphasises the negative effects of smoking on the bleeding response in the 
periodontium. Nevertheless, this finding is inconsistent with the results from the GLM 
analysis, which showed that there was only a visit and a patient effect on the whole- 
mouth clinical indices. This disagreement could be explained by the fact that the GLM 
analysis examined the interactions of several factors on the clinical parameters of all 
patients, while the current test is restricted to assess only the smoking effect on the 
whole-mouth clinical indices in a subgroup of patients. Taking these considerations into 
account, although this finding has a rational meaning it should be interpreted with 
caution. The site-specific analysis showed that post-treatment smokers had significantly 
less clinical improvement, in terms of PD, RAL, BOP and GCF volume reductions than 
did non-smokers. After treatment, smokers in the Q-SRP group retained lower serum 
antibody titres compared with non-smokers, and this was significant for A. 
actinomycetemcomitans. Significantly higher GCF antibody titres to T. denticola were 
found for smokers, indicating that these sites might still be challenged by this pathogen. 
No differences in the prevalence of putative periodontal pathogens were seen at Rl and 
R2 between smokers and non-smokers, both on a site- and a subject-basis.
At baseline, the effects of smoking on the clinical, immunological and microbiological 
parameters in the FM-SRP group were different from what was seen in the Q-SRP 
group. No significant baseline differences in the whole-mouth and site-specific clinical 
indices were found between smokers and non-smokers, as was the case with GCF 
volume. The pattern for lower serum antibody titres that was noted for smokers in the 
Q-SRP group was less clear in the FM-SRP group. The subject-based analysis showed 
no differences in the prevalence of specific microorganisms between smokers and non- 
smokers before and following FM-SRP therapy. However, significantly lower GCF 
antibody titres to A. actinomycetemcomitans and P. intermedia were seen for smokers
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than non-smokers and of great interest was the finding that the prevalence of the 
homologous organisms was also significantly lower at sites of smokers. This 
strengthens the hypothesis that specific local antibody levels are related to antigenic load 
(Ebersole et al. 1982a). Between BAS and R2, significantly less reduction in GCF 
antibody titres to P. gingivalis was found for smokers compared to non-smokers, and 
this was the case for T. denticola between BAS and R l . Significantly lower percentage 
of sites positive for A. actinomycetemcomitans was seen in smokers than non-smokers 
in the FM-SRP group at R l. Following FM-SRP, selected sites of smokers showed 
significantly less PD and RAL reduction than those of non-smokers. No significant 
differences in the reduction of GCF volume were seen between sites of smokers and 
non-smokers in this treatment group.
These results reinforce the concept that smoking results in a compromised clinical 
outcome following treatment. Several studies confirm the present findings that smokers 
have less clinical improvement post-treatment than non-smokers (Preber et al. 1995; 
Kaldahl et al. 1996c; Haffajee et al. 1997a; Kinane and Radvar, 1997; Renvert et al. 
1998). There is evidence that during maintenance smokers exhibit more periodontal 
destruction (Kaldahl et al. 1996b; Bostrom et al. 1998). The present data agree with 
other reports which found no differences in the presence of pathogens in supra- or 
subgingival plaque between smokers and non-smokers after treatment (Preber et al. 
1995; Bostrom et al. 1998; Renvert et al. 1998). However, although the present study 
failed to show any pre- and post-therapy differences in the subgingival microflora 
between smokers and non-smokers when all subjects (in particular Q-SRP subjects) 
were analysed, differences in the site-prevalence of specific organisms were found 
between smokers and non-smokers in the FM-SRP group.
6.2.3 Comparison of smokers before and after Q-SRP and FM-SRP
Quirynen et al. (2000) examined three groups of patients. The two test groups received 
FM-SRP with the adjunctive use of chlorhexidine (Fdis) and without (FRp), whereas the 
control group received Q-SRP at two-weekly intervals. Each group comprised 12 
patients and, although the authors reported that groups were well balanced for smoking 
habits, the Fdis group included 3/12 (25.0%) smokers, the FRp group 3/12 (25.0%) 
smokers, while the control group included 5/12 (41.5%) smokers. That study showed
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that the smoking effect on the treatment outcome was unclear, although most of the 
smokers showed the least gain in attachment levels.
The findings of the current study demonstrated that smoking and treatment approach (Q- 
SRP and FM-SRP) over a period of six months had a significant effect on PD and RAL 
of the selected sites. Although this three-way interaction is complicated and difficult to 
interpret and may not be clinically significant, it appears to be that Q-SRP non-smokers 
had the greatest PD reduction between BAS and Rl compared to the others.
In order to clarify whether Q-SRP and FM-SRP had different effects on the clinical, 
immunological and microbiological parameters of smokers and non-smokers, these 
parameters were compared between smokers in the Q-SRP group and those in the FM- 
SRP group. This analysis found no significant differences in any clinical index at 
baseline between smokers in the Q-SRP and the FM-SRP groups. FM-SRP seemed to 
result in significantly lower bleeding scores at R2 and higher antibody titres to P. 
intermedia at R2. The reason why FM-SRP causes lower bleeding scores in smokers at 
six months compared to Q-SRP is difficult to explain and may be a spurious statistical 
finding.
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CHAPTER 7
RELATIONSHIP BETWEEN SEVERITY OF PERIODONTAL 
DISEASE AND IMMUNOLOGICAL AND MICROBIOLOGICAL
PARAMETERS
7. Relationship between severity of periodontal disease and immunological and 
microbiological parameters
7.1 Results
7.1.1 Correlation between immunological parameters and whole-mouth clinical 
indices
Serum IgG antibody titres (EU) to tested organisms were correlated negatively with 
baseline whole-mouth clinical indices, PD and No. of sites > 5 mm and this was 
statistically significant for A actinomycetemcomitans only (R=-0.49, p=0.001) (data not 
shown). In addition, IgG avidity (M at ID5o) tended to correlate negatively with baseline 
PD and No. of sites > 5 mm, but this observation failed to reach statistical significance 
for any of the test bacteria.
In order to clarify these results and also compare the changes in clinical indices and 
changes in immunological and microbiological parameters, the subjects of this study 
were categorised as moderate and advanced diseased periodontitis patients and as 
having moderate and greater clinical improvement post-treatment. Then the 
immunogical and microbiological responses were compared in these patient subgroups 
and the results are discussed in the following section.
7.1.2 Relationship between severity of periodontal disease and immunological and 
microbiological parameters
Systemic immunological parameters (serum IgG titres and avidity) and microbiological 
parameters (percentage of patients positive for a species) were compared between 
subjects with advanced and subjects with moderate periodontal disease at baseline 
(Table 75). Serum IgG titres (EU) appeared to be higher in patients with shallower 
pockets (mean PD < median) than those with deeper pockets (mean PD > median) and 
this finding was statistically significant for A. actinomycetemcomitans (p<0.005) and 
close to statistical significance for P. intermedia (p=0.055). Similarly, the patients with 
shallower pocket depths tended to have greater IgG avidity (M at I D 5 0 )  to the majority of 
the organisms tested than the latter patients, but this observation failed to reach 
statistical significance. A. actinomycetemcomitans was found to be more prevalent in 
patients with shallower than deeper pockets (p<0.01), but no significant differences for 
the other bacteria were found.
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Between BAS and R2, the reduction in serum IgG titres seemed to be greater in patients 
with moderate clinical improvement (mean APD < median) than those with greater 
clinical improvement (mean APD > median) and this finding was significant for P. 
gingivalis (p<0.05) and B.forsythus (p<0.05) and close to significance for P. intermedia 
(p=0.054) (Table 76). In the former patients IgG avidity to T. denticola decreased, 
whereas in the latter patients avidity increased and this difference between the two 
categories of patients was significant (p<0.01). Significantly greater reduction in the 
prevalence of T. denticola was noted for patients with the large than the moderate 
clinical improvement (p=0.01).
In a similar way, IgG titres appeared to be higher in patients with fewer pockets > 5 mm 
((mean No. of sites > 5 mm) < median) than those with more deeper pockets ((mean No. 
of sites > 5 mm) > median) and this finding was statistically significant for A. 
actinomycetemcomitans (p<0.01) (Table 75). In addition, antibody avidity to all 
pathogens tended to be greater for the former patients but without reaching statistical 
significance. A. actinomycetemcomitans was found to be more prevalent in patients 
with fewer deep pockets (pO.Ol). A greater reduction in serum IgG titres was found in 
patients who showed moderate clinical improvement ((mean ANo. of sites > 5 mm) < 
median) than those with large clinical improvement ((mean ANo. of sites > 5 mm) > 
median) (Table 76). This was statistically significant for P. gingivalis (p<0.05) and P. 
intermedia (p<0.05) and close to significance for T. denticola (p=0.054). No significant 
differences in IgG avidity were found between the two categories of patients. A greater 
reduction in the prevalence of T. denticola was noted for the patients with the greater 
reduction in the number of sites > 5 mm (p<0.05).
A comparison between the severity of disease and immunological and microbiological 
parameters was also made at a site-specific level, comparing the GCF IgG titres and the 
prevalence of the bacteria at sites of deep and moderately deep pocket depth. The 
subgingival microflora was compared between deep periodontal pockets (mean PD > 7 
mm) and moderately deep pockets (mean PD < 7mm) and no significant differences in 
the prevalence of the putative pathogens were found between the two categories of sites 
(Table 77). The comparison of BOP between deep and moderately deep pockets 
revealed higher BOP in the deep pockets than the moderately deep (84.4% versus 
79.4%), but this finding was not statistically significant (Table 77). A higher percentage
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of deep pockets suppurated compared to moderately deep pockets (78.0% versus 
59.6%), but this observation just failed to reach statistical significance (p=0.05) (Table 
77).
Table 78 compares the GCF volume (jil / 30 sec) and GCF IgG titres (EU / 30 sec) to 
the five putative periodontal pathogens between deep pockets (mean PD > 7mm) and 
moderately deep pockets (mean PD < 7mm). Deep pockets seem to give rise to more 
GCF, but this observation did not reach statistical significance. In addition, significantly 
higher GCF antibody titres to A. actinomycetemcomitans (p<0.05), P. intermedia 
(p=0.005) and B. forsythus (p<0.005) were found in deep pockets compared to 
moderately deep pockets. No significant differences in the GCF antibody titres to P. 
gingivalis and T. denticola were seen between sites of deep and moderately deep pocket 
depth.
7.2 Discussion
7.2.1 Relationship between severity of periodontal disease and immunological and 
microbiological parameters
At baseline there was a negative trend between serum antibody titres and clinical indices 
(PD and No. of sites > 5mm). This observation was statistically significant for 
antibodies to A. actinomycetemcomitans only. In other words, the less the severity of 
disease, the higher the antibody levels were, implying that antibodies to the suspected 
pathogens play a protective role in the pathogenesis of periodontitis. However, the 
present data also showed that antibody levels were elevated in presence of a pathogen, 
implying that specific antibody levels reflect infection with a pathogen. Since A. 
actinomycetemcomitans was found to be more prevalent in subjects with shallower 
pockets and in subjects with more localised disease (fewer sites > 5 mm), one would 
expect that serum antibody titres to this organism increase as pocket depth decreases. 
However, antibody avidity tended to follow the same pattern with antibody titres and 
correlated negatively with these clinical indices, suggesting that the shallower the 
pockets or the less widespread the disease, the higher the antibody avidity was. These 
findings strengthen the hypothesis that increased levels of antibodies that are of high 
avidity result in less disease severity in chronic periodontitis patients. The present data 
agree with previous reports which associated the failure of the host to elicit an immune
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response to specific organisms with greater and more widespread periodontal disease 
(Ranney et al. 1982; Gunsolley et al. 1987).
It was of great interest to note that between baseline and R2 the smaller reductions in 
antibody titres were found for the subjects with the greater reduction in PD or number of 
deep sites. This observation implies two things. Firstly, it has been shown that PD 
reduction post-treatment is related directly to the initial PD with the greatest reduction 
seen for the deepest pockets (Knowles et al. 1979). The fact that antibody levels were 
higher in subjects with lower pocket depths and fewer deep sites may result in a greater 
reduction in antibody levels for these patients after treatment. The second and more 
likely possibility is that, despite the fact that antibody levels to all tested organisms 
decreased six months post-treatment, patients with a large clinical improvement retained 
higher antibody levels than those with a moderate clinical outcome. These patients 
showed a greater reduction in selected putative pathogens and this was significant for T. 
denticola. Antibody avidity to this pathogen was found to be significantly higher for 
patients with greater clinical improvement than those with less clinical improvement. 
These findings highlight the protective role of antibodies against bacterial infections and 
also support a role for T. denticola as a pathogen in periodontitis lesions (Simonson et 
al. 1988, 1990, 1992).
In conclusion, after treatment patients who had large clinical improvement also had 
higher antibody levels and higher antibody avidity against specific organisms compared 
to patients with moderate clinical improvement. This observation may reflect a 
maturation of the host response possibly accomplished by active immunisation during 
treatment. Alternatively, patients who can elicit a substantial immune response to 
suspected pathogens may be the ones with the lower pocket depths at baseline and the 
greater clinical improvement after treatment. There is evidence that seropositive 
patients respond better to treatment (Mouton et al. 1987; Mooney et al. 1995), and that 
the induction of an immune response in immunocompetent patients contributes to 
disease resolution after treatment (Ebersole et al. 1992). However, these inoculation 
benefits of root planing to the immune response were not evident when the 
immunological parameters were compared before and after therapy, regardless of the 
periodontal status of the patients. In general, a reduction in antibody titres to most of
136
the tested organisms was seen at six months, reflecting a reduction in the levels of 
pathogens.
The site-specific analysis showed that deep pockets had significantly higher GCF 
antibody titres to A. actinomycetemcomitans, P. intermedia, and B. forsythus than 
moderately deep pockets and tended to give rise to higher GCF volumes. No significant 
differences in the prevalence of suspected pathogens were found in deep versus 
moderate to deep pockets. Deep pockets have more pocket lining epithelium and it is 
assumed that they are more inflamed and have a greater reservoir of fluids and antibody 
producing plasma cells, giving rise to GCF and specific antibodies than shallow pockets. 
In accordance with this, Johnson et al. (1993) examined the GCF IgG titres to P. 
gingivalis in generalised aggressive periodontitis patients and found that GCF volume 
correlated with antibody titres, and that both of these parameters correlated with pocket 
depth. However, Mann (1963) suggested that inflammation had a stronger relationship 
to the amount of GCF than did the pocket depth. Conversely, Mooney and Kinane 
(1997) found lower GCF antibody titres in deep periodontal pockets than gingivitis 
sites, implying that increased consumption of local antibodies may take place in the 
deep pockets. Similar findings were found in an earlier study by the same investigators, 
but this report examined maintenance patients who received extensive periodontal 
therapy and therefore these results are not comparable with those in the current study 
(Kinane et al. 1993). However, there is evidence that there is no relationship between 
clinical disease status and elevated GCF antibody titres (Tew et al. 1985; Baranowska 
et al. 1989). The present data support the concept that PD is related to both GCF 
antibody levels and GCF volume, although significantly to the former only.
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CHAPTER 8 
GENERAL DISCUSSION
8. General discussion 
8.1 Methodological considerations
8.1.1 Sample size
The present study followed the patients over a period of six months, and given time 
limitations and the fact that only one operator administered treatment, a size of forty 
patients was deemed suitable to give sufficient power for the analysis of 
microbiological, immunological and clinical data. Initially 60 patients were recruited, 
but ten subjects were excluded due to poor attendance and another eight subjects were 
excluded from the study due to antibiotic intake during the course of therapy. 
Therefore, the present data were based on 42 patients, with 20 and 22 of them 
comprising each treatment group (Q-SRP and FM-SRP, respectively).
This number of participants appears to agree with other studies and exceeds the number 
of patients in some of them (Lindhe et al. 1982a; Badersten et al. 1984a, 1984b; Isidor 
et al. 1984; Mouton et al. 1987; Lopatin et al. 1991; Kinane et al. 1993; Mooney and 
Kinane, 1997; Lie et al. 2001). The number of participants in each group exceeds that 
of a series of clinical trials, which assessed the efficacy of the one-stage full-mouth 
disinfection. The pilot studies of this laboratory were based on ten subjects, five in each 
treatment group (Quirynen et al. 1995; Vandekerckhove et al. 1996), and later studies 
from the same investigators examined a total number of 16 patients, eight in each group 
(Bollen et al. 1998), 40 patients, 20 in each group (Mongardini et al. 1999), and 36 
subjects in the most recent study with 12 subjects in each treatment group (Quirynen et 
al. 2000).
8.1.2 Statistical considerations
There is conflicting data in the literature as to what the most appropriate unit of analysis 
should be. It has been suggested that the site should be used as the unit of analysis for 
identification of site-specific relationships (Haffajee et al. 1983a, 1983b; Haffajee and 
Socransky, 1986). It is argued that the evaluation of treatment outcome that assesses the 
whole-mouth clinical indices is inappropriate, since many sites are not diseased and 
these sites tend to negatively affect the statistical power of treatment effects. In contrast, 
other studies are in favour of using the subject as the unit of analysis and the sites as 
subunits, since sites within a subject may not act independently (Imrey, 1986; Fleiss et 
al. 1987; Steme et al. 1988; Gunsolley et al. 1992).
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The present study examined the efficacy of two treatment procedures and analysed 
clinical data collected from all sites in the mouth, and from four selected sites per 
patient, in order to assess systemic responses and site-specific responses to treatment. 
For the site-specific analysis an assumption was made that sites are statistically 
independent units without exhibiting intra-subject correlation. However, since both 
treatment procedures (Q-SRP and FM-SRP) had a systemic effect on the subjects, 
reliance on the GLM analysis of the full-mouth clinical indices and the GLM analysis of 
the pooled site-specific clinical indices per patient seems sensible. Efforts were made to 
minimise clinical measurement errors by recording valid and reproducible site-specific 
clinical indices. This resulted in similar findings after the analysis of the site-specific 
clinical indices when sites were used as independent experimental units, and after the 
analysis of the pooled site-specific clinical indices per subject when the subject was 
used as the experimental unit.
8.1.3 Site selection
Several studies estimated the necessary number of sites that need to be sampled from 
one patient to verify bacterial infection. It has been shown that two to four sites > 5 mm 
need to be sampled to detect P. gingivalis, P. intermedia, and B. forsythus, while it has 
been claimed that more than 25 random sites are required to detect A. 
actinomycetemcomitans (Christersson et al. 1992; Gunsolley et al. 1992). These 
studies utilised indirect immunofluorescence and DNA probes for detecting the 
pathogens. The selection of the deepest pocket in each quadrant has been deemed 
sufficient both for the detection of A. actinomycetemcomitans as well as for the 
estimation of the highest cultivable count of the organism (Mombelli et al. 1994a). 
Another study showed that a species was not detected in 25% of the positive subjects if 
the four deepest pockets were sampled using a colony lift method and DNA probes 
(Haffajee and Socransky, 1992). The error in the false-negative detection of the species 
was higher for infrequently detected microorganisms, such as A. 
actinomycetemcomitans serotype b. This organism was not detected in 38% of positive 
subjects when the four deepest pockets were sampled. Nevertheless, this sampling 
strategy was found to be superior to other partial-mouth sampling methods in detecting 
the presence of a species (Mombelli et al. 1991; Haffajee and Socransky, 1992).
139
The present study assessed the presence or absence of selected pathogens in the four 
deepest sites per subject using the PCR method. Since PCR method is an extremely 
sensitive method for detecting specific organisms, the use of four deepest sites per 
subject, provided that their PD > 5mm and they were on single-rooted teeth, seemed to 
be an efficient method to determine infection with a specific organism.
8.1.4 Plaque sampling for PCR analysis
In the present study plaque samples were collected using a sterile periodontal hand 
instrument, taking care to access the most apical part of the pocket. The plaque sample 
was collected with a single vertical stroke and it was a pooled sample including 
gingival, mid-pocket and apical samples. In a review by Tanner and Goodson (1986), 
different methodological approaches for plaque sampling were compared and some of 
these considerations are presented here. It has been shown that curettes can remove up 
to 90% of the subgingival plaque and this method of plaque collection is recommended 
if an estimate of the total pocket contents is required. Since hand instruments remove 
larger plaque samples than the other commonly used techniques (paper point, barbed -  
broach cannula, irrigation devices) they are more effective for sampling pockets with 
few organisms i.e., healthy sites or recently treated sites. Therefore, for studies in which 
disturbance of the ecosystem is not of major importance, this method appears to be the 
best sampling technique (Tanner and Goodson, 1986). Nevertheless, there is evidence 
that sampling per se has no statistically detectable effects on the composition of the 
microbial flora of subsequent samples from the same sites (Moore et al. 1982). Based 
on this finding, sampling using a curette may not significantly alter the subgingival 
ecosystem and therefore affect subsequent samples.
8.1.5 GCF sampling for ELISA
In the present study, GCF was collected with paper strips using Whatman filter paper 
cut in dimensions of 2 x 8 mm. The Whatman filter paper has been shown to be more 
advantageous than the Periopaper (Griffiths et al. 1988). That study demonstrated that 
2 mm x 8 mm filter paper strips absorbed larger amounts of fluid while still remaining 
within the measuring scale of the Periotron 6000. The elution of serum-derived 
antibodies from Periotron filter papers was demonstrated to recover almost all of the 
antibody activity, compared with serum diluted directly into the antibody assay plates 
(Ebersole et al. 1984; Griffiths et al. 1988).
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It has been suggested that calibration of the Periotron 6000 should be based on a range 
of volumes from very low to high, to be able to assess the quantities of fluid recovered 
from healthy or inflamed sites (Van der Bijl et al. 1986). In the present study, the 
calibration curve of the Periotron 6000 was split into two parts, the upper, including 
high volumes, and the lower, including lower volumes, and the two lines were fitted by 
regression (Lamster et al. 1985; Chappie et al. 1995). However, the range of volumes 
used to construct the lower part of the calibration curve in the present study was not as 
low as that used in the studies of Lamster et al. (1985) and Chappie et al. (1995). 
Nevertheless, the slope of linear regression found in this investigation was 
approximately 3.5 nl per unit for the lower part, and 6.3 nl per unit for the upper part of 
the curve, which is in agreement with other studies (Bickel and Cimasoni, 1984; 
Chappie et al. 1995).
It must be stressed that in the present study GCF antibody titres were expressed as 
ELISA units / 30 sec sample. These were independent of the volume of the GCF 
sample. As a result, the calculation of the GCF antibody levels were subjected to less 
variation with respect to the calibration of the Periotron 6000 and to evaporation of the 
fluid that may occur, regardless of the sampling technique used. The present results 
showed a large site-to-site variability in GCF antibody titres. In general, the levels of 
GCF antibodies were low for the majority of putative pathogens. One possible reason 
for the low values of GCF antibody titres is that GCF was eluted into 1 ml buffer for the 
ELISA analysis against five putative periodontal pathogens, which could result in a 
large dilution of the fluid’s constituents. As noted in materials and methods, because 
GCF was eluted into 1 ml (1/1000 dilution) and the ELISA was standardised with a 
1/200 dilution of the control serum, GCF titres should have been multiplied by five. 
However, even when this correction was made the GCF antibody titres were still low.
8.1.6 Periodontal probing
Listgarten et al. (1980) reviewed problems associated with probing and showed that a 
variety of factors seemed to influence the probing measurements, such as positioning of 
the probe, anatomic features of the tooth surface and the force exerted on probing. 
Histological evidence showed that errors related to periodontal probing appeared to not 
exceed 1.5 mm in the worst case (Listgarten, 1980). PD measurements are known to
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depend on the probing force (Mombelli and Graf, 1986). Inflamed tissues offer less 
resistance to probe penetration than clinically healthy tissues (Armitage et al. 1977; 
Listgarten, 1980; Fowler et al. 1982), and a decrease in the variability of probing 
attachment levels was found after periodontal therapy (Badersten et al. 1984c).
Several studies have assessed the efficacy of constant force electronic probes in making 
reproducible recordings and have compared this technique with conventional probing. 
There is evidence that measurements obtained with an electronic probe were 
significantly superior to those obtained with a manual probe (Magnusson et al. 1988), 
while other studies failed to show any significant differences between manual and 
standardised probing (van der Velden and de Vries, 1980; Quirynen et al. 1993). A 
high correlation has been shown to exist between manual and electronic probing, but 
pocket depths recorded with a conventional probe were deeper than those recorded with 
an electronic probe (van der Velden and de Vries, 1980; Magnusson et al. 1988; Osborn 
et al. 1992; Quirynen et al. 1993). A further study showed that the percentage of 
agreement between the two techniques tended to decrease as pocket depth increased, 
although it was impossible to determine which technique recorded the periodontal status 
most accurately (Kalkwarf et al. 1985). In another study, both examiners were shown 
to be able to reproduce their measurements to within ±1 . 0 mm on more than 96% of 
occasions with manual probing and on 100% of occasions with the constant-force probe 
(Walsh and Saxby, 1989). This was also the case in approximately 90% occasions when 
an electronic probe was used (Badersten et al. 1984c).
The main difference in reproducibility of the recordings taken with a manual probe 
compared with an electronic probe is the difficulty in applying a standard force when 
using a manual probe. In addition, the fact that measurements with a manual probe are 
recorded to the nearest mm while the constant force probe measurements are read to the 
nearest 0.1 or 0.2 mm also contributes to the disagreement between the two techniques. 
With this in mind, in the current study periodontal probing was performed using a 
manual probe for the whole-mouth PD and AL recordings and an electronic pressure 
sensitive probe (the Florida probe) for PD and RAL measurements at selected sites. The 
use of the Florida probe excluded errors, such as variations in probing force and 
inaccuracies with visual readings due to impaired vision, mainly pre-treatment. In the 
present study one examiner performed probing and therefore inter-operator variability
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did not exist. It should be noted, however, that manual probing is a classical method of 
probing and has been widely used over the years and there are merits to this method. It 
is a simple procedure in the clinical setting and, additionally an experienced examiner 
can use tactile sensation to overcome problems that may obscure accurate probing, such 
as anatomic features of the root surface or the presence of subgingival restorations and 
calculus.
8.2 Conclusions
8.2.1 Comparison of Q-SRP and FM-SRP treatments
The GLM analysis showed no significant effects of smoking and / or treatment strategy 
on the whole-mouth clinical indices (PD, AL, BOP and No. of sites>5 mm). However, 
when the selected sites were considered a significant combined effect of smoking and 
treatment strategy was seen on PD and RAL over the six month period. When the two 
treatment groups were compared at a site-specific level, the Q-SRP group was found to 
have a significantly greater PD reduction at R1 in moderately deep pockets and a 
significantly smaller gain in RAL at R2 in deep pockets compared to the FM-SRP 
group. No differences in any other clinical index were found between the two treatment 
strategies.
There were no significant differences in IgG antibody avidity between the two treatment 
groups before and after therapy. However, FM-SRP resulted in a significantly greater 
reduction in serum antibody titres to P. intermedia and T. denticola between baseline 
and R1 and higher GCF antibody titres to T. denticola at R1 compared to Q-SRP. In 
addition, significantly lower site prevalence of P. intermedia was seen at R1 for the FM- 
SRP group and a greater reduction was noted in subject prevalence of T. denticola at R1 
and R2 from baseline for the FM-SRP group compared to the Q-SRP group. These 
findings imply that changes in immunological parameters parallel changes in 
microbiological parameters. However, the clinical interpretation of these results is 
difficult.
The data from the present study showed no evidence of microbial re-colonisation or 
clinical deterioration in the first scaled quadrant (quadrant one) compared to quadrant 
four that was scaled last. The former quadrant was treated six weeks before quadrant 
four was root planed when Q-SRP treatment was completed. This finding tends to
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contradict the hypothesis of Quirynen et al. (1995) that bacterial contamination may 
occur during the active phase of Q-SRP treatment, re-infecting already treated sites from 
the remaining untreated pockets.
During consecutive sessions of Q-SRP at two weekly-intervals, pockets in the untreated 
quadrants showed significant improvements in clinical indices (PD, MGI, PI, Sup). 
This may have been due to improved oral hygiene measures or a host-induced effect by 
Q-SRP. Nevertheless, these improvements were smaller compared to changes seen after 
the completion of treatment. The assessment of the humoral immune response indicated 
that reductions in antibody titres and increases in antibody avidity occurred during the 
active phase of treatment with reference to baseline, but this was significant for some of 
the tested organisms. These findings indicate that reductions in the antigenic load 
occurred at the early stages of treatment and these microbial changes appeared to have a 
significant effect on the host response. No significant differences in serum antibody 
levels or antibody avidity were found between the two treatment groups during therapy 
to support the hypothesis of a strong immunological reaction induced by bacteraemia 
after the one-day full-mouth treatment as suggested by Quirynen et al. (2000).
Despite the fact that FM-SRP resulted in higher pain scores and higher frequency of 
labial herpes, this treatment approach seemed to be well tolerated by patients. FM-SRP 
patients considered this approach to be more practical, since fewer treatment visits are 
required to complete this therapy than the classical treatment of consecutive sessions of 
root planing. However, it should be emphasised that in the current study FM-SRP 
patients were seen as frequently as Q-SRP patients to receive equal amounts of 
motivation and oral hygiene instructions.
8.2.2 Effect of smoking
The site-based analysis revealed that smokers had significantly lower PD, MGI and GCF 
volume, and a tendency for higher RAL and lower BOP at baseline compared to non- 
smokers. Significantly lower GCF antibody titres and a tendency for lower serum 
antibody titres were found in smokers than non-smokers at baseline. No significant 
differences in the subgingival microflora were noted between smokers and non-smokers 
at baseline. These results imply that smoking depresses the inflammatory response of
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the periodontium to plaque challenge and has a tendency to modify the immunological 
profile of periodontitis patients.
A significantly smaller PD reduction and significantly less RAL gain were noted in 
smokers compared to non-smokers after both treatment strategies, which emphasises the 
negative effects of smoking on the treatment outcome. The GLM analysis showed that 
smoking and treatment strategy (Q-SRP and FM-SRP) had a significant effect on the 
clinical indices (PD and RAL) of the selected sites over the course of treatment. It was 
interesting to note that smokers and non-smokers from both treatment groups showed a 
different pattern in the clinical, immunological and microbiological responses before 
and after treatment. In order to clarify this observation an attempt was made to compare 
smokers in the Q-SRP and FM-SRP groups. No significant differences in any clinical 
index were found between Q-SRP smokers and FM-SRP smokers at baseline, while a 
greater BOP reduction was seen after treatment (at R1 and R2) for smokers in the FM- 
SRP group compared to the Q-SRP group. This finding is difficult to interpret, based on 
their immunological and microbiological differences before and after treatment and the 
small numbers in the study.
8.2.3 Immunological and microbiological responses
The current study showed significant reductions in serum antibody titres with a 
concomitant decrease in the prevalence of putative periodontal pathogens. This finding 
implied that post-SRP antibody titres decreased as the microbial burden lessened and 
these changes were more pronounced at six months. Although, antibody avidity tended 
to increase post-scaling, this observation failed to reach statistical significance for most 
of the bacteria tested. In conclusion, treatment resulted in lower antibody levels, but of 
similar avidity for the majority of the microorganisms.
The finding that antibodies reflect the presence of the homologous organisms 
subgingivally is confirmed by the fact that subjects who harboured a specific 
microorganism had elevated serum antibody titres to that species, and this was 
statistically significant for P. gingivalis and A. actinomycetemcomitans. In addition, 
GCF antibody levels were significantly higher at sites positive for A. 
actinomycetemcomitans. The subjects that became negative for a pathogen post­
treatment tended to have a greater reduction in serum antibody levels. This finding was
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significant for A. actinomycetemcomitans and those subjects who no longer harboured 
A. actinomycetemcomitans after treatment, also showed a greater clinical improvement 
compared to the subjects who had no change or became positive for this species.
8.2.4 Relationship between severity of disease and immunological and 
microbiological parameters
At baseline, subjects with more advanced periodontal disease demonstrated lower serum 
antibody titres than those with moderate periodontitis. After treatment, subjects with 
large clinical improvement exhibited a smaller reduction in serum antibody levels 
compared to subjects with moderate clinical improvement. For T. denticola this 
observation just failed to reach statistical significance (p=0.054), but coincided with a 
significantly greater increase in antibody avidity and a significantly greater reduction in 
the prevalence of this pathogen post-treatment. These findings suggest that subjects 
who are able to mount a specific immune response to suspected pathogens exhibit less 
severe disease and also show a better clinical outcome and greater reductions in the 
prevalence of these species. This strengthens the hypothesis that antibodies are 
protective against disease and also that T. denticola plays an important role in the 
pathogenesis of periodontitis.
A. actinomycetemcomitans was found to be more prevalent is subjects with less severe 
periodontal disease in contrast to T. denticola and B. forsythus. This finding is 
consistent with A. actinomycetemcomitans being a facultative anaerobic organism, 
unlike the latter species which are fastidious anaerobes.
At a site-specific level, deep sites exhibited higher GCF antibody titres (significantly for 
A. actinomycetemcomitans, P. intermedia and B. forsythus) and also a tendency for 
higher GCF volume compared to moderately deep sites. This observation suggests that 
deeper sites are more inflamed and give rise to higher levels of specific antibodies in the 
GCF than shallower pockets. In addition, a higher percentage of deep pockets was 
found to suppurate and also sites that harboured A. actinomycetemcomitans and B. 
forsythus had a higher frequency of suppuration.
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Effect of periodontal therapy on the antibody response and 
subgingival microflora. D. APATZIDOU,* D.F. KINANE, M.P. 
RIGGIO (Glasgow Dental Hospital & School, Glasgow, UK).
Previous studies have shown that periodontal treatment stimulates the host immune 
response to produce antibodies of higher avidity and lower antibody titres. The aim of 
this study was to examine the clinical, microbiological and immunological effects of 
four sessions of quadrant root planing at two-week intervals. 20 patients with advanced 
periodontitis were followed over a period of 6 months. Clinical measurements and 
subgingival plaque samples were taken from 4 selected sites at baseline, reassessment 
one (RAS1) and reassessment two (RAS2). Moreover, full mouth pocket charts and 
serum samples were collected at these visits. Antibody titre was assayed by ELISA and 
avidity was measured by thiocyanate dissociation against five putative periodontal 
pathogens, P. gingivalis, A. actinomycetemcomitans, P. intermedia, T. denticola and B. 
forsythus. The presence of the homologous bacteria in subgingival plaque samples was 
determined by PCR. Periodontal treatment resulted in significant improvements for all 
clinical parameters with the more marked differences detected at RAS2, (p<0.05). 
Immunoglobulin G (IgG) titres decreased after treatment but did not reach significance 
for any of the five tested bacteria, whereas IgG avidities increased post-treatment with a 
significant increase in P. gingivalis (p<0.05). Microbiological data indicated reductions 
of all pathogens detected in subgingival plaque samples after treatment. These results 
indicate that scaling and root planing affects the dynamics of the immune response and 
reduces the subgingival pathogenic microflora.
1
Clinical findings following quadrant root planing versus full mouth 
root planing. D.A. APATZIDOU,* D.F. KINANE (Glasgow Dental 
Hospital & School, Glasgow, UK).
Full mouth root planing (FMRP) has recently been claimed to be superior to quadrant 
root planing (QRP) in terms of clinical and microbiological responses. The aim of this 
study was to examine the clinical effects of full mouth root planing within the same day, 
compared to the more typical therapy of four sessions of quadrant root planing at two 
weekly intervals. 40 patients with advanced periodontitis were randomly allocated to 
QRP (n=20) and FMRP (n=20) groups and were followed intensively over a period of 6 
months. Clinical measurements were taken from 4 selected sites at baseline and at the 
reassessment visits at 3 months (Rl) and 6 months (R2). Full mouth pocket charts and 
serum samples were also collected at these visits. Both treatment modalities resulted in 
statistically significant improvements for all clinical parameters with the more marked 
differences detected at R2. At baseline, the mean and standard deviation for the pocket 
depth (PD) was 4.3 ±0.6mm for FMRP, and 4.5 ±0.7mm for QRP. The mean PD 
reduction was significant for both groups (p<0.005) at Rl (FMRP: 1.5 ±0.5mm; QRP:
1.7 ±0.7mm) and at R2 (FMRP: 1.7 ±0.6mm; QRP: 1.9 ±0.7mm). All pockets equal or 
greater than 5mm were significantly reduced at R l (FMRP: 70%; QRP: 72%) and at R2 
(FMRP: 84%; QRP: 86%). No differences in any of the clinical indices were seen 
between the two groups after treatment. In conclusion, both treatment strategies appear 
to be equally effective in the treatment of advanced periodontitis.
2
Antibody dynamics following quadrant root planing versus full 
mouth root planing. D.A. APATZIDOU, D.F. KINANE* (Glasgow 
Dental Hospital & School, Glasgow, UK).
Full mouth root planing (FMRP) has recently been claimed to be superior to quadrant 
root planing (QRP) in terms of clinical and microbiological responses. The aim of this 
study was to examine the immunological effects of full mouth root planing within the 
same day compared to the more typical therapy of four sessions of quadrant root planing 
at two weekly intervals. 40 patients with advanced periodontitis were followed over a 
period of 6 months. Clinical data were recorded before and after treatment and serum 
samples were collected at these visits and at two week intervals during the active phase 
of therapy for both QRP (n=20) and FMRP (n=20) groups. Antibody titre was assayed 
by enzyme-linked immunosorbent assay (ELISA) and avidity was measured by 
thiocyanate dissociation against five putative periodontal pathogens: P. gingivalis; A. 
actinomycetemcomitans; P. intermedia; T. denticola and B. forsythus. Overall, 
Immunoglobulin G (IgG) titres decreased after treatment, with a statistically significant 
decrease in antibody titre to T. denticola (p<0.05). In contrast, IgG avidities increased 
post treatment for all bacteria, with a statistically significant increase noted for A. 
actinomycetemcomitans (p=0.05). No significant differences in antibody titres or 
avidities were detected between the two treatment groups. In conclusion, both treatment 
strategies appear to have a similar impact on the magnitude and quality of the immune 
response.
3
Clinical, immunological and microbiological responses to periodontal therapy in 
smokers and non-smokers with periodontal disease.
Apatzidou D.A.,* Riggio M.P., Kinane D.F. University of Glasgow, Scotland, UK
Objectives: The aim of this study was to determine the clinical, microbiological and 
immunological profiles of smokers and non-smokers periodontitis patients before and 
after conventional non-surgical periodontal therapy.
Materials and Methods: 20 patients with moderate to severe periodontitis received 
mechanical debridement and were followed over 6 months. Clinical data were recorded 
and serum, gingival crevicular fluid (GCF) and subgingival plaque samples were 
collected before and after treatment. Antibody titres were assayed by enzyme-linked 
immunosorbent assay (ELISA) and avidity was measured by thiocyanate dissociation 
against five putative periodontal pathogens: P. gingivalis; A. actinomycetemcomitans; P. 
intermedia; T. denticola and B. forsythus. The presence of these bacteria in plaque was 
determined by polymerase chain reaction (PCR).
Results: Smokers showed significantly less gingival inflammation and GCF volume at 
baseline than non-smokers (p<0.05). Less pocket depth reduction, less attachment gain 
and a smaller reduction in GCF volume was seen in smokers compared with non- 
smokers after treatment (p<0.05). At baseline, serum IgG titres were lower for smokers 
(p<0.05 for A. actinomycetemcomitans and P. intermedia) while their change with 
treatment was similar for both subgroups. No significant differences in IgG avidity and 
subgingival microflora were seen between smokers and non-smokers before and after 
treatment.
Conclusion: Smoking has an adverse effect on the clinical outcome of periodontal 
therapy and appears to affect the immunological profile of periodontitis patients. 
Smoking reduces gingival inflammation and thus masks early signs and symptoms of 
periodontal disease.
4
Changes in rheological cardiovascular risk factors after periodontal therapy.
Marshall G.J., Kinane D.F., Lowe G.D.O., Losche W., Rumley A., Apatzidou D,
This short-term interventional study aimed to detect changes in rheological risk factors 
for atheromatous disease following periodontal therapy. 40 patients with periodontitis 
(probing depths >5.5mm in at least 2 quadrants) were recruited. Resting blood pressure 
and a baseline venous blood sample were taken and clinical indices recorded. All 
patients received quadrant root planing and oral hygiene instruction and were reviewed 
6-8 weeks after treatment was completed. Preliminary analysis of the first 33 completed 
patients confirmed that periodontal treatment gave a significant reduction in pocket 
depth (PO.OOOl) and bleeding on probing (PO.OOOl). There were significant rises in 
clotting factors VII and VIII after treatment (P<0.05). Factor IX also rose after 
treatment, but this change did not reach statistical significance (P<0.066). No other 
statistically significant changes in the rheological variables tested were noted, however 
there was a trend towards elevated levels of tissue plasminogen activator (TPA) and 
fibrin D-dimers after treatment. In contrast, serum from 33 patients were analysed for 
activity of the enzyme Platelet Activating Factor - Acetylhydrolase (PAF-AH) and 
revealed a decrease in enzyme activity after treatment (PO.OOl). In conclusion, this 
preliminary analysis suggests that within 6-8 weeks of periodontal therapy there is a 
reduction in systemic PAF-AH activity and a perturbation of clotting factors VII. VIII 
and IX.
A further report on the effects of periodontal therapy after 6-9 months will follow and 
will inform us as to whether the effects seen post initial treatment are transient as for 
exercise and blood clotting factors, and drop during the stable maintenance period.
